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Cannabis has been used as a medicinal and natural product for thousands of 
years. Whether it has been used to make rope or paper, or been used to treat 
pain or depression, cannabis has always had a place in human civilisation.  
 
With the isolation of the psychoactive compounds responsible for cannabis’ 
effects, the discovery of two human cannabinoid receptors and an expanding 
knowledge of the therapeutic uses of cannabis, interest in the development of 
novel cannabinoids grew. The CB2 cannabinoid receptor has gained particular 
attention, as the often unwanted central and psychoactive effects of 
cannabinoids has been attributed to the CB1 cannabinoid receptor. 
Development of CB2 receptor selective ligands offers treatment opportunities 
in many areas, but most especially for pain, multiple sclerosis and 
immunomodulation. 
 
The preparation of fluorescently labelled ligands for a variety of receptors has 
improved compound screening techniques, as well as allowing use as 
biomolecular probes for aiding our understanding of the receptor . The 
aim of this work is to design, synthesise and evaluate novel fluorescently 
labelled cannabinoids, with a particular interest in CB2 selective compounds. 
 
Focusing on the CB2 receptor selective alkylindole JWH-015, targeted 
substitutions were made to its naphthyl ring to identify sites that might be 
suitable for fluorophore attachment. With a site chosen, a series of fluorescent 
JWH-015 analogues was synthesised and evaluated for their CB2 receptor 
binding affinities. Though none of the evaluated compounds showed sufficient 
binding affinity for them to be used as biomolecular tools, the structure 
activity relationships gained suggested that improved design of fluorescent 
JWH-015 analogues in future could lead to the first ever active fluorescent 
cannabinoid.  
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AcOH  acetic acid 
aq  aqueous 
BBr3  boron tribromide 
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min  minute 
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Rt  retention time 
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 L., hereafter referred to as cannabis, is a species of the hemp 
family Cannabaceae, which also contains the genus L., or hops, used 
in the brewing of beer1. There are currently two subspecies of cannabis, sativa 
and indica, as well as a number of varieties, though there is some discussion 
whether these subspecies may actually be separate species or not. It is thought 
that these two subspecies both originate from the plateaus of Central Asia, 
with sativa having been predominately found in Europe and indica in 
Indochina2.  
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Extensive cultivation of cannabis, since the development of agriculture over 
10,000 years ago, has lead to its ubiquitous presence throughout the inhabited 
world, both as a cultivated and feral plant2, 3. Cannabis is a versatile crop 
providing a source of food, medicine, fuel, oil, paper, building materials and 
textiles3.  
 
Hemp, the common name for cannabis used when referring to the whole plant, 
was, and still is, cultivated for its fibres and seeds and not for its psychoactive 
content, which is indeed very low when grown for industrial uses. There is 
evidence that ancient cultures used hemp as a textile for clothing, the seeds as 
a food source, and as an incense in funeral rites4. The first paper, possibly 
invented in China, was produced from hemp5. In Tudor England, hemp was so 
essential for the production of rope, needed in large supplies for the success of 
the navy, that Henry VIII issued a royal edict that all farmers should grow the 
plant or pay a fine5, 6. During the twentieth century, due to the introduction of 
national and international legislation controlling the use of cannabis and the 
introduction of synthetic materials, hemp was decreasingly cultivated for its 
practical uses. However, with the general growth of interest in natural and 
2 
organic products, hemp is increasingly being used for a wide variety of 
applications including in cosmetics, textiles and food, to name but a few7. 
 
Cannabis has also been used for a vast array of medicinal purposes for 
thousands of years. Though almost certainly used before, the first documented 
evidence of the medicinal use of cannabis was in the famous Chinese 
pharmacopoeia, the  (The Divine Farmer’s Materia 
Medica), written in the first or second century AD, which advocated its use to 
allay senility and as a surgical anaesthetic4. The Egyptians are thought to have 
used cannabis as a suppository to stimulate vaginal contractions, it was used 
by the Persians as an analgesic4 and by the Romans as a method of 
contraception6. In the last millennium Europeans and Americans have 
continued to use cannabis for applications described by the classical 
civilisations, and have also used it for the treatment of other conditions 
including jaundice, gout and as an anti-anorexic.  
 
During the twentieth century, legislation quickly turned against the use of 
cannabis, for reasons described in Section 1.2.3. Doctors in the UK could 
legally prescribe cannabis up until when it was reclassified under the Misuse 
of Drugs Act 1971, which effectively implied that cannabis had no medicinal 
value, contrary to thousands of years of experience4. Cannabis is still used 
illegally by many individuals to treat such conditions as neuropathic pain and 
glaucoma, despite the risk of prosecution in many countries across the world8, 
9. For a detailed insight into the evidence for the extensive history of the 
medicinal uses of cannabis see the work of Russo2, 4. 
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There are over 60 terpenoid compounds known as the natural cannabinoids, 
found exclusively in cannabis, the major source being found in the leaves and 
the female flower. Why the plant produces such an array of cannabinoids is not 
clear, but there are suggestions that they act as antioxidants and as 
antimicrobials. Cannabis also contains many other natural products thought to 
3 
be of biological and medicinal interest including terpenes, flavonoids and 
carotenoids3.  
 
(-)-∆9-tetrahydrocannabinol (THC) $ (Figure 1.1) was first identified as the 
major active component of cannabis, and in particular of hashish (the active 
resin of the female flowering top of cannabis), in 196410. Its absolute 
stereochemistry was determined in 196711. Other important cannabinoids 
include ∆8- tetrahydrocannabinol  and cannabinol '12, and it is the mixture of 
these natural cannabinoids and other natural products that gives cannabis its 
physiological and psychological effects13. 




	
	






 
  
Figure 1.1 Structures of some natural cannabinoids. 
 
With the isolation of the natural cannabinoids, and an interest in their 
therapeutic effects, a significant amount of research was attempted in trying to 
improve these molecules. This has led to a vast array of structurally similar 
compounds which has helped to develop our knowledge on the important 
cannabinoid structure activity relationships14. It was not until the discovery of 
the cannabinoid receptors (Section 1.2), their endogenous ligands (Section 
1.4.1), and the development of novel cannabinoid ligands and pharmacophores 
(Section 1.4) that our understanding of the cannabinoid system really 
advanced. 
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Before the discovery of the cannabinoid receptors, all research into the activity 
of natural and synthetic cannabinoids involved use of 

 animal models, 
with all their associated disadvantages. The identification of the membrane 
bound G-protein coupled receptors or guanosine binding protein coupled 
receptors (GPCRs) CB1 in 1988
15 and CB2 in 1993
16 was a major breakthrough 
in cannabinoid research. This section will offer a brief overview of the 
characterisation and pharmacology of the two known cannabinoid receptors. 
For an excellent and detailed recent review on this area see work by Howlett 
AC 17. 
 
The two receptors, both with the characteristic seven transmembrane α–helix 
domain structure of all GPCRs (Figure 1.2), are distinguished by their 
differences in amino acid sequence, tissue distribution and function17. CB1 and 
CB2 receptors have an overall amino acid sequence homology of 44% and in 
the transmembrane α–helix domains this rises to 68%16, 18. CB1 rat, mouse and 
human receptors have been cloned and show a higher cross species sequence 
homology (97-99%) than that of cloned CB2 mouse and human receptors 
(82%)17, 19, 20. 

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The GPCR super family are generally found imbedded in the cellular 
phospholipid membrane. These proteins comprise of seven α-helixes that span 
the phospholipid membrane in a cylinder like conformation, and are connected 
by a total of three intra-cellular and three extra-cellular loops. The GPCR 
position within the phospholipid membrane provides both opportunities and 
difficulties for their investigation. As the receptors are designed to interact 
with ligands at the extracellular side of the membrane, investigation of ligand 
affinity and efficacy can be assessed in whole cell populations. If the receptor 
was internalised, as found with steroid receptors, any investigation into 
receptor-ligand binding would need to overcome the problems of introducing 
the ligand into the intracellular compartment. On the other hand, direct 
5 
investigation of the GPCR structure itself is made very difficult because its 
structure is designed to reside within the phospholipid membrane bilayer, with 
therefore a varying hydrophobic and hydrophilic nature across the 
macromolecule. GPCRs therefore have poor solubility in both organic and 
aqueous solvents, making their isolation, purification and crystallisation 
difficult. Standard methods of whole protein analysis such as X-
crystallography and nuclear magnetic resonance are extremely difficult to 
achieve with the cannabinoids receptors, as with all GPCRs. 

 
Figure 1.2 A cartoon description of a GPCR receptor. Purple cylinders represent α–helix 
transmembrane domains; black lines represent intra and extracellular loops; red ellipse 
represents bound ligand. 
 
Until recently all GPCR modelling studies were based on homology modelling 
from rhodopsin, a ubiquitous protein important for the detection of light. 
Homology modelling involves using a known crystal structure of a GPCR, 
aligning the desired sequence in the transmembrane α-helix domains using 
such methods as FASTA21 or BLAST22, mutating residues, addition of 
extracellular and intracellular loops from structural databases and energy 
minimisation using molecular mechanics leading to the ultimate validation of 
6 
the designed model. For detail on this process see Leach’s in depth work23 and 
the step by step guide by Oliveira 24. 
 
Such modelling began using the crystal structure of bacteriorhodopsin25, 26, 
which is not considered a true GPCR as it is not associated with a G-protein, 
and so the subsequent determination of the crystal structure of bovine 
rhodopsin was a major breakthrough27, 28. It has been commented that although 
bacteriorhodopsin homology modelling leads to good general GPCR 
conformation, it is not so suitable for rational drug design, and hence has been 
superseded by bovine rhodopsin homology models29.  
 
Recently the publication of a high resolution crystal structure of a ligand 
bound, antibody tagged, β2-adrenoceptor, grown in a lipid medium has been 
elucidated30-32. In detail, the β2-adrenoceptor was expressed in Sf9 insect cells, 
whose membrane was suitably solublised and purified by a range of processes 
including antibody chromatography. Once purified a β2-adrenoceptor Fab (a 
fragment of the antigen binding region that was cloned that could bind to the 
third intracellular loop of the receptor) was formed and isolated. Crystals were 
then grown from a mix of the β2-adrenoceptor Fab complex, bound to the 
inverse agonist carazolol, in a bicelle medium over seven to ten days. 
Diffraction images obtained by microcrystallography were of high resolution 
(3.4Å within plane and 3.7Å perpendicular to plane of membrane) allowing 
residue identification of the complex, even with the Fab component present. 
This work, as well as the possibility of using solid state nuclear magnetic 
resonance techniques to analyse isotopically labelled proteins in their 
membranes33, leads to hopes that similar methods may be utilised for other 
GPCRs, helping to validate existing models and lead to the development of 
improved receptor understanding, though significant hurdles still need to be 
overcome34. 
 
The main reason for interest in the GPCR structure is because minor changes 
in structure can greatly affect how a GPCR ligand interacts with its receptor. 
GPCR ligands bind in a receptor active site somewhere within the cylinder like 
structure, formed by the seven transmembrane spanning α-helixes, at varying 
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depths depending on the GPCR. Though the active site is generally composed 
of amino acid residues from the α-helixes, the three extracellular loops can 
play a role in both ligand binding and in restricting access to the receptor 
active site35. 
 
When a ligand binds to a GPCR it causes a cascade of events, whereby the 
conformation of the GPCR structure is altered, which affects various 
interactions with intracellular bound proteins. The G-protein coupled receptors 
are named so, as their intracellular bound protein is a heterotrimeric G-protein, 
made up of three different subunits (α, β, and γ). On the binding of a GPCR 
agonist, the resulting conformational change leads to the release of the G-
protein. Once released from the GPCR, the G-protein α subunit changes 
conformation allowing binding of guanosine triphosphate (GTP) and 
displacement of guanosine diphosphate (GDP). This allows the βγ complex 
and α subunit to separate, and leads to various effects depending on their type.  
 
There are a number of different α, β, and γ subunits available, with different 
cell types having different distributions, and the effects of the GPCR are 
related to what G-proteins are available in the cell, as well as which G-proteins 
it can couple with. In the case of both cannabinoid receptors, they interact with 
the Gi/o protein
17, and on activation leads to the release of both the αi/o subunit 
and less variable βγ complex. Due to the intrinsic GTPase activity of the α 
subunit, it has a limited activated life span before dephosphorylation reforms 
the deactivated α subunit – GDP complex and a complete G-protein is 
reformed with the βγ complex. Activation of the cannabinoid receptor leads 
the activated αi/o subunit, via inhibition of adenylate cyclase, and βγ complex, 
via activation of mitogen-activated protein and phospholipase C, resulting in 
signal transduction (Figure 1.3). In the case of the CB1 receptor, the αi/o 
subunit is also involved in various ion channels e.g. positively to inwardly 
rectifying potassium channels and negatively to calcium channels17, 36. 
Generally the effect of the activated Gi/o protein is to induce a chemical brake 
to the cell. This is particularly due to inhibition of adenylate cyclase, which 
decreases the production of cyclic adenylate monophophate which is essential 
for direct or indirect activation of numerous cellular proteins. Depending on 
8 
the location and role of the specific cell, its effects may be inhibitory or 
excitatory on the physiology of interest. 
 
 
Figure 1.3 A cartoon description of the cascade effect on activation of a GPCR receptor 
coupled to a Gi/o protein. Agonist (red circle) binding to the GPCR receptor (purple), causes 
dissociation and activation of the activated αi/o-subunit (green) from βγ-subunit (orange), 
leading to signal transduction. 
 
Other factors affecting signal transduction, are that activation of a GPCR can 
lead to activation of more than one G-protein, contributing to signal 
amplification, but excess activation of GPCRs can lead to their cellular 
internalisation and desensitisation37. Furthermore, some GPCRs, including the 
cannabinoid receptors, are likely to have a degree of constitutive activity even 
without the presence of ligands, as some antagonists can actually act as inverse 
agonists reducing cellular responses below basal levels17. GPCR effects, like 
most physiological systems, are sensitive to numerous variables and are 
controlled by multiple negative feedback processes. 

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The CB1 receptor is mainly distributed in the central nervous system e.g. brain 
and spinal cord, as well as some peripheral tissues e.g. reproductive and 
gastrointestinal systems. Its central distribution is not homogenous and is most 
densely located in the cerebellum, basal ganglia, hippocampus, and the 
cerebral cortex17. Its pharmacological action causes alteration of 
neurotransmission by inhibition of the release of excitatory and inhibitory 
neurotransmitters e.g. acetylcholine, noradrenaline, serotonin, glutamate, γ-
aminobutyric acid and dopamine17, 20. The CB2 receptor is mainly distributed 
in the immune system e.g. spleen and lymph glands, as well as in some parts of 
9 
the nervous system38. Its pharmacological action results in regulation of 
cytokine release in both physiological and pathological states, and affects 
immune cells, either directly or indirectly, e.g. macrophages, natural killer 
cells and other T-lymphocytes17, 20. 
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The cannabinoid receptors offer a range of therapeutic opportunities. Cannabis 
has shown itself to be potentially one of the most versatile herbal medicinal 
products available to mankind, with applications in pain and inflammation, 
nausea and vomiting, anorexia, anxiety, depression, psychosis, substance 
dependence, muscle spasticity, epilepsy, glaucoma and neuroprotection39-41. 
Although cannabis is generally well tolerated, and overdose is unlikely to be 
associated with toxicity, this herbal product is harshly controlled when 
compared with another psychoactive medicinal product, alcohol, or with 
tobacco which is significantly more toxic than cannabis in the long term. It is 
due to its place in history that cannabis is somewhat of an oddity as an illegal 
drug. 
 
Throughout civilisation, attempts have been made to restrict or ban cannabis as 
a recreational drug, but such attempts failed up until the 20th century4. During 
this time of industrialised labour, the smoking of cannabis was said to be a 
social evil as it decreased productivity of the workers. Another herbal 
medicine at the time that was also causing concern was opium. In the western 
world its overuse as a pain killer resulted in middle class addicts. Though, 
restriction of opium eventually occurred, due to cannabis being used 
predominately by the working class, and the relevant authorities seeing little to 
no medicinal use for it, a rush of legislation, led by the U.S., saw the 
criminalisation of cannabis across the world. This criminalisation of cannabis, 
which still applies to the vast majority of developed countries, is not only 
relevant to its recreational use, but to all medicinal uses as well42. 
 
Ironically, since its criminalisation, interest and research in the medicinal use 
of cannabis has steadily grown. In the U.K. this led a Royal College of 
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Physicians working party in 2005 to support the development of oral or other 
alternative delivery system cannabis products for a number of therapeutic 
uses43, and the establishment of GW Pharmaceuticals in 1998, which is 
currently in extensive human trials of a cannabis oral spray Sativex® for the 
treatment of chronic pain in multiple sclerosis44. It is hoped that these 
developments will soon lead to declassification of cannabis Schedule 1 
Controlled Drug in the U.K., allowing doctors to again prescribe cannabis for 
medicinal purposes42.  
 
The main hurdle to the therapeutic use of cannabis is the public and authorities 
concern of its psychoactive effects. This is particularly the case, as a 
systematic review of the literature shows that cannabis use does increase the 
chance of developing psychoses45. With the identification of the two 
cannabinoid receptors, it became possible to isolate which receptor is 
responsible for which effects. It was unsurprising that the activation of the 
centrally located CB1 receptors was responsible for the undesired central 
effects. Of course some of CB1 receptor activated central affects have 
therapeutic potential themselves e.g. in anxiety, anorexia, depression and 
nausea and vomiting17. Nevertheless, the targeting of the CB2 receptor and 
preparation of CB2 receptor selective ligands, would remove the largest hurdle 
to the use of cannabinoids – the removal of the CB1 receptor mediated 
psychoactive effects that mean it can both be abused and lead to long term 
psychiatric problems.  
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The CB2 receptor is implicated in the therapy of numerous disease states, 
including most notably in pain, multiple sclerosis, and for its use as an 
immunosuppressant and anti-inflammatory agent.  
 
$&'&$&*
It was previously thought that the analgesic effects of cannabis was mediated 
by the CB1 receptor, but evidence that a selective CB2 receptor agonist 
provides analgesia in a neuropathic pain model in mice46, 47, and that a 
selective CB2 receptor antagonist blocks the analgesia
47, meant that the CB2 
receptor was a potential therapeutic target for peripheral and neuropathic pain. 
It is still unknown as to the mechanism of this analgesia, though the possible 
presence of CB2 receptors on peripheral neurons may suggest a locally 
mediated effect. It is generally accepted that the CB2 receptor is likely to be 
modulating pain as a local level, possibly involving inhibition of the immune 
system. For a comprehensive review of the possible mechanism, as well as 
CB2 receptor agonist evaluated in pain models, see the work of Whiteside 

48. With neuropathic pain and injury often resistant to treatment, CB2 
receptor selective agonists offer another valuable therapeutic option48. 
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Cannabis is thought to have a number of applications in treatment of multiple 
sclerosis, especially for the control of spasticity, pain, tremor and bladder 
function. Multiple sclerosis is a complicated disease, but at a simple level, all 
these problems are associated with impaired neural transmission and control. 
The cannabinoid system is thought be in important in the inhibition of synaptic 
transmission, and therefore its activation improves neural control49. As 
commented upon in Section 1.2.3, GW pharmaceuticals are currently have 
their cannabis preparation Sativa® in human trials for the treatment of multiple 
sclerosis. 
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With respect to the CB2 receptor, muscle spasticity in multiple sclerosis 
models is decreased with use of a selective CB2 receptor agonist and increased 
with the selective CB2 receptor antagonist SR144528 $
50. In another study the 
CB2 receptor selective agonist JWH-015 , significantly improved neurological 
defects51. Multiple sclerosis is a disease that cannabis shows great promise for, 
with at least some of its effects appearing to be mediated by the CB2 receptor. 
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Due to their location, CB2 receptors are thought to be important in 
immunomodulation and there is evidence that the cannabinoid receptor agonist 
CP55-940 - causes immunosuppression, and increasing susceptibility to the 
herpes simplex virus in mice52. An aggressive glioma tumour has been shown 
to have a positive correlation with CB2 receptor expression and its severity, 
and inhibition of the tumour can be achieved with a selective CB2 receptor 
agonist53. Furthermore administration of the selective CB2 receptor agonist 
JWH-015 , has been shown to induce apoptosis 

of thymocytes, leading 
to decrease T-cell response to mitogens. This suggests that CB2 receptor 
selective ligands may be used as immunosuppressive therapy e.g. in 
rheumatoid arthritis, Crohn’s disease, organ or bone marrow transplant 
patients, or at lower doses as an anti-inflammatory. 
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A vast array of natural cannabinoids have been identified and synthetic 
cannabinoids designed and evaluated. Khanolkar 54 divided the 
cannabinoids into six main classes and each which will discussed in more 
detail below (Figure 1.4). Over the last decade there has been the development 
of numerous other cannabinoid structures both similar and quite different from 
the six main classes discussed below, see the review of Padgett for more 
details55. 
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Figure 1.4 Examples of the main six cannabinoid ligand types. 
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The discovery of the endogenous ligands for the cannabinoid receptors 
identified two new structurally similar types of cannabinoid ligand with the 
prototypical anandamide . of the arachidonoylethanolamides56, 57 and 2-
arachidonyl glycerol (2-AG) /of the arachidonoylglycerols58, amongst 
others17, having helped to give a greater understanding of the physiological 
role of the cannabinoid receptors in the body. Their biosynthetic routes have 
been extensively investigated59 and their metabolism by the enzymes fatty acid 
amide hydrolase and monoacylglycerol lipase, as well as proposed membrane 
transportation protein, anandamide transporter, have been described54, 59, 60. 
14 
 
All of the endocannabinoids ligands have affinity for both cannabinoid 
receptors with a degree of selectivity for the CB1 receptor
17. Work has focused 
on increasing this selectivity for CB1 receptor, and the synthesis of several 
chiral methylated arachidonoylethanolamides 0 and $1 potentially highlighting 
a CB1 receptor hydrophobic sub-site (Figure 1.5)
61. 
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Figure 1.5 Examples of synthetic arachidonoylethanolamide cannabinoids. Receptor binding 
affinities (Ki) quoted61. 

With an increasing knowledge of this endocannabinoid system, further studies 
might be able to elucidate the roles of this system and the cannabinoid 
receptors in physiological and pathological states. The development of fatty 
acid amide hydrolase enzyme inhibitors as well as anandamide transporter 
inhibitors will aid this study62. 
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
Classical cannabinoids are based upon the structure of natural cannabinoids 
detailed in Section 1.1.2, and in particular of THC $. They retain the tricyclic 
dibenzopyran structure, with investigation limited to alteration of functional 
groups and side chains. For example, the introduction of the northern aliphatic 
hydroxyl at the C9 position, which leads to increased activity, and removal of 
the C9 double bond, which is not essential for activity, led to 9-nor-9-
hydroxyhexahydrocannabinol $$63 (Figure 1.6). Optimisation of the alkyl side 
chain to the 1,1-dimethylheptyl group has led to dimthylhepyl-HHC $62 and 
HU-210 $'17, 36, the latter having binding at both the CB1 and CB2 receptors in 
the sub-nanomolar range.  

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Figure 1.6 Examples of synthetic classical cannabinoids. 
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The discovery that the pyran ring of classical cannabinoids was not required 
for cannabinoid activity was first seen with the synthesis of CP47-497 $.64 
leading to the development of non-classical cannabinoids by Pfizer (Figure 
1.7). Further refinement led to the introduction of an additional pharmacophore 
to that of classical cannabinoids, the C12 southern aliphatic hydroxyl e.g.  
CP55-940 - with binding at the CB1 and CB2 receptors in the sub-nanomolar 
range65. Tricyclic derivatives have also been developed e.g. CP55-244 $-66, 
whereby the C12 southern aliphatic hydroxyl is locked into a set conformation, 
theoretically decreasing the entropy of binding. 
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Figure 1.7 Examples of non-classical cannabinoids. 
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To take advantage of this new C12 southern aliphatic hydroxyl pharmacophore 
in the tricyclic classical cannabinoids, a number hybrids were developed e.g. 
AM919 $/67 (Figure 1.8). Further development of the C12 southern aliphatic 
side chain has led to some degree of CB1 receptor selectivity with AM938 $, 
and CB2 receptor selectivity with $3
68, 69. 
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Figure 1.8 Examples of classical / non-classical cannabinoid hybrids. 

A more detailed review of the important structure activity relationship for the 
classical and non-classical cannabinoid pharmacophores is presented in 
Chapter 4, as well as the more detail on alterations that lead to CB2 receptor 
selectivity. 

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The alkylindole cannabinoids were developed by a Sterling Winthrop group 
during research into new non-steroidal anti-inflammatory agents70, and they 
are not based on the any previously known cannabinoid structures. They 
include both the prototypical WIN-55212 $071, which has a small degree of 
CB2 receptor selectivity, and other more selective CB2 receptor agonists e.g. 
JWH-015 , (Figure 1.9)72. Evidence suggests that the alkylindoles bind at a 
sub-site lower in the cannabinoid receptor active site but overlapping with the 
classical cannabinoid sub-site, allowing mutual displacement36. 
17 
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Figure 1.9 Examples of alkylindole cannabinoids. 

As with the classical and non-classical cannabinoids, a more detailed review of 
the important structure activity relationships and alterations that lead to CB2 
receptor selectivity are presented in Chapter 2. 

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The first cannabinoid receptor antagonists were developed by Sanofi and are 
based on a diarylpyrazole structure. They include both the highly selective CB1 
receptor antagonists e.g. SR-141716A 173, 74, as well as highly selective CB2 
receptor antagonists e.g. SR-144528 $75, and there is great interest in their 
development both as biomolecular tools and potential therapeutic agents 
(Figure 1.10)36, 76. It is currently thought that the diarylpyrazoles act at the 
same binding site as the cannabinoid agonists discussed above, though 
interacting with different amino acid residues, and not at an allosteric binding 
site36. 
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Figure 1.10 Examples of diarylpyrazole cannabinoids.  
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Fluorescence is the property of certain molecules to absorb electromagnetic 
radiation, normally ultraviolet (UV) or visible light, at a discrete wavelength 
and then emit radiation of a longer wavelength (lower energy), with the 
fluorescence persisting only as long as the stimulating radiation is continued77. 
For example the green fluorescent protein, that is used extensively for 
visualisation of expressed protein in molecular biology, absorbs UV light at 
398 nm and emits green light at 508 nm78.  
 
Fluorescence occurs in three steps (Figure 1.11). First, absorption of a photon 
raises an electron from its ground state (S0) to an excited singlet state (S1) with 
a variety of vibrational levels. This may be followed by small loses of energy 
by non-radiation pathways, moving the electron to a lower vibrational level. 
Finally the electron emits its energy in the form of electromagnetic radiation, 
as it returns to its ground state (S0), the whole process occurring over 10
-8 s. 
The loss of energy between excitation of the electron and emission of 
radiation, leads to a longer wavelength of radiation being emitted than is 
absorbed, and this change in wavelength is called the red or Stokes shift. 
 
 
Figure 1.11 Excitation and emission of fluorescent molecules.  
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Competing with this fluorescence are a number of other processes that can 
interfere, causing quenching of the desired fluorescence79. Internal conversion 
occurs when energy is transferred from the S1 level of one molecule to the S1 
level of another molecule of the same compound. This process can take place 
over relatively long distances and so can occur when the fluorescent 
compound is in solution. Intersystem crossing involves the formation of a 
triplet state, where there is an alteration of the direction of spin of the S1 
electron. This spin state has a much longer life time than normal, and means 
that its energy will likely be lost through non-radiative pathways and lead to 
fluorescence quenching. Finally photobleaching can occur if a high energy 
excitation light source such as a laser is used, which can initiate a free radical 
mediated chemical reaction. This not only quenches the fluorescence but more 
importantly degrades the fluorophore. The fluorescent efficiency of a 
compound is measured as quantum yield i.e. the proportion of fluorescence 
photon emissions compared to the number of photons absorbed by the system. 
The greater the fluorescence quenching the lower the quantum yield. 
Knowledge of the importance of these competing processes and the quantum 
yields in various environments for different fluorophores, can be important for 
choosing the right fluorophore for a specific application.  
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Fluorescent labelled small molecules, specifically GPCR ligands, have three 
main uses; high-throughput screening, fluorescent confocal microscopy and 
small molecule detection techniques. Potentially they could also be used in 
bioassays to determine the presence of a particular receptor. If the presence of 
that receptor was a marker of a specific pathophysiology, then such a 
technique would have use as a diagnostic tool. 
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Fluorescently labelled GPCR ligands are a valuable tool for drug discovery, 
especially when used in high-throughput screening (HTS). Generally HTS are 
performed with radiolabelled ligands, which require both the use of significant 
volumes of scintillation fluid for processing and additional costs for the 
20 
disposal of radioactive waste. Any fluorescent-based HTS assays would enable 
screening of new lead compounds from libraries of hundreds to millions of 
compounds, which would be faster, cheaper and avoid the use of radioactive 
materials. Whereas radioligand assays requires filtration of the GPCR bound 
ligand and then addition of scintillation fluid to allow counting of radiation 
present, use of fluorescent ligands only need to be filtered before a measure of 
the remaining fluorescence need be taken. Fluorescent-based HTS assays can 
be combined with confocal and small molecule techniques, detailed below, to 
allow miniaturisation of the assay and allow for quick analysis at small 
volumes80. 
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Confocal microscopy with fluorescent labelled ligands allows visualisation 

 of receptor binding and can be used to identify receptor localisation, 
density and internalization in three dimensions, as well as following its 
progress over time. Confocal microscopy offers the advantage over 
conventional light microscopy, in that it can allow identification within a 
single cell of the location of a fluorescent ligand receptor complex, and may 
change how we approach experimental pharmacology81. When designing 
fluorescent ligands for confocal applications the large excitation energies that 
must be used, can increase photobleaching and therefore fluorescence 
quenching, with not all fluorophores suitable79. 
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Single molecule detection covers a number of techniques that detect bursts of 
fluorescence, meaning that they are capable of monitoring systems with a 
small volume and hence small concentrations of fluorescent ligand. Such 
techniques reduce the use of potentially expensive and difficult to synthesise 
materials. 
 
One of the most important small molecule detection techniques is fluorescence 
correlation spectroscopy. It is minimally invasive and allows with high 
temporal and spatial resolution the study of dynamic processes in biological 
systems, both in vitro and in vivo. For a ligand GPCR interaction, it would 
21 
give a highly accurate picture of their location and reaction to binding. 
Fluorescence correlation spectroscopy is an ever growing field, for an 
overview of current developments see Haustein and Schwille’s review82.  
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A number of fluorescent ligands have been prepared for a variety of GPCRs, 
including for the α and β-adrenoceptors, nicotinic, opiod, and histamine 
receptors77, 81. Our research group has also been developing fluorescent ligands 
for example for the A1-adenosine receptor
83. If a fluorescent GPCR ligand with 
suitable affinity can be prepared, then it is an extremely valuable biomolecular 
tool, not only for the use in HTS but also in other techniques mentioned above 
to help improve our knowledge of the location and properties of the GPCR 
itself. 
 
There have been two previous attempts to prepare a fluorescent cannabinoid 
receptor ligand. The first was by fluorescein labelling anandamide  (Figure 
1.12), which had no detectable CB1 receptor binding affinity, though it is taken 
up by anandamide transporter system and can be used to track the cellular re-
uptake of anandamide .84. The other work was by our group using homology 
modelling led design. A fluorescently labelled aminoalkyl analogue .was 
found to have a very small amount CB2 binding affinity
85, detailed in Section 
2.1. Other fluorescent cannabinoids were based on a novel cannabinoid 
structures known as Japan Tobacco ligands. A dansyl attached analogue 'is 
shown, with all of the series having no affinity for the CB2 receptor
86. This 
means there is still an interest in developing a fluorescently labelled CB2 
receptor ligand. 
22 
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Figure 1.12 Structures of previously synthesised fluorescent cannabinoids.  
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The ultimate aim of this research is to design, synthesise and evaluate a 
fluorescent CB2 receptor ligand, primarily for use as a molecular tool in HTS 
or single molecule detection techniques.  
 
A suitable starting ligand needs to be chosen and sites for fluorophore ligation 
investigated. Such a starting ligand will have high affinity for the CB2 receptor 
and well understood structure activity relationships. Choosing a site for 
fluorophore ligation will be aided by published structure activity relationships, 
homology modelling and mutagenesis studies, as well as our own site specific 
investigations on whether a fluorophore could be accommodated at that site. 
 
$&/&78*
· To determine suitable starting cannabinoids for fluorophore ligation. 
· To review the published structure activity relationships, homology 
modelling and mutagenesis studies to identify suitable sites for 
fluorophore ligation. 
· To design, synthesise and evaluate novel cannabinoid ligands to help 
confirm a site’s suitability for fluorophore ligation. 
· To design, synthesise and evaluate novel fluorescently labelled 
cannabinoids at the CB2 receptor. 
· To use the developed structure activity relationship to develop a second 
generation of novel fluorescently labelled cannabinoids. 
· To evaluate the most promising fluorescently labelled cannabinoids in 
fluorescent based 
 assays and small molecule detection 
techniques. 
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This chapter describes the design, synthesis and pharmacology of indole 
cannabinoid analogues for the CB2 receptor. The main aim of this chapter is to 
study various substitutions to the indole cannabinoid scaffold and to identify 
possible sites for fluorophore ligation. 
 
Previous work by our group using homology modelling led design resulted in 
the synthesis and evaluation of 3-(3-[-(7-nitrobenz-2-oxa-1,3-diazol-4-
ylglycylamino naphthoyl)-2-methyl-1--propylindole . (Figure 2.1) based on 
a 3-naphthyl substitution to JWH-015 ,. This work was only partially 
successful with . displacing 25% of [3H]CP55-940 -at 10 µM85, 86. 
 
















 
Figure 2.1 Fluorescent indole cannabinoid .. 
 
In this chapter we continue the investigation of JWH-015 , substitutions to 
help determine suitable sites for fluorophore ligation. CB2 receptor affinity and 
not activity is the primary endpoint, as the desired fluorescent cannabinoid will 
have use as a molecular tool to further our knowledge of the CB2 receptor and 
in high throughput screening assays to identify new cannabinoids. 
25 
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An ideal ligand for the development of a selective CB2 fluorescent ligand will 
possess the following: 
· High affinity for the CB2 receptor. 
· High CB2 to CB1 selectivity or potential for modifications leading to 
CB2 selectivity. 
· Good understanding of the ligand’s pharmacophore and structure 
activity relationships. 
· Suitable sites for fluorophore ligation, as well as the length and type of 
linker required. 
 
JWH-015 , meets three of these four criteria. It has the desired pharmacology 
with a CB2 receptor Ki = 13.8 nM, and a CB2/CB1 selectivity of 24.3
87, with a 
wealth of knowledge on substitutions that increase or decrease this 
selectivity88, 89. There is also an excellent understanding of the important 
pharmacophores and structure activity relationships for JWH-015 ,, which is 
detailed in Section 2.2.1. What is currently lacking are detailed studies into 
suitable sites for fluorophore ligation, with our own group’s work being the 
sole attempt in such coupling to indole cannabinoids85, 86. 
 
Furthermore, while dealing with cannabinoids in the UK, the legal 
requirements as laid out in the Misuse of Drugs Act 1971 need to be followed 
as only cannabis, its extracts and natural cannabinoids, in particular THC $ and 
cannabinol and their derivatives are currently subject to the act; indole 
cannabinoids can be synthesised without license90.  
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The indole class of cannabinoids were first discovered by the Sterling-
Winthrop group with pravadoline - (Figure 2.2), while trying to create a new 
non-steroidal anti-inflammatory drug70. Conformationally restrained analogues 
of pravadoline led to aminoalkylindole WIN51522-2 $0, with decreased non-
steroidal anti-inflammatory but increased cannabinoid activity71. It was soon 
26 
realised that a morpholino or other cyclic groups were not needed for 
activity91, and that a simple unbranched alkyl chain produced good CB1 and 
CB2 receptor affinities with JWH-015 (n=2) ,
87 and JWH-007 (n=4) / 
respectively91. 
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Figure 2.2 Examples of indole cannabinoids. Receptor binding affinities (Ki) quoted
92. 
 
An aminoalkyl chain is required for activity at both the CB1 and CB2 receptors, 
with -methyl and -ethyl chain analogues showing very poor affinity. -
Propyl to -hexyl chains lead to good affinity at both receptors, with the -
pentyl chain giving greatest affinity87. Extension beyond a -hexyl chain leads 
to loss of affinity87, which draws comparison to the C3 alkyl chain side 
extension in classical and non-classical cannabinoids, whereby beyond a 
certain point affinity is gradually lost93. Though CB2 receptor affinity is 
greatest in -pentyl analogues, CB2 receptor selectivity is found to be greatest 
in -propyl analogues whilst still retaining good affinity87. 
 
2-Methylindole analogues with no substitution on the naphthyl ring e.g. JWH-
015 ,, generally have increased affinity for both receptors compared to 
unmethylated analogues e.g. JWH-072 ,, and also induce a modest degree of 
CB2 receptor selectivity. Extending the 2-alkylindole chain further leads to 
loss of CB2 receptor selectivity, as well as significant loss of activity at both 
receptors87. Greatest CB2 selectivity is found with the 2-methyl -propyl 
analogues e.g. JWH-015 ,94. 
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Studies have also investigated whether the indole could be reduced to a pyrrole 
ring. Initially it was found that such alterations led to significant loss of 
activity and the complete indole structure was thought to be required for 
cannabinoid binding91. However, both with the development of the pyrazole 
cannabinoid antagonists SR-141716A 195 and SR-144528 75 (Section 
1.4.5), as well as investigation by Huffman  of various -pentyl-4-
substituted pyrroles 3 (Figure 2.3), good affinity for both the CB1 and CB2 
receptors is not reliant on the indole ring96. It has been suggested that these 
aromatic substitutions investigated by Huffman , and hence also the 
complete indole, improve receptor binding through aromatic stacking 
interactions and are important for high affinity for both the CB1 and CB2 
receptors. 
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Figure 2.3 Examples of pyrrole cannabinoids. Receptor binding affinities (Ki) quoted
96. 
 
A number of groups have studied the effect of varying the 3-indole substituent, 
and have found that a variety of aromatic groups are tolerated including the 3-
para-anisoyl97, 3-phenylacetyl92 and morpholinylacetyl ring systems98. Unlike 
the indole ring system, the 3-indole substituent does not have to be aromatic in 
nature, with the recently developed 3-yl-tetramethylcyclopropylketones 0 
having good affinity for the CB1 and CB2 receptors if the indole ring is 
unsubstituted99 (Figure 2.4), suggesting that the 3-indole may not be 
interacting by an aromatic stacking mechanism.  
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Figure 2.4 Examples of 3-yl-tetramethylcyclopropylketone indole cannabinoids. Receptor 
binding affinities (Ki) quoted
99. 
 
Finally, a few studies have looked at whether substitution at the 4, 5, 6 and 7-
indole positions can modify cannabinoid receptor selectivity98. In particular, 
the series of 3-yl-tetramethylcyclopropyl ketones 0 showed thathydrophobic 
substitutions at the 4 and 5-indole position can induce significant CB2 receptor 
selectivity without a large loss of CB2 receptor binding
99. The same research 
shows though that it is difficult to predict which substitutions produce these 
effects, especially with concurrent alteration of the -alklyl and 2-indole 
positions. For example, a 5-benzyloxy substitution of the indole '1 would 
appear to be ideal for high CB2 affinity and selectivity, but the same 
substitution in the conservative -morpholino-ethyl analogue '$ leads to a 
drastic loss of affinity for both receptors (Figure 2.5). There is certainly 
potential for significant modification of the indole ring to increase CB2 
receptor selectivity without undue loss of affinity, but currently it is 
undetermined which substitutions will reliably achieve this goal. 
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Figure 2.5 3-yl-tetramethylcyclopropylketone indole cannabinoids with alteration of the -
alkyl group. Receptor binding affinities (Ki) quoted
99. 
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In summary this research shows; the importance of choosing the correct length 
-alkyl chain on cannabinoid receptor affinity and CB2 receptor selectivity; 
that a 2-methyl substitution can improve CB2 receptor selectivity; that an 
indole ring system is not required and can be replaced by a pyrrole with 
appropriate aromatic substitution; that only a hydrophobic group and not an 
aromatic one needs to be attached to the 3-indole position; and that various 
substitutions to the 4 and 5-indole positions can help increase CB2 receptor 
selectivity.  
 
In summary, JWH-015 and related indole cannabinoids interact with the CB2 
receptor mostly through the hydrophobic interactions of the indole, naphthyl 
and -alkyl and 2-indole side chains (Figure 2.6), offering limited possibilities 
for extensive substitution. Although it is thought that a number of these 
receptor interactions are via aromatic stacking (see Section 2.2.2), both the 
naphthyl and indole structures can be replaced with non-aromatic ring systems 
or substituted pyrroles respectively and still retain excellent binding affinities. 
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Figure 2.6 Main pharmacophores of JWH-015 and related indole cannabinoids. 
 
Since their development, the indole cannabinoids have been greatly studied 
and it is beyond the scope of this work to cover this in further detail. For an up 
to date review of the large number of different indole cannabinoids and their 
variants that have been evaluated please see the work of Manera 100. 
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A number of homology modelling studies have been carried out for both the 
CB1 and CB2 receptors, with WIN55212-2 $0 being used as the archetypical 
indole for such research. Due to a 44% homology between the CB1 and CB2 
receptors, raising to 68% if only the seven transmembrane α–helix domains are 
taken into account16, 18, CB1 homology models are not automatically relevant 
to the CB2 receptor. Furthermore, as noted above, homology modelling based 
on bacteriorhodopsin has been superseded, and therefore only CB2 models 
derived from the bovine rhodopsin crystal structure will be explored here.  
 
Amino acid residues are identified by transmembrane α-helix placement, with 
CB1 and CB2 sequences aligned at the most highly conserved residue in each 
α-helix, with this residue given a value of x.50 (where x is the helix number), 
and all other residues numbered accordingly, as devised by Ballesteros and 
Weinstein101. CB2 receptor amino acid residues are also identified by a 
sequence number as catalogued by Universal Protein Resource, UniProt 
Knowledgebase for the human CB2 receptor
102.  
 
CB1 receptor models have consistently shown that the aromatic groups of 
WIN55212-2 $0 are embedded in the receptor, with the indole and naphthyl 
ring systems interacting with the aromatic residues F3.36 and W5.43, and that 
the aromatic residues W6.48 and Y5.39 are also likely to be important36, 100. 
The CB2 receptor has a slightly different active site, and a translation of these 
results might not be appropriate, hence a number of groups have developed 
CB2 receptor homology directly from the bovine rhodopsin crystal structure.  
 
Xie  and Montero  have both published extensive work on the 
development of their model, but have as yet not published any results 
concerning the positioning of indole cannabinoids in the receptor binding 
site103-105.  
 
Salo , who have developed both CB1 and CB2 receptor models, used the 
CB2 receptor model for virtual screening for novel cannabinoids, using the 
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classical cannabinoid HU-210 $' as a reference ligand106. Again no 
alkylindole cannabinoid docking data is presented, and as the classical 
cannabinoids bind higher in the receptor than alkylindole the results are not 
useful36. 
 
Tuccinardi’s group and our own group’s work present the only published 
research for the docking of an alkylindole into a CB2 receptor homology model 
based directly on the structure on bovine rhodopsin. Tuccinardi’s group found 
that WIN55212-2 $0 had important interactions with the conserved 
F3.36(117), W5.43(194), W6.48(258) as found with the CB1 receptor, but that 
the unconserved F5.46(197) of the CB2 receptor is also likely to interact with 
WIN55212-2 $0 aromatic systems, possibly explaining its CB2 selectivity
107. 
These results were obtained by orientating the WIN55212-2 $0 with the 
naphthyl imbedded deep within the active site, and with a hydrophilic 
interaction between WIN55212-2 $0 morpholinic group and the unconserved 
S3.31(112) residue. Our own group’s work similarly found that the lowest 
energy minimisation was found with WIN55212-2 $0 naphthyl embedded 
within the active site85, 86. JWH-015 , and its analogues do not have this 
hydrophilic side chain, but instead similar sized straight chain alkyl chains and 
whether this one result is applicable to all alkylindoles is undetermined. It 
would suggest that if the naphthyl ring system was so embedded, that any 
substitution to the naphthyl ring would lead to rapid loss of binding, yet a 
number of analogues have proven this not to be the case (Section 2.2.4). 
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Extensive single-point mutation and chimeric studies have been carried out for 
both the CB1 and CB2 receptors. Like the cannabinoid receptor homology 
modelling detailed above, WIN55212-2 $0 is used as the archetypical indole 
cannabinoid for such studies, and due to a modest 68% homology between the 
two receptors in the transmembrane α–helix domains16, 18, CB1 receptor 
mutagenesis studies are not automatically relevant to the CB2 receptor. For a 
comprehensive list of both CB1 and CB2 receptor mutagenesis studies see the 
reviews by Manera 100 and Ortega-Gutierrez 108.  
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Mutagenesis studies have identified a number of amino acid residues, 
including D3.49(130)109, W4.50(158)110, W4.64(172)110, C174 (extra-cellular 
loop 2)111, C179 (extra-cellular loop 2)111 and Y7.53(299)112, that either 
maintain the correct conformation for binding of WIN55212-2 $0 or allow 
signal transduction to the CB2 receptor. These amino acids are thought to be 
too far away from the active site of the receptor for their mutation to directly 
affect binding, especially as they are essential for the binding of a number of 
cannabinoid ligand types and mutation will often abolish all binding.  
 
It has been found that the conserved aromatic amino acid residues F3.36, 
W5.43 and W6.48 are important for WIN55212-2 $0 CB1 binding with the 
F3.36A, W5.43A and W6.48A mutations leading to significant loss of 
activity113. The replacement of the aromatic phenylalanine or tryptophans with 
non-aromatic alanine backs up the modelling studies detailed above, that these 
residues are involved in aromatic stacking interactions in the cannabinoid 
active site, and that indole cannabinoid binding is in a higher pocket of the 
active site compared with classical cannabinoid ligands. Chimera studies have 
shown that the same 4th transmembrane helix to 5th transmembrane helix 
region is essential for WIN55212-2 $0 activity at the CB2 receptor
114, and that 
as the F3.36(117), W5.43(194) and W6.48(258) are conserved in both 
receptors, they are also the site for indole cannabinoid binding in the CB2 
receptor100, 113, 115. 
 
Another residue that has been identified as important for WIN55212-2 $0 CB2 
binding is Y5.39(191). A conservative mutation of Y5.39F produced only 
modest changes in CB1  and CB2 receptor activities for a number of ligands, 
whereas Y5.39I mutation led to complete loss of binding for WIN55212-2 $0
as well as non-classical cannabinoid CP55-940 -115. This leads to the 
possibility that this residue may also be important for indole cannabinoid 
binding via aromatic interactions, especially due to its proximity to the known 
active site115. 
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Finally, as WIN55212-2 $0 has been reported to be slightly selective for the 
CB2 (Ki 0.3 nM) over the CB1 receptor (Ki 1.9 nM)
116, a number of 
mutagenesis studies have investigated the amino acid residues that may be 
responsible for this  selectivity. In particular it has been found that the CB2 
receptor residues S3.31(112) and F5.46(197) compared with the CB1 receptor 
residues G3.31 and V5.46 may be responsible for this selectivity. F5.46V 
mutation of the CB2 receptor led to a 12 fold loss of WIN55212-2 $0 binding 
compared to wild type, while the opposite V5.46F mutation at the CB1 
receptor led to a 14 fold gain in binding, with neither mutation having any 
significant effect on binding of the classical cannabinoid HU-210 $', the non-
classical cannabinoid CP55-940 $0 or the endogenous cannabinoid 
anandamide .117. This suggests that F5.46 is part of the CB2 receptor active 
site for indole cannabinoids and probably important for its aromatic stacking 
interactions. 
 
S3.31G mutation of the CB2 receptor led to a three fold loss of WIN55212-2 
$0 binding118, while the opposite G3.31S mutation at the CB1 receptor led to a 
4 fold gain in binding119. The CB2 receptor mutagenesis study involved the 
double-point mutation K3.28A/S3.31G, which also led to the complete loss of 
binding of the classical cannabinoids THC $ and cannabinol , the non-
classical cannabinoid CP55-940 - and the endogenous cannabinoid 
anandamide ., as well as its more minor effect on the indole cannabinoids 
WIN-55212-2 $0 and JWH-015 ,. It is thought that this serine of the CB2 
receptor, though by no means essential, may improve indole cannabinoid 
binding through a hydrogen bonding interaction, helping to explain WIN-
55212-2 / selectivity for the CB2 receptor
119. Further evidence has been found 
in the 3D QSAR study which identified a possible H-bonding interaction in the 
CB2 receptor, absent in the CB1 receptor, between the carbonyl of the indole 
cannabinoid and a H-donor in the active site120. 
 
In similar vein to the homology modelling studies detailed above, mutagenesis 
studies have not offered any conclusive insight into the orientation of the 
indole cannabinoids within the CB2 receptor active site, and therefore can not 
help in identifying suitable sites for fluorophore ligation. It is thought that a H-
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bonding interaction available at S3.31(112) allows a degree of specificity for 
the CB2 receptor, though the likely H-bond donor, the carbonyl linker between 
e.g. the indole and naphthyl groups of JWH-015 ,, is present in the vast 
majority of indole cannabinoids, and does not offer an obvious method to 
improve selectivity. It might be that only the -morpholinic alkylindoles such 
as WIN55212-2 $0 can utilise this sub-site, and that S3.31(112) has no role in 
CB2 receptor selectivity for other alkylindoles. 
 
&&.	9:6)1$-
In Section 2.2.1 we noted that the -alkyl chain and 2-indole position will not 
tolerate excessive extension before complete loss of CB2 receptor binding. An 
indole or other aromatic structure is required for aromatic stacking interactions 
needed for cannabinoid binding, and currently the limited studies of 
substitutions of the 4, 5, 6, and 7-indole positions suggest a role for 
substitution at these positions in enhancing CB2 selectivity but not for 
fluorophore attachment. Furthermore, homology modelling and mutagenesis 
studies have been inconclusive as to the orientation of the indole cannabinoids 
within the active site. Therefore the primary candidate for fluorophore 
attachment is the naphthyl ring, and this is especially the case due to the 
substantial amount of work already completed on the effect of various 
substitutions. Here we review that work, and prioritise the naphthyl positions 
most suitable for study. 
 
Previous work by our group, and in particular Yates85, 86, identified by way of 
CB2 receptor homology modelling the 3-naphthyl position of JWH-015 , as a 
site where a small fluorophore could be attached via a short linker glycine. The 
final fluorescent compound . as well as the intermediates in its synthesis, 
were investigated for their CB2 receptor affinities (Table 2.1). 
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R substituent CB2 receptor Ki (nM) 
H (JWH-015) , 36 (lit. 13.887) 
NO2 143 
NH2 191 
NH-Gly 420 
NH-Gly-NBD 25% displacement at 10 µM 
Table 2.1 3-naphthyl substitutions to JWH-015 ,85, 86. 
 
These results show that increasing the steric bulk of the 3-naphthyl substitution 
leads to a loss of CB2 receptor affinity. Even so, the relatively bulky and 
hydrophilic R = NH-Gly analogue retains a degree of binding. If there was no 
room in the active site for any substitution at the 3-naphthyl position, one as 
relatively bulky as a glycine group would abolish binding affinity. 
Furthermore the original fluorescent ligand identified during Yates’s work as a 
potential compound that could fit into the active site, did not have a glycine 
linker. This linker had to be added to prevent quenching of the NBD 
fluorophore by the naphthyl ring system, and might be responsible for 
increasing the substitution size beyond what the CB2 receptor can easily 
accept85, 86. It could also be the case that the linker length is not sufficient to 
allow removal of the attached fluorophore from interfering with cannabinoid 
binding, where as a longer linker might. Therefore the 3-naphthyl is still a 
promising candidate for investigation, especially as no other published 
research has been carried out on substitution at this position. 
 
One other group has looked at the effect on naphthyl substitution on 
cannabinoid receptor binding, detailed in the extensive work by Huffman 
36 
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92, and of particular interest is the -propyl naphthyl substituted series (Table 
2.2). 
 
Looking at the naphthyl substitutions in order, the 2-naphthyl position appears 
poorly suited for investigation. Though the 2-methoxy substitution is tolerated, 
it is likely to be competing with the 2-methylindole substituent which, if 
removed, improves 2-methoxy substituted analogues greatly (data not 
shown)92. As extension of the 2-indole substituent leads to loss of binding 
affinity for both receptors, it is likely that extension of the 2-naphthyl position 
will do the same. Hence the 2-naphthyl position is not an ideal candidate for 
investigation. 
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R R´ R´´ R´´´ CB2 receptor Ki (nM) 
H  H H H 13.8 (JWH-015 ,) 
OCH3 H H H 455 
H CH3 H H 14 
H C2H5 H H 12 
H C3H7 H H 12 
H C4H9 H H 49 
H OCH3 H H 97 
H OC2H5 H H 221 
H H OCH3 H 30 
H H H CH3 16 
H H H C2H5 240 
H H H OCH3 441 
Table 2.2 2, 4, 6 and 7-naphthyl substitutions to JWH-015 ,94. 
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The 4-naphthyl position tolerates both alkyl and alkoxy substitutions, with 
alkoxy substitutions leading to a greater loss of CB2 receptor binding. The fact 
that a 4-butyl substitution leads to only a modest loss of affinity compared to 
JWH-015 , is very encouraging and, with the 4-methyl, -ethyl and -propyl 
analogues having very similar binding to JWH-015 ,, shows that there is at the 
very least room for a certain amount of 4-naphthyl substitution. There has also 
been a number of longer 4-alkoxy naphthyl substitutions made, but 
unfortunately their cannabinoid receptor affinities have not been published121. 
Even so, the 4-naphthyl position, like the 3-naphthyl position of our group’s 
work detailed above, is a good prospect for investigation. 
 
The 6 and 7-naphthyl positions will be considered together, as although 6-
methoxy and 7-methyl substitutions are well tolerated, further extension of the 
7-naphthyl substitution to a 7-ethyl or 7-methoxy leads to a large loss of CB2 
receptor binding affinity. With no further extension of the 6-naphthyl itself, the 
poor results for 7-naphthyl may also translate to similar results for the 6-
naphthyl substitution extension, as the two occupy a close location. Therefore, 
neither offer a good prospect for investigation, especially as the 4-naphthyl 
position has shown positive results with a number of larger substitutions. 
 
These two pieces of research have shown that the 3 and in particular the 4-
naphthyl position may be the most suitable for substitution, but that 
substitution at either site will likely lead to some loss of CB2 receptor affinity. 
To offset this, the use of a -pentyl side chain, i.e. an analogue of JWH-007 
/, may improve binding at both cannabinoid receptors, while decreasing any 
CB2 receptor selectivity. Therefore investigation of -propyl and -pentyl 
indole cannabinoids with substitution at the 4-naphthyl position will be the 
primary objective and investigation of substitution at the 3-naphthyl position a 
secondary objective of this current work. 
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In order to make various analogues of JWH-015 ,and JWH-007 /, with 
substitution at the 3 and 4-naphthyl positions, a strategy was required that 
allowed efficient analogue production with the fewest synthetic steps.  
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Figure 2.7 Disconnections (A and B) for the synthesis of JWH-015 analogues. X = 
heteroatom, R = desired substitutions. 
 
There are two important disconnections shown in Figure 2.7: A and B. 
Disconnection A is between the indole and naphthyl rings, and disconnection 
B is between the R substituent and the naphthyl ring. Coupling of the two ring 
systems before the addition of the R substituent allows bulk production of the 
completed ring system as well as addition of R substituents that may interfere 
with the coupling reaction, leading to the retrosynthesis depicted in Scheme 
2.1. 
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Scheme 2.1 Retrosynthetic analysis of JWH-015(n = 2) and JWH-007 (n = 4) analogues with 
substitution at the 3 and 4-naphthyl position. 
 
Due to the difficulties in controlling aromatic addition chemistry, a heteroatom 
linker to the R substituents was used to facilitate analogue synthesis. Oxygen 
was chosen as this heteroatom (X = O in Figure 2.6) as previous research had 
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shown that alkoxy compared with alkyl substituents at the 2 and 4-naphthyl 
position can be tolerated, leading to a modest lost of affinity at the CB2 
receptor (see Table 2.3 for a comparison of 4-methoxy versus similarly sized 
4-ethyl naphthyl substituted analogues)88. 
 


	7


	
 
R R´ N CB2 receptor Ki (nM) 
CH2CH3 H 2 10 
OCH3 H 2 32 
CH2CH3 CH3 2 12 
OCH3 CH3 2 97 
CH2CH3 H 4 0.69 
OCH3 H 4 12.4 
CH2CH3 CH3 4 0.42 
OCH3 CH3 4 1.9 
Table 2.3 Comparison of JWH-015 ,(n = 2) and JWH-007 / (n = 4) analogues with 4-ethyl 
and 4-methoxy naphthyl substitutions, from Huffman 88. 
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The 4-hydroxy JWH-015/JWH-007 analogues ',;'3 were synthesised from 
the commercially available 2-methylindole and 4-methoxy-1-naphthaldehyde 
as shown in Scheme 2.2. 
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Scheme 2.2 Synthesis of 4-hydroxy JWH-015/JWH-007 analogues ',;'3 (a) NaH, DMF, n=2: 
1-bromopropane (89 %); n=4: 1-bromopentane (98 %); (b) NaClO2, NaH2PO4, H2O, BuOH, 
2-methyl-2-butene (34 %); (c) (i) SOCl2, reflux; (ii) ' or '', Et2AlCl, DCM (n=2 50 %, n=4 
71 %); (d) BBr3, DCM (n=2 58%, n=4 67 %). 
 
2-Methylindole was N-alkylated using sodium hydride as the deprotonating 
base and the corresponding straight chained 1-bromoalkene to produce 2-
methyl--propylindole ' and 2-methyl--pentylindole ''. Purification by 
flash column chromatography gave almost quantitative yields, but both indoles 
were found to partially degrade from a colourless to brown oil with orange 
precipitate, even whilst protected from light and stored at below 0 °C. 
Therefore for all subsequent reactions, these alkylated indoles were freshly 
purified by flash column chromatography. 
 
Oxidation of the 4-methoxy-1-naphthaldehydeto the corresponding naphthoic 
acid '. was performed using sodium chlorite, in the presence of the chlorine 
scavenger 2-methyl-2-butene, which gave modest but repeatable yields with 
multiple recrystallisations from methanol122-124. An attempt to use Jones 
Reagent for this oxidation failed to produce the desired carboxylic acid. 
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For the acylation of indoles it has been found that traditional Friedel Crafts 
coupling with aluminium chloride, even with protected -alkylindoles, leads 
to poor or non-existent conversion88, 125, 126. Okauchi  found that use of the 
milder alkylaluminium chlorides, in particular dimethyl or diethylaluminium 
chloride, led to much improved yields of 50-90%125. Therefore the acylation 
between 2-methyl--aklylindole ';'' and the acyl chloride formed when 4-
methoxynaphthalene-1-carboxylic acid '. was heated at reflux with thionyl 
chloride, was catalysed with diethylaluninium chloride producing the 2-
methyl--alkyl-3-(4-methoxy-1-naphthoyl)-indoles '-;'/ in good yields of 
50-71% after flash column chromatography purification.  
 
Demethylation with boron tribromide of '-;'/ afforded the 2-methyl--alkyl-
3-(4-hydroxy-1-naphthoyl)-indoles ',;'3, which when carefully purified by 
flash column chromatography produced reasonable yields of 58-67%127-129. 
These 4-hydroxyl analogues were produced in sufficient quantity to allow the 
synthesis of a variety of 4-alkoxynaphthoyl substituted analogues of JWH-015 
, and JWH-007 / (Scheme 2.3).  
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Scheme 2.3 Synthesis of 4-alkoxynaphthoyl substituted analogues of JWH-015 and JWH-007 
(a) NaH, DMF, 1-BrR (17-32 %). 
 
The -propyl-4-propoxy, butoxy, hexyloxy, benzyloxy and vinyloxynaphthoyl 
analogues ('0).' respectively) of JWH-015 , and the -pentyl-4-hexyloxy 
and benzyloxynaphthoyl analogues (..).- respectively) of JWH-007 , were 
produced by alkylation of the relevant 2-methyl--alkyl-3-(4-hydroxy-1-
naphthoyl)-indoles ',/'3 using sodium hydride base with the corresponding 
straight chained 1-bromoalkane, benzyl bromide or allyl bromide (Scheme 2.3) 
and purified by preparative layer chromatography. Low purified yields for 
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these alkylations were recorded (17-32%); this was due to the isolation of only 
the purist part of the compound’s chromatographic band and that some 
compounds (e.g. . and .-) required multiple purifications to remove side 
products with similar rates of flow. It was found impossible to suitably purify 
the n=4 benzyloxy analogue .- to allow its pharmacological evaluation due to 
these side products, even when a variety of different mobile phases were used. 
 
 
8


 8

 
Scheme 2.4 Synthesis of 4-fluoronaphthoyl JWH-015 analogue ./ (a) (i) SOCl2, reflux; (ii) 
', Et2AlCl, DCM (43 %). 
 
Finally the -propyl-4-fluoronaphthoyl analogue ./ was synthesised by 
coupling the commercially available 4-fluoronaphthalene-1-carboxylic acid, 
with 2-methyl--propylindole ' and, as with the synthesis of '-;'/ a 
variation of Friedel Crafts acylation utilising diethylaluminium chloride was 
used (Scheme 2.4)125. Purification was by preparative layer chromatography, 
produced a slightly lower yield of 43% than the previous Friedel Crafts 
acylations. This was due to the desire for a purer compound appropriate for 
pharmacogical evaluation and the generally lower yields achieved with 
preparative layer compared to flash column chromatography. 
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To synthesise the 3-methoxynaphthoyl JWH-015 analogue -', and thereafter 
other desired 3-ethernaphthoyl analogues, 3-methoxy-1-naphthoic acid - had 
to be first synthesised as shown in Scheme 2.5. 
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Scheme 2.5 Synthesis of 3-methoxy-1-naphthoic acid - (a) HNO3, H2SO4 (69 %); (b) (i) 
HgO, NaOH(aq), microwave 200 °C; (ii) HCl(aq), reflux (35 %); (c) H2, Pd/C, EtOH, NaOH(aq) 
(98 %); (d) NaNO2, H2SO4(aq), (63 %); (e) MeI, NaH, DMF (70 %); (f) KOH, MeOH, reflux 
(57 %). 
 
Though commercially available 3-nitro-1,8-naphthoic anhydride ., was 
simply prepared from 1,8-naphthoic anhydride by a single  nitration using 
one equivalent of nitric acid in concentrated sulfuric acid, and purified by 
recrystallisation from acetic acid130, 131. Though crude yields were quantitative, 
difficulties with the filtration of insoluble particulates from the hot acetic acid 
crystallisation solution lead to only a modest purified yield of 69%. 
 
Selective decarboxylation of 3-nitro-1,8-naphthoic anhydride .,to form the 3-
nitro-1-naphthoic acid geometric isomer .3was performed using yellow 
mercury (II) oxide. Previous studies of this reaction have suggested that 
although the mechanism is not clear, mercury (II) acetate is formed and that 
this mercury species initially adds between the carboxyl groups, and then onto 
the naphthyl ring releasing one carboxyl group as carbon dioxide (Scheme 
2.6). The organo-mercury intermediates are stable but undergo acid hydrolysis 
to release the mercury salt and the desired mono acids132. The presence of an 
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electron withdrawing group such as the 3-nitro group leads predominantly to 
the 3-nitro-1-naphthoic acid geometric isomer .3 in good yields132, 133.  
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Scheme 2.6 Selective decarboxylation of 3-nitro-1,8-naphthoic anhydride ., (a) (i) NaOH(aq); 
(ii) HgO, 3:1 AcOH:H2O, reflux (b) HCl, reflux. 
 
The initial insertion of the mercury species into the anhydride is thermally 
driven and even at reflux the reaction may take 2-4 days to complete133-136. A 
previous study85 and trial reactions followed this procedure, but after 
recrystallisation, it was necessary to remove any undesired geometric isomer, 
hence yields on the trial reactions were found to be less than 20%. A way to 
improve both yield and reduce reaction time had been demonstrated by 
Moseley and Gilday using microwave irradiation with temperatures up to 
200 °C, for 15-30 min132. Replication of this method, with microwave 
irradiation for 28 min at 200 °C, followed by acid hydrolysis and 
recrystallisation from acetone led to an improved yield of 35%, with the whole 
reaction taking less than 24 h to reach completion. To prevent excessive 
pressure build up from carbon dioxide release in the microwave reactor, initial 
heating was gradual. Once at 200 °C, the pressure was stable and the carbon 
dioxide was safely contained within the microwave tube.  
 
Isolation of the single geometric isomer 3-nitro-1-naphthoic acid .3 was 
confirmed by proton and COSY nuclear magnetic resonance. Analysis of 
COSY NMR spectrum with H1 NMR overlaid, shown in Figure 2.8, identifies 
six protons in the aromatic region, two of which are sharp doublets with a 
coupling constant of = 2.4-2.5 Hz. The COSY spectrum shows one set of 
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coupling between the two sharp doublets and another set of coupling between 
the four one proton multiplets. Both of these observations are consistent with 
the  substitution pattern of 3-nitro-1-naphthoic acid, confirming this 
isomer’s purity and the absence of 6-nitro-1-naphthoic acid. 
 
 
Figure 2.8 COSY NMR of 3-nitro-1-naphthoic acid .3, with H1 NMR on left and top axis. Red 
lines show coupling between 2-H and 4-H, and blue lines show coupling between 5-H, 6-H, 7-
H and 8-H.  
 
3-Nitro-1-naphthoic acid .3was reduced with hydrogen and palladium 
catalysis over activated charcoal, to produce sodium 3-amino-1-naphthate .0 
in quantitative yields133. 3-Amino-1-naphthoic acid was converted to 3-azido-
1-naphthoic acid, by precipitating the free acid and then oxidising with sodium 
nitrite. Immediate treatment with refluxing 40 % sulphuric acid(aq), hot 
filtration, and precipitation produced 3-hydroxy-1-naphthoic acid -1 in a good 
yield of 63% considering the harshness of the conditions used133, 137. 
 
To obtain the desired 3-methoxy-1-naphthoic acid -, 3-hydroxy-1-naphthoic 
acid -1 was methylated at both the phenol and carboxylic acid using methyl 
iodide and sodium hydride base in excess to form methyl 3-methoxy-
naphthalene-1-carboxylate -$, with lower yields than expected obtained due to 
loss of some material during workup. Base hydrolysis of the ester with 
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potassium hydroxide and recrystallisation from ethanol:water (1:1) produced 
the 3-methoxy-1-naphthoic acid - required for the synthesis of 3-
ethernaphthoyl JWH-015 analogues. A modest yield of 57% was obtained due 
to the need for multiple recrystallisations to ensure sufficient purity for the 
Friedel Crafts acylations. 
 
The -propyl-3-methoxynaphthoyl analogue -' was synthesised by coupling 
the synthesised 3-methoxy-1-naphthoic acid -, with 2-methyl--propylindole 
' and as with the synthesis of 4-methoxy analogues in section 2.4 a variation 
of Friedel Crafts acylation utilising diethylaluminium chloride was used, again 
producing an excellent yield of 90% after flash column chromatography 
purification (Scheme 2.7)125. 
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Scheme 2.7 Synthesis of 2-methyl--propyl-3-(3-alkyloxy-1-naphthoyl)-indoles (a) (i) SOCl2, 
reflux; (ii) ', Et2AlCl, DCM (90 %); (b) BBr3, DCM (71 %).(c) NaH, DMF, 1-BrR, (16-
32 %). 
 
Demethylation with boron tribromide of -' produced 2-methyl--propyl-3-(3-
hydroxy-1-naphthoyl)-indole-. in good yields after flash column 
chromatography purification127-129. The -propyl-3-hexyloxy -- and 
benzyloxy -/ analogues of JWH-015 , were produced by alkylation of -. 
using sodium hydride with either straight chained 1-bromohexane or benzyl 
bromide respectively, and were purified by preparative layer chromatography. 
Similar yields were obtained as with the 4-naphthyl analogues, with the 
benzyloxy analogue -/ again being difficult to purify due to side products with 
similar rates of flow. 
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All synthesised 3 and 4-naphthyl analogues, except 2-methyl--pentyl-3-(4-
benzyloxy-1-naphthoyl)-indole .- were assessed for their CB2 binding affinity 
(Table 2.4).  
 



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Compound N R R´ CB2 Ki (nM) 
JWH-015 , 2 H H lit. 13.887 
./ 2 F H 32.3 (± 8.93) 
', 2 OH H 418 (± 159) 
JWH-094 '- 2 OMethyl H 31.4 ± 10.3 
lit. 97.387 
JWH-261 2 OEthyl H lit. 22192 
'0 2 OPropyl H 91.8 (± 4.12) 
.1 2 OButyl H 271 (± 94.3) 
.$ 2 OHexyl H 843 (± 81.1) 
. 2 OBenzyl H 560 (± 70.1) 
.' 2 OAllyl H 87.1 (± 10.3) 
JWH-007 / 4 H H lit. 2.94
87 
'3 4 OH H 6.86 ± (2.50) 
JWH-098 '/ 4 OMethyl H 2.71 (± 0.918) 
lit. 1.8887 
JWH-260  4 OEthyl H lit. 2592 
.. 4 OHexyl H 143 (± 23.0) 
.- 4 OBenzyl H not tested 
-. 2 H OH 77.3 (± 22.4) 
-' 2 H OMethyl 92.8 (± 18.9) 
-- 2 H OHexyl 809 (± 230) 
-/ 2 H OBenzyl 166 (± 67.4) 
Table 2.4 CB2 receptor Ki were determined from radioligand binding assays with     [
3H]CP55-
940 -. The results in parentheses are standard error of the mean for three individual 
experiments run in triplicate. 
 
To ensure appropriate purity for pharmacological testing, all compounds were 
analysed using two different HPLC methods to confirm greater than 98 % 
purity. Compounds that were not sufficiently pure were further purified by 
48 
preparative layer chromatography until they were. In the case of the n=4 
benzyloxy analogue .-, it was not found possible to separate this compound 
from a side product with a very similar rate of flow in a range of different 
systems. Microanalysis was not used to assess purity due to the majority of 
compounds being oils, and the inherent difficulties in ensuring complete 
solvent removal necessary for the accuracy of this technique. 
 
The -propyl-4-naphthyl series demonstrates that increasing the bulk of the 
substitution at this position leads to a gradual loss of CB2 binding affinity. This 
loss of affinity is in line with results of other 4-naphthyl analogues developed 
by Huffman  94, with a gradual reduction of affinity with the 4-methoxy '-, 
-ethoxy, -propoxy '0, -butyloxy .1 and -hexyloxy .$ series. Although the 4-
ethoxy, -propoxy and -butyloxy analogues still have modest affinity, the 4-
hexyloxy analogue has poor affinity. The unsaturated substitutions of 4-
vinyloxy .' and -benzyloxy . also result in a loss of CB2 receptor binding 
affinity. This loss is greatest with the bulkier 4-benzyloxy analogue but it still 
has a higher affinity than the 4-hexyloxy analogue. The 4-vinyloxy analogue 
has comparable affinity to the similar sized 4-propoxy analogue. The 4-
hydroxyl ', analogue led to a large drop in CB2 receptor binding affinity, 
which cannot be explained with respect to its size, and is likely due to this 
region of the active site being intolerant of hydrophilic groups. This backs up 
previous research that showed 4-alkoxy substituents cause a greater reduction 
in binding than similar sized 4-alkyl substitutions92. Lastly the 4-fluoro ./ 
substitution appeared to have little effect on CB2 receptor binding affinity as 
this compound had only a slight loss of affinity compared to JWH-015 ,.  
 
These results suggest that there may be a limit to the 4-naphthyl substitution 
size that can be accommodated, and that hydrophilic substitutions such as a 4-
hydroxyl hinder binding greatly. It is also likely that there is not a hydrophobic 
sub-site near the 4-naphthyl available to interact with saturated or unsaturated 
hydrophobic groups. 
 
The -pentyl-4-naphthyl series demonstrate an increase in CB2 receptor 
binding compared with the same substitutions in the -propyl-4-naphthyl 
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series, as found in previous work92. With no CB1 receptor binding affinities 
available it is not possible to say whether the -pentyl series has lost a degree 
of CB2 receptor selectivity compared to the -propyl series. However, it is 
very interesting that the -pentyl-4-hydroxyl '3 and -4-hexyl .. analogues 
have sixty and six fold increases respectively in CB2 binding affinity compared 
to the same substitutions in the -propyl series. 
 
These results add weight to previous research that -pentyl analogues have 
greater CB2 receptor binding affinity when compared to the similarly 
substituted -propyl analogues. Furthermore, the large increases in binding 
affinity of the -pentyl-4-hydroxyl and -4-hexyl analogues compared with -
propyl analogues, suggest that though these groups may not be well suited for 
-propyl analogues, the extra affinity of the -pentyl means a wider range of 
both hydrophilic groups and larger hydrophobic groups may be tolerated. 
These results, therefore, cast into doubt the suggestion from the -propyl 
analogues results that there may be a limit to the 4-naphthyl substitution size 
that can be accommodated. 
 
Finally the -propyl-3-naphthyl series show a similar profile to the -propyl-
4-naphthyl series. The 3-methoxy -' analogue retains modest affinity for the 
CB2 receptor, whilst the 3-hydroxyl -. analogue also retains modest affinity 
with over four fold greater affinity than experienced by the -propyl-4-
hydroxyl analogue. The 3-hexyloxy -- analogue has a similarly poor affinity 
for the CB2 receptor as the -propyl-4-hexyloxy analogue, where as the 3-
benzyloxy -/ analogue retains modest affinity with over three fold greater 
affinity than experienced by the -propyl-4-benzyloxy analogue. 
 
These results suggest that as with the -propyl-4-naphthyl series, increasing 
chain length and bulk leads to loss of affinity, with the potential that, beyond a 
certain point, chain extension could not be accommodated. Considering the 
results with the -pentyl-4-naphthyl series, this suggestion should be judged 
with care, especially as the -propyl-3-hydroxyl and -3-benzyl analogues have 
significantly greater CB2 receptor binding than their comparable -propyl- 4-
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naphthyl analogues. Also, it may be the case that the 3-naphthyl position offers 
a more suitable substitution site for hydrophilic and unsaturated groups. 
 
Both the 3 and 4-naphthyl positions show the ability to accommodate 
relatively bulky groups, although with a moderate degree of CB2 receptor 
binding affinity loss, though not complete abolition. In particular the -propyl 
and -pentyl-4-naphthyl series have included substitutions much larger, and of 
a greater variety than have been investigated before.  
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We have successfully synthesised a series of seventeen -alkyl-3/4-naphthyl 
substituted JWH-015 analogues for the CB2 receptor. These have shown a 
mixture of results, but generally confirm that, although larger or hydrophilic 
substitutions are tolerated to a degree, they do lead to a significant reduction in 
CB2 receptor binding affinity. Furthermore, unsaturated substitutions do not 
appear to be interacting with any aromatic stacking receptor sub-site, and 
instead lead to a loss of CB2 receptor binding at a rate comparable to their size. 
However, the -pentyl-4-naphthyl substituted series showed that although 
larger substitutions may lead to significant loss of CB2 receptor binding, this 
effect can be reduced with other modifications to the indole cannabinoid 
scaffold. It also showed that the 4-naphthyl position can tolerate large 
substitutions, suggesting that there is significant space in, or outside of, the 
receptor active site to accommodate such substitutions.  
 
These results provide sufficient promise that fluorophore substitution at the 3 
and especially the 4-naphthyl position may indeed be tolerated. In Chapter 3 
we utilise these results to continue our work towards an understanding of the 
structure activity relationships of 4-naphthyl substitutions, as well as 
synthesising fluorescently labelled CB2 receptor ligands based on the JWH-
015 , indole cannabinoid scaffold. 
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This chapter describes the design, synthesis and pharmacology of fluorescent 
indole cannabinoid analogues for the CB2 receptor. The main aim of this 
chapter is to study various linker lengths and types from the indole 
cannabinoid scaffold, as well as the effect of attaching various fluorophores to 
that linker.  
 
In this chapter we utilise the efforts detailed in Chapter 2, as well as the work 
by Yates on the synthesis and evaluation of the fluorescently labelled JWH-
015 analogue 3-(3-[-(7-nitrobenz-2-oxa-1,3-diazol-4-ylglycylamino 
napthoyl)-2-methyl-1--propylindole .85, 86, to help in the design and 
synthesis of a series of new fluorescent compounds. We also investigate the 
effect of linker length on CB2 receptor binding as well as if a more hydrophilic 
linker affects CB2 receptor binding affinity. 
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A number of variables need to be decided upon when designing any 
fluorescent JWH-015 analogues for synthesis. Firstly, where on the JWH-015 
- scaffold should substitution take place? The aim of Chapter 2 was to help 
identify if the 3 and 4-naphthyl positions would be suitable choices for 
fluorophore attachment. Secondly, to both prevent quenching of the 
fluorophore by the naphthyl ring system and to remove the fluorophore far 
enough away from the cannabinoid ligand to decrease interference on its CB2 
receptor binding, what is a suitable length and type of linker for these 
purposes? Finally, with numerous fluorophores available on the market, with 
varying size and fluorescent properties, which should be chosen for 
attachment? 
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The research in Chapter 2, helped to confirm that both the 3 and 4-naphthyl 
positions of JWH-015 - are good prospects for investigation. Considering the 
greater number of results for the 4-naphthyl substitutions that show a large 
range of additions can be accommodated, and that a previous attempt by Yates 
to synthesise a 3-naphthyl substituted fluorophore with very limited affinity 

85, 86, efforts for fluorophore ligation will be focused on the 4-naphthyl 
position.  
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The results presented in Section 2.6, as well as the previous work by Yates85, 86 
and Huffman 94 detailed in Section 2.2.6, show that hydrophobic 
substitutions as the 4-naphthyl position is favoured over smaller hydrophilic 
substitutions. This suggests that any linker between the indole cannabinoid 
scaffold and fluorophore should be generally hydrophobic in nature. As such 
linkers have, for practical synthetic purposes, terminal hydrophilic functional 
groups to allow coupling, the rest of the linker should probably be of a straight 
chain saturated nature.  
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The optimum length that the hydrophobic linkers should be, is unclear. Yates’ 
3-(3-[-(7-nitrobenz-2-oxa-1,3-diazol-4-ylglycylamino napthoyl)-2-methyl-1-
-propylindole .85, 86 contained a glycine linker which may be either too 
large for the active site when added to the bulk of the NBD fluorophore, or too 
short and therefore not removing the NBD fluorophore far enough away from 
the active site. The -alkyl-4-naphthyl analogues, detailed in Section 2.6 and 
by Huffman 92, show that there is certainly space for 4-butyl or 4-ethoxy 
substitutions, and that even larger groups such as 4-benzyloxy and 4-hexyloxy 
can be tolerated with moderate loss of CB2 receptor binding. This suggests that 
there may either be a sub-site pocket within the active sight that can 
accommodate some steric bulk, or that substitutions at the 4-naphthyl are 
directed towards the exit of the receptor active site. The latter option is of 
particular interest, because if true, the loss of affinity on increasing chain 
length may partly be due to an entropic effect, and the 4-naphthyl may be ideal 
for attaching a long linker to remove any fluorophore from the active site. 
Obviously with increasing linker length, entropy costs increase and so 
decreases CB2 receptor binding affinity. If though an allosteric binding site 
could be found that interacted with either the fluorophore’s functional groups 
or aromatic nature, then binding affinity may be restored. With the prospect of 
both room in the active site for a small fluorophore substitutents, or access to 
an exit from it, a range of different length hydrophobic linkers should be 
investigated to determine their effects. Therefore preparation of ethyl, butyl, 
hexyl and octyl linker lengths will be the synthetic target. 
 
Although the priority should be in using hydrophobic linkers, preparing similar 
sized hydrophilic analogues might allow useful comparisons. For example, an 
analogue of a straight chained octyl linker could be (2-(2-ethoxy)ethoxy)ethyl, 
which has two regularly placed oxygens instead of carbons in the chain, and 
where the main difference is in hydrophilicity not size. As the results in section 
2.6 confirm that hydrophilic groups near the naphthyl ring system e.g. 4-
hydroxyl, are not well tolerated, any investigation using hydrophilic linkers 
should be of sufficient length that they may interact with favourable amino 
acid residues outside of the immediate indole cannabinoid active site. 
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Therefore preparation of the partially oxygen substituted octyl linker analogue 
e.g. (2-(2-ethoxy)ethoxy)ethyl will also be part of the synthetic strategy. 
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The selection of the fluorophore for ligation is essential in creating suitable 
fluorescent cannabinoids. Generally small amine reactive fluorophores e.g. 
dansyl chloride -, and 4-fluoro 7-nitrobenzofurazan (NBD-F) -3 (Figure 3.1) 
are used, with a number of GPCR ligands being successfully labelled with 
these fluorophores138. Small fluorophores may have a number of advantages 
over larger fluorophores in that they are generally cheap and are less likely to 
interfere with ligand binding. The larger the substitution, the greater the 
entropic costs of binding, as well as the increased risk of the substituent 
directly preventing the ligand receptor interaction. The dansyl and NBD 
fluorophores do suffer from relatively poor fluorescent properties, especially 
that their fluorescence is attenuated in aqueous environments139, meaning that 
increased radiation intensity may be required for confocal microscopy or small 
molecule detection techniques, that may damage cells.  
 
At the other end of the scale are the much larger BODIPY® and Cyanine 
fluorophores which have also been successfully used to produce fluorescent 
GPCR ligands138. With longer excitation wavelengths, hence they are termed 
red absorbing dyes, and good fluorescence in aqueous environments, these 
fluorophores are more suited for small molecule detection techniques. 
However BODIPY® compounds are only commercially available from 
Molecular Probes, Invitrogen, as are Cyanine compounds from GE Healthcare, 
both are expensive and come with a pre-attached activated linker .e.g. Bodipy 
630/650-X Osuccimide /1 and Cy5-Osuccimide /$. This is ideal for 
fluorescently labelling proteins, nucleotides and other macro molecules where 
a pre-attached linker removes the need for an extra synthetic step. For small 
molecule work, whereby the length and nature of the linker may be crucial, 
fluorophores with pre-attached linkers reduce the choice of both length and 
nature of linker. As we wish to assess the linker intermediates for their CB2 
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receptor binding and so help develop structure activity relationships, use of 
BODIPY® and Cyanine fluorophores would prevent this. 
 
In between these two fluorophore extremes are moderately sized fluorophores 
such as 5-carboxyfluorescein -0. Fluorescein has similar fluorescence 
properties to dansyl and NBD, absorbing at a slightly longer wavelength, but is 
considerably larger in size, comparable to BODIPY® and Cyanine. 5-
carboxyfluorescein has no pre-attached linker, and offers a cheap alternative to 
BODIPY® and Cyanine. If 5-carboxyfluorescein attachment is tolerated then 
investigation of BODIPY® and Cyanine may be warranted.  
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Figure 3.1 Structure and spectral data for amine reactive fluorophores. λmax absorbances and 
emission are quoted. Dansyl chloride and NBD-F data taken from Lakowicz139, and, as dansyl 
chloride alone is non-fluorescent, a range of values of its conjugates are given. 5-
carboxyfluorescien data is taken from product specifications of Sigma-Aldrich140, and Bodipy 
630/650-X Osuccimide and Cy5-Osuccimide data taken by work from Buschmann 141. 
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As this investigation of fluorophore ligation at the 4-naphthyl position of 
JWH-015 - requires preparation of a number of varying linker length and 
types, the use of fluorophores such as BODIPY® and Cyanine would be both 
expensive and inconvenient. If the synthesis and evaluation is successful in 
producing a fluorescently labelled indole cannabinoid, then BODIPY® and 
Cyanine analogues could be developed to try and improve fluorescent 
properties. 
 
Though the dansyl and NBD fluorophores do not have ideal fluorescent 
properties, their smaller size is less likely to interfere with binding of indole 
cannabinoid scaffold, which is especially important as the results of Chapter 2 
show that increasing steric bulk leads to loss of CB2 receptor binding affinity. 
Furthermore, the dansyl and NBD fluorophores are a good choice for 
investigation, as they do not have an integrated linker and so allow the use of a 
greater variety of linkers. This also allows pharmacological evaluation of the 
initial 4-naphthyl JWH-015 linker coupling products, before the fluorophore 
attachment. To investigate what effect a larger sized fluorophore might have 
on CB2 receptor binding affinity in comparison to the smaller dansyl and NBD 
molecules, 5-carboxyfluorescein is also a fluorophore for investigation. 
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During the previous Chapter’s synthesis of various JWH-015 analogues, 
sufficient quantities of the starting material for this synthetic strategy, 2-
methyl--propyl-3-(4-hydroxy-1-naphthoyl)-indole ',, were produced to 
allow for preparation of a number of fluorescent analogues. To allow efficient 
analogue production, a synthetic strategy with the fewest number of steps as 
well as the opportunity to investigate any promising intermediates’ structure 
activity relationships was sort. 
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Figure 3.2 Disconnections (A and B) for the synthesis of fluorescent JWH-015 analogues.  
X = linker, R = fluorophore. 
 
There are two important disconnections shown in Figure 3.2, A and B. 
Disconnection A is between the hydroxyl and the desired linker, and 
disconnection B is between the linker and the desired fluorophore. Linker 
attachment to the naphthyl ring before coupling to any fluorophore prevents 
loss of potentially expensive fluorophore starting material. Any pre-attachment 
of the fluorophore to the linker would likely involve protection of the linking 
functional group, which would need to be deprotected before any coupling to 
the naphthyl ring, which itself will be unlikely to be a high yielding reaction. 
As the JWH-015 - scaffold contains no functional groups requiring protection 
during the addition of the linker or fluorophore, leaving the fluorophore 
attachment to the final step removes two extra steps involving the fluorophore. 
Furthermore, the preparation of a number of JWH-015 analogues with various 
linker lengths and types allows them to be isolated and their CB2 binding 
affinities evaluated, hence adding to our understanding of structure activity 
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relationships on the effect of substitution at the 4-naphthyl position of JWH-
015 -. This rationale leads to the retrosynthesis depicted in Scheme 3.1. 
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Scheme 3.1 Retrosynthetic analysis of fluorescent JWH-015 analogues. X = linker, R = 
fluorophore and R´ = amine protecting group. 
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Before attachment of the desired linkers to 2-methyl--propyl-3-(4-hydroxy-1-
naphthoyl)-indole ', the linkers needed to be suitably protected as detailed in 
Scheme 3.2. 
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Scheme 3.2 Synthesis of -butoxycarbonyl or -trityl protected linkers (a) butylphenyl 
carbonate, TEA, EtOH  n=1 (76 %), n=2 (65 %), n=3 (96 %); (b) PTSA, EtOH, reflux, (96 %); 
(c) trityl chloride, TEA, CHCl3, (89 %); (d) LiAlH4, THF, (65 %); (e) NaN3, DMF, (99 %); (f) 
SnCl2, EtOH, (54 %), or Ph3P, H2O, ether, reflux (31 %); (g) di-butyl dicarbonate, KOH(aq), 
(68 %). 
 
The ethyl, butyl and hexyl butylhydroxyalkylcarbamates /-/. were prepared 
from the corresponding aminoalcohols with standard amine boc protection 
with butylphenyl carbonate, all purified by flash column chromatography to 
produce good yields. 8-Aminooctan-1-ol and 2-(2-(2-
aminoethoxy)ethoxy)ethanol were not commercially available and a different 
strategy was required for the production of their amine protected counter parts.  
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8-Aminooctanoic acid was the starting material used for the octyl linker, 
following a synthetic pathway devised by Ammann 142. Before any amine 
protection could take place the carboxylic acid needed to be protected and this 
was achieved by acid catalysed ethyl esterification and flash column 
chromatography purification to formethyl 8-aminooctanoate /- in near 
quantitative yields. Esterification also improved handling of the compound, as 
the hydrophilic nature of 8-aminoctanioc acid made it insoluble in most 
organic solvents. This ester was now amine protected by treatment with trityl 
chloride, to form the trityl protected ethyl 8-(tritylamino)octanoate // in good 
yield after purification by flash column chromatography. A trityl protection 
was chosen as it is resistant to the strong reducing conditions required for 
conversion of the ester to an alcohol, unlike other amine protecting groups 
such as boc. Lithium aluminium hydride reduction yielded the desired amine 
protected aminoalcohol 8-(tritylamino)octan-1-ol /,, again purified by flash 
column chromatography to a modest yield expected with this type of 
reduction, which was then ready for coupling to 2-methyl--propyl-3-(4-
hydroxy-1-naphthoyl)-indole ',.  
 
Finally, a method was found to synthesise the desired 2-(2-(2-
aminoethoxy)ethoxy)ethanol /0 from the starting material 2-(2-(2-
chloroethoxy)ethoxy)ethanol. Nucleophilic substitution of the terminal chloro 
functional group using sodium azide gave 2-(2-(2-azidoethoxy)ethoxy)ethanol 
/3 in quantitative yields, which it was envisaged could be reduced to the 
terminal amine analogue. Previous research had performed this azide reduction 
with use of hydrogen with a palladium on activated carbon catalyst143, but 
attempts to follow this method were unsuccessful, and therefore two 
alternative methods were investigated for this reduction. Both of these 
methods were successful, but after flash column purification a method utilising 
tin (II) chloride heated at reflux in ethanol144, provided a greater yield of 2-(2-
(2-aminoethoxy)ethoxy)ethanol/0, than a method utilising triphenylphosphine 
heated at reflux in water145. This aminoalcohol then underwent standard amine 
boc protection with di-butyl dicarbonate and purification yielded the desired 
butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate ,1 in good yields. 
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With the five desired linkers prepared in Section 3.3, they could now be 
coupled to 2-methyl--propyl-3-(4-hydroxy-1-naphthoyl)-indole ', as 
detailed in Scheme 3.3. 
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Scheme 3.3 Coupling of protected linkers and deprotection (a) /)/./,,1, DEAD, Ph3P, 
THF, (37-91 %); (b) TFA, H2O, DCM, (29-62 %). 
 
All coupling was via the mild Mitsunobu reaction146 between the 4-hydroxyl 
of the indole cannabinoid and the unprotected terminal alcohol of the desired 
linker. Standard conditions were used, with an excess of diethyl 
azodicarboxylate and triphenylphosphine, to form the protected 4-naphthyl 
linker attached indole cannabinoid analogues ,$),-. Good yields of the crude 
products were obtained for all reactions, but due to the presence of the 
reduction product diethyl hydrazine-1,2-dicarboxylate, which had a very 
similar rate of flow to some of the desired products, flash column 
chromatography was needed to be repeated for a number of compounds 
resulting in a lower purified yield of between 37-91%, with the lowest yields 
resulting from the need for multiple purifications. Standard removal of the boc 
and trityl amine protecting groups under acidic conditions, and purification by 
preparative layer chromatography yielded the desired amines ,/)31, ready for 
fluorophore ligation. Though high crude yields were obtained for these simple 
deprotections, purification greatly lowered the yields, as only the purist part of 
the compound’s chromatographic band was isolated and some compounds 
required multiple purifications to remove side products with similar rates of 
flow that were identified by HPLC. 
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As well as investigating the effect of fluorophore attachment on CB2 receptor 
binding, the protected and free amine linker analogues would also be assessed 
for their affinity. As the octyl linker analogue utilised a trityl protection, a boc 
protected analogue was synthesised so that it could be compared (Scheme 3.4). 
Boc protection was achieved using butylphenyl carbonate in alkaline aqueous 
conditions, and purification by preparative layer chromatography gave in 
modest yields, the desired amine protected analogue 3$. 
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Scheme 3.4 Preparation of boc protected X = octyl linker analogue 3$ (a) butylphenyl 
carbonate, NaHCO3(aq), (37 %). 
 
The final fluorophore coupling could now take place, as detailed in Scheme 
3.5. All three fluorophores readily undergo nucleophilic substitution by the 
primary amine of the 4-naphthyl linker analogues ,/)31. After preparative 
layer chromatography purification, dansyl 3)3/ and NDB 3,)0$ analogues 
were isolated in modest yields, partly due to incomplete coupling and partly 
due to some of these analogues not being found to be suitably pure on HPLC 
analysis, and were repurified as required. In some cases this meant that 
insufficient compound was left remaining to allow either further HPLC 
analysis or use in CB2 radioligand binding assays. 
 
In the case of the 5-carboxyfluorescein analogues, initial attempts to use the 
unactivated 5-carboxyfluorescein for coupling failed to produce the desired 
compounds. The activated 5-carboxyfluorescein--succinimdyl ester did 
produce the desired results, with very high yields of 0)0/ after purification by 
preparative layer chromatography. 
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Scheme 3.5 Preparation of fluorescent JWH-015 analogues (a) dansyl chloride, TEA, DCM, 
(29-46 %); (b) 4-fluoro-7-nitrobenzofurazan TEA, DCM, (15-29 %); 5-carboxyfluorescein--
succinimdyl ester, TEA, DCM, (80-96 %). 
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All synthesised JWH-015 4-naphthyl linker (boc protected or free amine) 
analogues, as well as the majority of JWH-015 4-naphthyl fluorophore 
analogues were assessed for their CB2 binding affinity (Table 3.1). 
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Compound X R CB2 Ki (nM) or % 
displacement at 10 µM 
,$ (CH2)2 Boc 25% 
, (CH2)4 Boc 44% 
,' (CH2)6 Boc 566 (± 229) 
3$ (CH2)8 Boc 52% 
,- ((CH2)2O)2(CH2)2 Boc 1810 (± 162) 
,/ (CH2)2 H 1260 (± 194) 
,, (CH2)4 H 1270 (± 117) 
,3 (CH2)6 H 762 (± 372) 
,0 (CH2)8 H 1580 (± 212) 
31 ((CH2)2O)2(CH2)2 H 1210 (± 311) 
3 (CH2)2 Dansyl 48% 
3' (CH2)4 Dansyl 34% 
3. (CH2)6 Dansyl not tested 
3- (CH2)8 Dansyl not tested 
3/ ((CH2)2O)2(CH2)2 Dansyl not tested 
3, (CH2)2 NBD 71% 
33 (CH2)4 NBD 61% 
30 (CH2)6 NBD 34% 
01 (CH2)8 NBD not tested 
0$ ((CH2)2O)2(CH2)2 NBD 57% 
0 (CH2)2 5-Carboxyfluorescein 25% 
0' (CH2)4 5-Carboxyfluorescein 41% 
0. (CH2)6 5-Carboxyfluorescein 41% 
0- (CH2)8 5-Carboxyfluorescein 33% 
0/ ((CH2)2O)2(CH2)2 5-Carboxyfluorescein 21% 
Table 3.1. CB2 receptor Ki or % specific binding displacement at 10 µM were determined from 
radioligand binding assays with [3H]CP55-940 -. Displacement results are from two individual 
experiments run in triplicate and Ki results are the mean from three individual experiments run 
in triplicate with the standard error of the mean in parentheses. 
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To ensure appropriate purity for pharmacological testing, all compounds were 
analysed using two different HPLC methods to confirm greater than 98 % 
purity. Compounds that were not sufficiently pure were further purified by 
preparative layer chromatography until they were. In the case of one NBD (01) 
and three dansyl (3.)3/) analogues, it was not found possible to separate these 
compounds from trace impurities without rendering the quantity of compound 
insufficient for testing. Microanalysis was not used to assess purity due to all 
compounds being oils and the majority of purified fluorescent compounds 
being isolated in small quantities, where such analysis would consume a 
significant portion. 
 
With regard to the ten 4-naphthyl linker analogues ,$),', ,--31 and 3$, the 
general effect of the attachment of all linkers is a substantial drop in CB2 
receptor binding affinity when compared with JWH-015 ,. Apart from the 
hexyl analogues ,' and ,3, the free amine linker analogues have greater CB2 
receptor affinity than their boc protected precursors. This effect is difficult to 
quantify as the majority of boc protected analogues, in particular the ethyl, 
butyl and octyl linkers, have insufficient CB2 receptor binding to allow 
calculation of a Ki value. All compounds for pharmacological testing were 
prepared as a stock solution by dissolving in a suitable organic solvent, e.g. 
DMSO or ethanol. Beyond a certain concentration of compound, in this case 
10 µM, these organic solvents would be at a concentration that significantly 
interferes with the binding assay. Therefore, for compounds with a very high 
Ki, their CB2 receptor binding affinity is measured as the percentage of 
specific [3H]CP55-940 - binding displaced at 10 µM. In the case of the (2-(2-
ethoxy)ethoxy)ethyl analogues, Ki values were obtainable for both the boc 
protected ,- and free amine 31 analogues, with the free amine analogue 
having 33% greater affinity.  
 
In the case of the hexyl analogues, both have moderately poor CB2 receptor 
binding affinity, with the free amine analogue ,3 having slightly lower Ki than 
its boc protected precursor ,', but both have relatively large error margins that 
makes conclusive interpretation difficult. These two hexyl analogues do stand 
out from the other 4-naphthyl linker analogues with the two lowest Ki of the 
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series. Finally a comparison between the octyl 3$ and,0 and (2-(2-
ethoxy)ethoxy)ethyl ,- and31analogues shows that there is a slightly greater 
affinity for the hydrophilic rather than the similar sized hydrophobic chain. 
 
These results suggest that, whatever their length or nature, linkers with a 
terminal free amine or boc-protected amine lead to a large loss of CB2 receptor 
binding affinity. Whether the free amine analogues are better tolerated than the 
boc protected analogues because of reduced steric bulk or interaction with a 
hydrophilic residue is unknown. The fact that increasing linker length does not 
gradually lead to a loss of affinity across the series, with the octyl and (2-(2-
ethoxy)ethoxy)ethyl analogues having similar or greater affinity than the ethyl 
and butyl, suggests that the 4-naphthyl position is not embedded deep within 
the active site. If it was, and there was not a large sub-site for the 4-naphthyl 
substitutions to be accommodated, then increasing chain length should rapidly 
lead to abolishment of CB2 receptor binding affinity. These results also suggest 
that a more hydrophilic linker such as (2-(2-ethoxy)ethoxy)ethyl may improve 
affinity compared to hydrophobic analogues, but whether this effect may be 
due to interaction with hydrophilic amino acid residues is unknown. Finally 
the hexyl linker analogues, showing the greatest CB2 receptor binding affinity 
of the series, suggest that at that linker length, and hence position of the 
primary or secondary amine, there may be an interaction with amino acid 
residues that is helping to improve affinity.  
 
Of the fifteen synthesised fluorescently labelled JWH-015 analogues, four 
were not tested due to difficulties in purifying to the required standard, and this 
unfortunately leaves the results table missing important data. With the eleven 
evaluated fluorescently labelled analogues, all substituents were found to 
reduce CB2 receptor binding affinity to the point where a Ki could not be 
calculated. 
 
The highest CB2 receptor binding affinity was found with use of the smallest 
fluorophore of NBD. In particular, the ethyl 3,, butyl 33 and (2-(2-
ethoxy)ethoxy)ethyl 0$ NBD analogues were the only fluorescent compounds 
to displace over 50% of [3H]CP55-940 - specific binding, suggesting that the 
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NBD fluorophore may be tolerated both close to the naphthyl ring and further 
away at the end of a longer linker. It is also surprising that all eleven 
fluorescently labelled analogues displaced [3H]CP55-940 - to a noticeable 
degree, from the small dansyl fluorophore with an ethyl linker to the large 
fluorescein fluorophore with octyl linker. This adds weight to the results of the 
4-naphthyl linker series above, which suggested that substitution at the 4-
naphthyl position is not embedded within the active site and may give access 
to an exit of the receptor site. 
 
The fluorescently labelled JWH-015 analogues show no discernable pattern 
except that the NBD fluorophore is better tolerated than either the dansyl or 5-
carboxyfluorescein fluorophore. This might be due to interactions between the 
heteroatoms of the NBD molecule and various receptor amino acid residues, as 
might be the case with primary amine 4-naphthyl linker analogues. The NBD 
fluorophore, as found with Yates work85, 86, seems to be a good fluorophore 
candidate for substitution of the indole cannabinoids. 
 
+!!,
We have successfully synthesised and evaluated a series of JWH-015 4-
naphthyl linker analogues and 4-naphthyl fluorescently labelled JWH-015 
analogues, with varying linker length and nature, coupled to three different 
fluorophores.  
 
For the JWH-015 4-naphthyl linker analogues, a number of aminoalcohols 
were amine boc protected to facilitate coupling to 2-methyl--propyl-3-(4-
hydroxy-1-naphthoyl)-indole ', using a mild Mitsunobu reaction. In the case 
of the amine boc protected 2-(2-(2-aminoethoxy)ethoxy)ethanol ,1, a synthetic 
pathway from the commercially available 2-(2-(2-chloroethoxy)ethoxy)ethanol 
was employed, whereas for the aminooctanol linker, a synthetic pathway from 
the commercially available 8-aminooctanoic acid was utilised, requiring amine 
trityl protection. 
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All five Mitsunubo couplings proceeded smoothly, with simply acid cleavage 
of the boc or trityl protecting group yielding the desired free amines for 
analysis and conjugation. For comparative purposes the boc protected octyl 
linker analogue 3$ was also synthesised. Simple nucleophilic substitution at 
the free amine by either dansyl chloride or 4-fluoro-7-nitrobenzofurazan 
yielded the desired dansyl or NBD fluorescent JWH-015 analogues 
respectively. In the case of the fluorescein JWH-015 analogues, 5-
carboxyfluorescein alone was not sufficiently reactive to allow conjugation, 
hence the activated 5-carboxyfluorescein--succinimdyl ester was used to 
achieve high yields of the desired products.. 
 
Pharmacological analysis of the series of JWH-015 4-naphthyl linker 
analogues showed a general loss of affinity with increasing linker length as 
expected. None of these analogues led to complete loss of affinity though, 
suggesting that an area, around the 4-naphthyl position of JWH-015 when 
bound to the CB2 receptor, can tolerate a reasonable degree of steric bulk. The 
fact that the free amine analogues were generally better tolerated than their 
corresponding boc protected analogues, and that the 2-(2-(2-
aminoethoxy)ethoxy)ethoxy linker was better tolerated than the similarly sized 
aminooctyl linker, suggests that this area of the CB2 receptor binding site may 
have a degree of hydrophilic character. Finally this series showed most 
promise with the boc protected ,' and free amine ,3 hexyl linker analogues, 
which against the general trend of lost affinity with increasing linker length, 
led to modest improvements suggesting possible positive interactions with 
receptor amino acid residues. 
 
The series of fluorescently labelled JWH-015 analogues all gave such low 
binding affinities that calculation of their binding affinities was not 
appropriate. There was no pattern found between the length of linker and 
binding affinity, suggesting that the fluorophore bulk is a greater factor in 
losing affinity than any affect of the linker, and that the linker position or 
length used was not sufficient to remove the fluorophore from interfering with 
receptor binding. Of the fluorophores used the NBD analogues showed most 
promise, consistently displacing a greater percentage of radioligand than the 
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other two fluorophores, possible because its smaller size is interfering less with 
receptor binding. 
 
It is disappointing that none of the fluorescently labelled indole cannabinoids 
showed significant CB2 receptor binding affinity. The results do however help 
to increase our understanding of the structure/activity relationship around 4-
naphthyl substitution. In particular, the hexyl linker analogues suggest that, at 
this position, the amine may be interacting with receptor amino acid residues, 
and that the NBD is the fluorophore of choice for future investigation of 
naphthyl-substituted indole cannabinoids. 
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This chapter describes the design and synthesis of non-classical cannabinoid 
analogues for the CB2 receptor. The main aim of this chapter is to study 
various substitutions to the non-classical cannabinoid scaffold and to identify 
possible sites for fluorophore attachment. 
 
There has previously been no published work investigating fluorophore 
ligation to either the classical or non-classical cannabinoid scaffold. Before 
any such molecules can be synthesised an investigation of the literature, as 
well as in house synthesis and evaluation of various substitutions to the non-
classical cannabinoid bicyclic structure is required. Ideally, substitutions that 
are both large and hydrophobic need to be investigated, due to the nature of the 
fluorophore ligation. The fluorophores likely to be used are large and generally 
hydrophobic in nature, and may even be larger than the original cannabinoid 
molecule. Furthermore the fluorophore needs to separate from the main 
cannabinoid ligand by a suitable length linker, to help prevent both 
interference with cannabinoid binding and any possible fluorescent quenching 
by the cannabinoid molecule. 
 
In this chapter we aim to investigate substitutions to the non-classical 
cannabinoid CP55-940 - to help determine suitable sites for fluorophore 
ligation. In a similar way to with the investigation of substitutions to the indole 
cannabinoid JWH-015 , in Section 2, CB2 receptor affinity and not activity is 
the primary endpoint, as the desired fluorescent cannabinoid will have use as a 
molecular tool to further our knowledge of the CB2 receptor and in high 
throughput screening assays to identify new cannabinoids. 
72 
$)/*
An ideal ligand for the development of a selective CB2 fluorescent ligand will 
possess the following: 
· High affinity for the CB2 receptor. 
· High CB2 to CB1 selectivity or potential for modifications leading to 
CB2 selectivity. 
· Good understanding of the ligand’s pharmacophores and structure 
activity relationships. 
· Suitable sites for fluorophore ligation, and the length/type of linker 
required. 
 
Unlike JWH-015 , in Section 2.2, CP55-940  (Figure 4.1) meets only two of 
these four criteria. It has the desired pharmacology, with a very high affinity 
for the CB2 receptor with a Ki = 0.7 nM, but is not selective for either the CB1 
or CB2 receptors
69. There are a number of possibilities for modification to 
CP55-940 that may induce CB2 receptor selectivity detailed in Section 4.2.1.3. 
Though CB2 selectivity is desired, in the case of CP55-940 a high degree of 
selectivity may be difficult to achieve without excessive modification. As any 
fluorescent cannabinoid will have primarily a use as a molecular tool, CB2 
selectivity in any assay could be induced by the addition of a CB1 receptor 
antagonist such as SR-141716A 1. 
 
We also have an excellent understanding of the important pharmacophores and 
the structure activity relationships for CP55-940 - that may allow 
identification of suitable sites for investigation, see Sections 4.2.1.2 and 4.2.4 
respectively. Unfortunately, like JWH-015 ,, there is a current lack of detailed 
studies into suitable sites for fluorophore ligation, with no attempts to make a 
fluorescent cannabinoid based on CP55-940. This means that an investigation 
into suitable fluorophore ligation sites needs to take place before the work and 
expense of synthesising fluorescent compounds. Finally, CP55-940 and its 
derivatives are not currently subject to the UK’s Misuse of Drugs Act, and 
hence can be synthesised without license90.  
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CP55-940 - is a bicyclic non-classical cannabinoid, that by definition lacks the 
pyran ring found in the classical cannabinoids. Both groups contain four 
important pharmacophores: the C3 alkyl side chain, optimised in CP55,940 - 
to the 1,1-dimethylheptyl group; the C1 phenol, the C9 northern aliphatic 
hydroxyl and the C12 southern aliphatic side chain and hydroxyl. When 
referring to the numbering of CP55-940 - and its analogues, the classical 
cannabinoid numbering used for THC $ and other classical cannabinoids will 
be used, and is detailed in Figure 4.1147. 
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Figure 4.1 CP55-940 -numbering. 
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The majority of work on improving cannabinoid receptor binding of classical 
cannabinoids was done before the discovery of the two cannabinoid receptors. 
For an excellent overview of this work see Razdan’s and Makriyannis’ in 
depth reviews on the subject14, 148. Hence, as only the centrally mediated 
effects of cannabinoids such as THC $ were directly observed, measures of 
cannabinoid efficacy were based on CB1 receptor binding alone. It was not 
until the discovery of the CB2 receptor in 1993
16 that a differentiation and 
eventual selectivity of binding at the two receptors could be investigated. 
 
Initially there were only two main pharmacophores of interest in the classical 
cannabinoids: The C3 alkyl side chain and the C9 northern aliphatic hydroxyl. 
It had been determined early on that any unsaturation on the C7 to C12 ring was 
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not required for activity14, and indeed with the C7 to C12 benzene ring of 
Cannabinol  CB1 and CB2, receptor binding is substantially reduced. 
 
It was found that extension of the C3 alkyl side chain beyond the pentyl of 
THC $ and other natural cannabinoids, to a straight chained heptyl side chain 
greatly improved CB1 and CB2 receptor binding and efficacy
14. It was later 
discovered that a dimethyl substitution at the C1 position of this alkyl side 
chain provided access to a hydrophobic sub-site that further improved binding 
at both receptors149-151. A number of investigations of this hydrophobic sub-
site show that it can also accommodate small hydrophobic cyclic 
substitutions152, 153, as well as unsaturation e.g. to a Z or E alkene, or alkyne154, 
155, but not hydrophilic groups such as alcohols156. The de facto C3 alkyl side 
chain now used is the 1,1-dimethylheptyl group for both classical and non-
classical cannabinoids. 
 
The development of the C9 northern aliphatic and C12 southern aliphatic 
groups have helped to boost both CB1 and CB2 receptor binding, leading to the 
knowledge and understanding of the four main pharmacophores detailed in 
Figure 2.2 36. C9 hydroxyl and methylhydroxyl substitutions are now 
commonly used in synthetic cannabinoid as they are thought to give access to 
a hydrophilic sub-site149, 157. 
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Figure 4.2 Main pharmacophores of CP55-940 and related non-classical cannabinoids. 
 
The invention of the non-classical cannabinoids discovered the C12 southern 
aliphatic pharmacophore and it is thought that it can interact with a hydrophilic 
75 
or hydrophobic sub-site67. Fixing the orientation of the side chain can 
differentiate between these receptor sub-sites158. 
 
.&&$&'

Unlike the alkylindoles, the classical cannabinoids offer limited possibilities 
for modification to allow CB2 receptor selectivity. The C1 phenol and the C1´ 
of the C3 alkyl side chain are the main options for the development of CB2 
selectivity in the non-classical cannabinoids. Of these positions, alteration of 
the C1 phenol is most useful, as it can be alkylated if the CP55-940’s other 
functional groups are protected. 
 
The C1 phenol was considered essential for cannabinoid activity until the 
discovery of the CB2  receptor, whereby modification at the C1 phenol led to 
selectivity for the CB2 receptor. 1-Deoxy e.g. 0,and 1-methoxy e.g. 03 
analogues in particular were found to give a degree of CB2 selectivity (Figure 
4.3)149, 159. 
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Figure 4.3 CB2 receptor selective modifications at C1 Phenol. Receptor binding affinities (Ki) 
quoted. 
 
Incorporation of larger substitutions at the C1´ position of the C3 alkyl side 
chain, than the traditional 1,1-dimethyl, may be better tolerated at the CB1 
receptor than at the CB2 receptor, leading to a degree of selectivity. Papahatjis’ 
group has investigated a series of analogues with varying bulky substitutions at 
the C1´ position, and found evidence for a difference in the size of between the 
CB1 and CB2 receptor sub-site pocket there
153, 156, 160. Though this mostly 
offers opportunities for CB1 receptor selectivity, a few analogues showed CB2 
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selectivity instead e.g. 00and $11 (Figure 4.4). Though of interest, these 
modifications are a not priority when designing a CB2 receptor select ligand. 
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Figure 4.4 CB2 receptor selective modifications at C1´ position. Receptor binding affinities 
(Ki) quoted. 
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CP55-940 -has four synthetically practical sites for fluorophore ligation: the 
C3 alkyl side chain; the C1 phenol, the C9 northern aliphatic hydroxyl and the 
C12 southern aliphatic hydroxyl. These are also the sites where most structure 
activity relationship studies have taken place, though the majority of these 
have looked at the CB1 receptor only and may not always be applicable to the 
CB2 receptor due to differences in their binding sites
36. Also many of these 
studies involved investigation of substitutions to the classical cannabinoid 
tricyclic scaffold, though in this case they are likely to be also relevant to the 
bicyclic non-classical cannabinoids due to large similarities between the two 
groups. Other parts of the CP55-940 - molecule may still be suitable for 
fluorophore ligation but limited investigation at these sites makes them less 
desirable as an initial choice to investigate. Of note though, is that substitution 
at the C2 and C4 positions of the phenyl ring
157, 161 and movement of the 
northern aliphatic hydroxyl side chain to the C10 position
14, 162 is tolerated and 
may provide alternative possibilities for fluorophore ligation. 
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The C3 alkyl side chain is unlikely to be a good site for fluorophore ligation or 
substitution, even though it would seem like an obvious choice for attachment 
as it is already quite a large hydrophobic alkyl chain. This is due to the alkyl 
77 
side chain being essential for the efficacy of the cannabinoid, as it is thought to 
be responsible for activating the cannabinoid receptor93. The alkyl side chain 
has been optimised for maximum efficacy to a 1,1-dimethylheptyl group150, 
and some modifications at the C1’ position have been utilised for CB1 or CB2 
selectivity (Section 4.2.1.3). 
 
Investigation at the CB1 receptor has found that a heptyl in the 1,1-
dimethylalkyl side chain analogues has greatest efficacy and, although some 
binding is maintained with chain extension, it leads to rapid loss of efficacy93. 
This, as well as results from quantitative structure activity relationship studies, 
suggests that the alkyl chain needs to be flexible and of appropriate length to 
bend around in the cannabinoid receptor active site to form the desired 
receptor ligand interactions for receptor activation93, 161. 
 
Introduction at the C1’ position of functional groups that could be used for 
fluorophore ligation, such as a ketone or an alcohol, led to a hundred fold 
reduction in binding affinity156. Furthermore, research suggests that the 1,1-
dimethyl moiety fits into a hydrophobic pocket of limited size which could not 
support a larger substitution such as a fluorophore153, 160. Therefore 
fluorophore ligation or substitution at either the C1’ position, at the alkyl chain 
terminus or somewhere along the C3 alkyl side chain is likely to cause 
complete loss of efficacy as well as binding affinity. 
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The C1 phenol was considered essential for cannabinoid activity until the 
discovery of the CB2  receptor whereby modification at the C1 phenol led to 
selectivity for the CB2 receptor (Section 4.2.1.3)
149, 159, 163. Interest has mainly 
stayed focused on modifications to promote CB2 receptor selectivity and there 
is little information on whether a large hydrophobic molecule would be 
appropriate for attachment at the C1 phenol. 
 
Work done before the discovery of the cannabinoid receptors, when ligands 
were evaluated with CB1 receptor 

 assays, suggests that esterification 
but not etherification could be tolerated e.g. L-Naboctate $1$ retains 
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cannabinoid activity (Figure 4.5)14. Care is needed with this result though, as 
the ester may be hydrolysed back to the phenol 

, and it may be this 
metabolised phenol that is responsible for the cannabinoid activity. 
 
More recent work suggests there is some room for extension around the C1 
phenol as cyclisation and etherification of the phenol and the C2 carbon $1 led 
to a modest ten fold loss of CB2 receptor binding
157. However, other work with 
modification of the C1 phenol to a diethyl phosphate group $1' led to a 
thousand fold loss of CB2 receptor binding
163. 
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Figure 4.5 Modification at C1 Phenol. CB2 receptor binding affinities (Ki) quoted. 
 
Unlike the C3 alkyl side chain, there is no significant evidence suggesting that 
fluorophore ligation at the C1 phenol would be inappropriate for CB2 receptor 
binding. However, due to no significant evidence suggesting that fluorophore 
ligation at the C1 phenol would be appropriate, it may be a useful target in 
developing SAR, but not first choice for fluorophore ligation. 

.&&'&'02
<

The northern aliphatic hydroxyl (NAH) is a versatile pharmacophore that can 
be extended, without loss of binding affinity, to a methyl alcohol e.g. AM919 
$1. 67, or substituted with modest loss of binding to a ketone149, 163, 
methylene149 or methyl ester $1- (Figure 4.6)164. This is encouraging, as any 
fluorophore ligation would obviously require modification of the northern 
aliphatic hydroxyl functional group. 
 
79 



4(




4(
 

)

4(
 	

-.)-)
Figure 4.6 Modification at C9 northern aliphatic hydroxyl. CB2 receptor binding affinities (Ki) 
quoted. 
 
Mahadevan  went on to investigate larger esterifications with the series 
$1/ R = methyl, isopropyl, propyl, hexyl, benzyl and naphthyl, but this 
time with a C1 methoxy substitution instead of the phenol found in $1-
164. This 
series had very poor binding affinities e.g. with the R = methyl analogue 
having a CB2 receptor Ki of 529 nM, and most others having a Ki > 10 µM. 
This suggests that loss of a hydroxyl at both the C1 and C9 is highly 
detrimental to cannabinoid binding. However, the R = propyl analogue had 
the greatest binding affinity of the series with a Ki of 214 nM, suggesting that 
there may be room for extension of a C9 side chain, and even the existence of 
an extra hydrophobic binding site within the CB2 receptor active site. 
 
The northern aliphatic hydroxyl is certainly a promising site for fluorophore 
ligation, both with the ability to accommodate different functional groups and 
with the potential to allow attachment of a large hydrophobic molecule. A 
continuation of the work of Mahadevan 164 would be especially interesting 
with a series of C9 esters with a conservative C1 phenol.  

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There has so far been only limited research into substitution or extension of the 
southern aliphatic hydroxyl (SAH). One investigation into the length and 
nature of the southern aliphatic side chain of classical cannabinoids found that 
either a hydrophobic e.g. 3-iodopropyl $1, or a hydrophilic e.g. 3-
hydroxypropyl $13 character can be given to the side chain without greatly 
affecting the CB2 receptor binding affinity (Figure 4.7)
67. These and earlier 
results suggest that there is both a smaller hydrophobic receptor sub-site and a 
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larger hydrophilic receptor sub-site for interaction with the southern aliphatic 
side chain, and that extension beyond a certain chain length begins to cause 
deterioration of binding affinity, but does not abolish it67, 165. Furthermore, 
changing the hydrophilic nature of the southern aliphatic hydroxyl to an amine 
$10, carboxylic acid $$1 or aldehyde $$$ leads to greater than one hundred 
fold loss of affinity for the CB1 receptor, suggesting that this pharamcophore is 
very sensitive to the functional group present165. 
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Figure 4.7 Modification of southern aliphatic hydroxyl. Receptor binding affinities (Ki) 
quoted.  
 
The southern aliphatic hydroxyl might not be the ideal site for fluorophore 
ligation, but is likely to be better choice than the C3 alkyl side chain or C1 
phenol, especially as it is not crucial for cannabinoid efficacy. There is also no 
evidence that further extension of this side chain will lead to total loss of 
binding affinity and this is worth investigating. Any substitution or extension 
will have to take into account that certain functional groups may lead to a large 
loss of affinity. 
 
.&&.**--)0.1
Investigation of the literature has shown that primarily the C9 northern 
aliphatic hydroxyl and then the C12 southern aliphatic hydroxyl sites should be 
the ones investigated, although the C1 phenol may also be of interest. 
Mutagenesis and modelling studies have been inconclusive, mostly due to 
difficulties in identifying which hydrophilic groups of the classical and non-
classical cannabinoids interact with which amino acid residues of the 
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cannabinoid receptors. This is further complicated by the innate flexibility of 
the non-classical cannabinoids, making it difficult to predict which part of the 
molecule is nearest the exit of the receptor binding site. 
 
Therefore, both substitutions to the northern aliphatic hydroxyl and southern 
aliphatic hydroxyl should be prioritised for investigation. Though substitution 
to the C1 phenol may still be possible within any synthetic strategy (Section 
4.3), initial investigations should limit its alteration to a C1 methoxy which 
should improve CB2 receptor selectivity. In particular it would be interesting to 
compare the C1 phenol and methoxy analogues with substitutions at the 
northern aliphatic hydroxyl. 
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Synthetic design of CP55-940 analogues was based on the work of a Pfizer 
research group who first developed CP55-940 - (Scheme 4.1). A Grignard 
reaction between a chirally pure (S)-alkyl 3-[4-(2-cyclohexenone)] propionate
$$
166-168 and a suitably phenol protected 1-bromo-4-(1,1-dimethylheptyl)-2-
hydroxybenzene $$'65, 167 forms the conjugate product $$., with 1,4 addition 
encouraged over 1,2 addition via transmetalation with a cuprous salt such as 
cuprous iodide65, 167. Thereafter, mild hydride reduction, e.g. with sodium 
hydride, of cyclohexanone $$. led to cyclohexanol $$-65, which if reduced 
further to the hydroxypropyl side chain and the phenol protecting group 
removed, yields CP55-940 -65. For our purposes of investigating various 
substitutions on the northern aliphatic, southern aliphatic and phenol 
pharmacophores, these protecting groups could be manipulated to allow 
various alkylations at the desired site before deprotection.  
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Scheme 4.1 Synthetic design of CP55-940 analogues (a) (i) $$', Mg, CuI, THF; (ii) $$; (b) 
NaBH4, THF, MeOH.  
 
Before such analogues could be made, the chirally pure cyclohexenone$$ 
and protected 2-bromophenol $$' needed to be synthesised. Cyclohexenone
$$ synthesis has been documented in great detail by the Pfizer research group 
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that designed CP55-940 -166-168, with our synthetic strategy following their 
work and is detailed in Section 4.4. 
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For the phenol protected 1-bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzene 
$$ the same Pfizer group devised the synthetic strategy detailed in Scheme 
4.265. This synthesis involves the double methylation of (3-
benzyloxyphenyl)acetonitrile $$/ with methyl bromide to 2-(3-
benzyloxyphenyl)-2-methylpropionitrile $$,, and then reduction with DIBAL 
to the carbonyl 2-(3-benzyloxyphenyl)-2-methyl-propionaldehyde $$3. Wittig 
condensation with pentyltriphenylphosphonium bromide to the olefin l-
(benzyloxy)-3-(l,l-dimethyl-2-heptenyl)benzene $$0 and then catalytic 
hydrogenation reduces both the alkene and removes the benzyl protecting 
group of the phenol to provide 3-(l,l-dimethylheptyl)phenol $1. Subsequent 
bromination is regioselective due to / activation by the phenol, and 
steric hindrance by the dimethylheptyl side chain, helping to protect the C2 and 
C4 positions. Protection with a suitable phenol protecting agent, in this case 
benzyloxy, yields 1-bromo-4-(1,1-dimethylheptyl)-2-benzyloxybenzene $. 
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Scheme 4.2 Synthetic strategy for protected 2-bromophenol $$' (a) MeBr, NaOH, DMSO; (b) 
DIBAL, THF; (c) pentyltriphenylphosphonium bromide, NaH, DMSO; (d) Pd/C, H2, EtOH; 
(e) Br2, CCl4; (f) benzyl bromide, KH, DMF.
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A number of problems were found with this proposed synthesis including the 
expense of the starting nitrile $$/, and the difficulties of handling methyl 
bromide required for the double alkylation of $$/. To investigate how the 
starting nitrile $$/ could be synthesised the literature was searched for 
possible strategies (Scheme 4.3). 
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Scheme 4.3 Possible synthesis of (3-benzyloxyphenyl)acetonitrile $$/ (a) NaNH2, NH3, 
MeCN; (b) SOCl2, dioxane; (c) tetraethylammonium cyanide, MeCN. 
 
The first published method involves a cyanomethyl substitution  to the 
chloro group of 2-benzyloxy-1-chlorobenzene $' to form the desired nitrile 
$$/. It is a violent reaction, with poor yields and the required starting material 
is not commercially available169, 170. The second published method involves 
two steps; first chlorination of 3-(benzyloxy)benzyl alcohol $. to afford 3-
(benzyloxy)benzyl chloride $-, and then reaction with the toxic hazardous 
tetraethylammonium cyanide salt to yield the desired nitrile $$/171. Although 
alcohol $. is commercially available it is expensive and comparative in price 
to nitrile $$/. Due to the expense and difficulty in synthesising the required 
starting material for the synthesis detailed in Scheme 4.2, as well as the 
associated difficulties and hazards involved with the alkylations involving 
methyl bromide, an alternative synthesis for a protected 2-bromo-5-(1,l-
dimethylheptyl) phenol $$' was sought. 
 
One alternative strategy is to synthesise the phenol protected 1-(3-
hydroxyphenyl)heptan-1-one $3, which can then be dimethylated to afford 
the required dimethylheptyl side chain $0. Two strategies were found for the 
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synthesis of this ketone $3 and are detailed in Scheme 4.4. The first strategy 
involves a Grignard reaction between the phenol protected 3-
hydroxybenzaldehyde $/ and 1-bromohexane to form the protected 3-(1-
hydroxyheptyl)phenol $,, and then suitable oxidation to form the desired 
ketone $3156. The second strategy, developed by the Makriyannis group, 
utilises a Grignard reaction between a protected Weinreb amide $'$172, formed 
by the substitution of a phenol protected 3-hydroxybenzoyl chloride $'1 with 
N,O-dimethylhydroxylamine, with 1-bromohexane to form the desired ketone 
$3
68, 173, 174. 
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Scheme 4.4 Alternative synthesis of the dimethylheptyl side chain (a) (i) 1-bromohexane, Mg, 
THF; (ii) $/ added, THF; (b) Jone’s reagent, acetone; (c) N,O-dimethylhydroxylamine, Et3N, 
DCM; (d) (i) 1-bromohexane, Mg, THF (ii) $'$ added, THF Scheme 4.4 (e) TiCl4, ZnMe2 or 
AlMe3, DCM. 
 
Unlike the disubstitution of ordinary carbonyls, a Weinreb amide only 
undergoes monosubstitution during a Grignard reaction, and so retains the 
carbonyl oxidation state needed for subsequent dimethylation. 
Monosubsitution forms a stable metal-chelated 5-membered cyclic 
intermediate, which protects the carbonyl carbon from further substitution by 
the Grignard reagent but will readily break down on acid workup (Figure 
4.8)172. This strategy avoids the need for oxidizing agents and an extra step to 
reform the carbonyl. 

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Figure 4.8 Grignard reaction mechanism with a Weinreb amide 
 
The final dimethylation to form the required dimethylheptyl side chain $0 can 
be achieved with either use of dimethyl zinc173, 174 or trimethyl aluminium68 in 
the presence of titanium chloride175. Dimethyl zinc is a better choice for this 
reaction as it produces superior yields, 84% c.f. 59%68, 173, 174. 
 
Hence it was decided that synthesis of the protected bromophenol $$' should 
utilise the methods of the Makriyannis group, with use of a Weinreb amide to 
allow conversion to the desired dimethylheptyl side chain, and thereafter 
follow Pfizer’s methods for bromination. This not only allows use of cheaper 
starting materials but also the use of more controlled and safer reaction 
conditions. The full synthetic pathway is detailed in Section 4.5. 
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Synthesis of the (S)-(+)-ethyl 3-[4(2-cyclohexenone)] propionate $$followed 
an established route as devised by the Pfizer research group (Scheme 4.5)166, 
168. 
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Scheme 4.5 (a) KOH, MeOH, reflux (87 %); (b) I2, KI, NaOH(aq), NaHCO3(aq) ()$'- 89 %* 
and )$'. 58 %*); (c) Zn, EtOH, reflux (69 %); (d) (+)-ephedrine, EtOAc, recrystallisation; 
(60 %); (e) 2M HCl(aq), DCM (95 %); (f) PTSA, EtOH, reflux (57 %); (g) BBr3, DCM, -30°C 
(61 %); (h) BuOK, BuOH, 35°C (78 %). Rac denotes a racemic mixture. * Theoretical yield 
calculated from the endo:exo ratio of 23:10. 
 
The starting material for this synthesis is a commercially available racemic, 
endo/exo mixture of methyl 1-methoxybicyclo[2.2.2]oct-5-ene-2-carboxylate 
)$'. This is prepared through the Diels-Alder reaction between 1-
methoxycyclohexa-1,3-diene and methyl acrylate (Figure 4.9), whereby the 
conjugated diene can be attacked at either face by the activated dienophile 
forming the racemic mixture )$'. 
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Figure 4.9 Diels-Alder reaction to form of rac-$'. 
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During the Diels-Alder reaction formation of the endo isomer, with 
substituents in the axial position, is kinetically favoured over formation of the 
exo isomer, with the substituents in the equatorial position. This is due to the 
preferred interactions that occur during endo isomer formation. As this is an 
irreversible Diels-Alder reaction, kinetic control favours endo isomer 
formation and a ratio of 2-3:1 endo to exo isomers would be expected.   
 
The initial aim of the synthesis described inScheme 4.5 was to isolate the 
enantiomer (2S,4S)-(-)-1-methoxy-bicyclo[2.2.2]-oct-5-ene-2-
[endo]carboxylic acid $'3 with high enantiomeric purity, and then to convert 
to the desired cyclohexanone $$. Cyclohexanone $$ can be derived from 
both this endo enantiomer $'3 as well as from the exo enantiomer (2R,4R)-
(+)-1-methoxy-bicyclo[2.2.2]-oct-5-ene-2-[exo]carboxylic acid, but work was 
focused on the endo enantiomer due to its predominance over the exo 
enantiomer. 
 
Before separation of the enantiomers could be achieved, the endo and exo 
isomers of starting material )$' needed to be isolated. This was achieved 
by the base hydrolysis of the esterto the acid )$'', which was purified by 
recrystallisation from 2,2,4-trimethylpentane to produce good yields of off 
white crystals. This unusual solvent was used after attempts with the standard 
range of solvents used for recrystallisation failed to produce good yields, with 
2,2,4-trimethylpentane been identified as a potential suitable candidate due to 
its similarity of structure to the solvent used by previous researchers167.)
$'' then underwent selective iodolactonisation under basic conditions. Only 
the endo iodolactone )$'- can be formed during this reaction, as the 
equatorial position of the exo acid prevents cyclisation even though the 
iodonium ion is still formed (Figure 4.10), and hence the exo acid )$'. is 
left unreacted. The iodolactone )$'- was isolated from the exo acid )
$'. during workup by organic extraction from the basic aqueous reaction 
mixture, and then purified by recrystallisation from isopropanol to give 
excellent a yield of white crystals. The ratio of isolated endo iodolactone to 
exo acid was found to be 2.5:1, as expected with such a Diels-Alder product. 
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The endo acid )$'/ was then reformed by refluxing with zinc, and purified 
by recrystallisation from petroleum ether 100/120 to give pure white crystals 
in modest yield. 
 
 
Figure 4.10 Selective endo iodolactonisation to form rac-$'- 
 
Chiral resolution of endo acid )$'/ was achieved by preparation of the 
dextrorotatory (+)-ephedrine salt $',, crystallised from hot ethyl acetate, with 
multiple recrystallisations to remove the undesired enantiomer176. Acidic 
breakdown of the (+)-ephedrine salt $', quantitatively yielded the (2S,4S)-(-)-
1-methoxy-bicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylic acid $'3. To 
determine how many recrystallisations of the (+)-ephedrine salt $', were 
required for a high enantiomeric purity, formation of a diastereoisomeric 
complex is required so that physical methods can identify the quantity of each 
enantiomer. Some published methods include the use of NMR techniques 
whereby short lived diastereoisomeric complexes can be formed , e.g. 
chiral lanthanide shift reagents, or long lived diastereoisomeric complexes are 
formed before analysis e.g. chiral derivatising agents177, 178.  
 
A simple method chosen here was to synthesise a long lived diastereoisomeric 
complex of (2S,4S)-(-)-endo acid $'3, by the formation of an amide $. with 
L-alanine benzyl ester $.$, using dicyclohexylcarbodiimide and N-
hydroxybenzotriazole catalysts (Scheme 4.6)179. This amide $. is a mixture 
of two diastereoisomers, and by use of H1 NMR spectroscopic analysis their 
relative amounts can be calculated. In this case, the integration of the C1 
methoxy group was used to compare the enantiomeric purity of products from 
different numbers of recrystallisations. The C1 methoxy is ideal, as it is both in 
an area of the spectrum devoid of other proton signals, and its relative position 
to the chiral carbon of interest means that each diastereoisomer has 
significantly different C1 methoxy signal positions. It was found that both two 
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and three recrystallisations of ephedrine salt $', gave moderate enantiomeric 
purity of $., with 64% and 88% enantiomeric excess. Therefore, three 
recrystallisations of the dextrorotatory (+)-ephedrine salt $', were chosen as, 
although each recrystallisation is associated with some loss of product, the 
greater enantiomeric purity was desirable. 
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Scheme 4.6 Formation of a long lived diastereoisomeric complex between (2S,4S)-(-)-1-
methoxy-bicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylic acid and L-alanine benzyl ester (a) 
DCC, HOBt, DIPEA. 
 
The (2S,4S)-(-)-endo acid $'3 was esterified to form(2S,4S)-(-)-ethyl 1-
methoxybicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylate $'0, purified by flash 
column chromatography to modest yields, with an ethyl ester being chosen 
over methyl or propyl analogues as it has been demonstrated to be more stable 
to the boron tribromide conditions then required for the cleavage of the methyl 
ether to form (+)-(2S,4S)-(-)-ethyl 1-hydroxybicyclo[2.2.2]-oct-5-ene-2-
[endo]carboxylate$.1, again giving modest yields166. This cyclic alcohol $.1 
then underwent base catalysed reverse Claisen rearrangement (Figure 4.11) 
and was purified by preparatory layer chromatography to give good yields of 
the desired (S)-(+)-ethyl 3-[4(2-cyclohexenone)] propionate $$. 
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Figure 4.11 Base catalysed reverse Claisen rearrangement to form cyclohexanone $$. 
 
Care was needed during this synthetic strategy to avoid certain extreme 
physical conditions. Once the endo acid )$'/ was isolated from the exo 
91 
diastereoisomers, very high temperatures were avoided that could cause 
isomerisation. Furthermore once the purified (+)-endo acid $'3 was prepared, 
extremes of pH were also avoided as these could cause base or acid catalysed 
racemisation at the α-carbon to the carboxylic acid.  
 
The synthesis of the ephedrine salt $', showed a comparative optical rotation 
to that of the literature166, 168, and helps to confirm that the three 
recrystallisations of this salt provide a high enantiomeric purity, as determined 
with the synthesis of the diastereoisomeric complexes investigation discussed 
above. On further modification, although the degree of optical rotation was 
found to be of a lower magnitude than that found in the literature, e.g. (2S,4S)-
(-)-1-methoxy-bicyclo[2.2.2]-oct-5-ene-2-[endo],carboxylic acid $'3 had an 
[α]D in dichloromethane of -20.7˚ compared to the literature values of -26.3˚ 
and -25.0˚, and (2S,4S)-(-)-ethyl 1-methoxybicyclo[2.2.2]-oct-5-ene-2-
[endo]carboxylate $'0 had an [α]D in chloroform of -3.08˚ compared to the 
literature value of -5.1˚166, 168. This suggests that a degree of racemisation 
occurred lowering the enantiomeric purity of the compounds, which will lead 
to a lower enantiomeric purity with any final compounds made.  
 
During this successful synthesis of (S)-(+)-ethyl 3-[4(2-cyclohexenone)] 
propionate $$, most compounds were either purified by crystallisation or 
chromatography, which had not been undertaken in the previously published 
work166-168. With the aid of more powerful analytical methods, there has been 
improved characterisation of these compounds, which is detailed in Section 
6.1.
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Synthesis of 1-bromo-4-(1,1-dimethylheptyl)-2-benzyloxybenzene $-1and 1-
bromo-4-(1,1-dimethylheptyl)-2-methoxybenzene $.0followed the devised 
route as discussed in Section 4.3.1, and described in Scheme 4.7, where all 
compounds were purified by flash column chromatography or preparative 
layer chromatography. 
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Scheme 4.7 Synthesis of the 1-bromo-4-(1,1-dimethylheptyl)-2-benzyloxybenzene $-1 and 1-
bromo-4-(1,1-dimethylheptyl)-2-methoxybenzene $.0 (a) ,-dimethylhydroxylamine, Et3N, 
DCM (65 %); (b) 1-bromohexane, Mg, cat I2, THF; (ii) $.. added, THF (92 %); (c) TiCl4, 
ZnMe2, DCM (98 %); (d) BBr3, DCM (77 %); (e) Br2, DCM (83 %);(f) K2CO3, DMF, methyl 
iodide (R = Me 61 % ); NaH, DMF, benzyl bromide (R = Bn 91 %). 
 
Formation of the Weinreb amide (3-methoxyphenyl)--methoxy--
methylcarboxamide $.. in good yields was by nucleophilic substitution of the 
commercially available 3-methoxybenzoyl chloride $.' with ,-
dimethylhydroxylamine using triethylamine base. The following Grignard 
reaction between this Weinreb amide $.. and 1-bromohexane led to the 
desired monosubstitution product 1-(3-methoxyphenyl)heptan-1-one $.- in 
excellent yields, and then dimethyl zinc with titanium (IV) chloride catalyst 
dimethylation proceeded smoothly to form the desired dimethylheptyl side 
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chain of 1-(1,1-dimethylheptyl)-3-methoxybenzene $./, again in excellent 
yields. 
 
Demethylation with boron tribromide gave 1-(1,1-dimethylheptyl)-3-
hydroxybenzene $.,, in modest yields associated with this deprotection, which 
could then undergo aromatic bromination with precisely one equivalent of 
bromine180, 181. The desired C6 bromination was achieved and yielded 1-
bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzene $.3, with minimal di and 
tribromination products that were easily removed during chromatographic 
purification while retaining good yields. C6 bromination of 1-(1,1-
dimethylheptyl)-3-hydroxybenzene $.3 was confirmed over other aromatic 
monosubstitutions through the use of H1 and COSY NMR spectroscopic 
analysis. The COSY NMR spectra with proton NMR overlaid, shown in 
Figure 4.12, has only three protons in the aromatic region, confirming a single 
purified product. Of these three protons, one is a doublet at 7.37 ppm with a 
coupling constant of 8.5 Hz, one is a doublet at 7.02 ppm with a coupling 
constant of 2.3 Hz and the last is a doublet of doublets at 6.80 ppm with 
coupling constants of 8.5 and 2.3 Hz. The 8.5 Hz coupling constant is 
suggestive of ortho coupling with the 2.3 Hz being suggestive of meta 
coupling. The COSY spectra confirms ortho coupling between the 8.5 Hz 
doublet and the doublet of doublets proton, as well as meta coupling between 
the 2.3 Hz doublet and the doublet of doublets proton. Both of these 
observations are consistent with either a C6 or C4 monobromination of 1-(1,1-
dimethylheptyl)-3-hydroxybenzene $',. C4 substitution can be ruled out 
though due to the relatively upfield position of 6.80 ppm of doublets proton. 
This indicates that this proton is unlikely to be ortho to the phenol group which 
would be found with a C4 substitution, and hence confirms the sole product as 
1-bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzene $'3. 
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Figure 4.12 COSY NMR of 1-bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzene $'3, with 
proton NMR on left and top axis. The red lines show ortho coupling and the blue lines show 
meta coupling. 
 
Before any Grignard reaction the phenol of the 1-bromo-4-(1,1-
dimethylheptyl)-2-hydroxybenzene $'3 needs to be protected. Previous work 
by other groups have used a benzyloxy protection65, 167, 168, but with an aim to 
improving CB2 receptor selectivity, a methoxy protection was also chosen so 
that eventual analogues with substitutions at the southern and northern 
aliphatic groups could be assessed with and without the methoxy protection. 
For these protections 1-bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzene $.3 
was alkylated with either benzyl bromide or methyl iodide to give 1-bromo-4-
(1,1-dimethylheptyl)-2-benzyloxybenzene $-1 and 1-bromo-4-(1,1-
dimethylheptyl)-2-methoxybenzene $.0 respectively, both in good purified 
yields.  
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With the successful synthesis of (S)-(+)-ethyl 3-[4(2-cyclohexenone)] 
propionate $$ and the two phenol protected 1-bromo-4-(1,1-dimethylheptyl)-
2-hydroxybenzenes $-1 and $.0 detailed above, a Grignard coupling between 
the two was attempted (Scheme 4.8). To encourage 1,4 addition at the 
conjugated ketone, transmetallation of the Grignard reagent with a copper salt 
was included in the process. 
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Scheme 4.8 Attempted Grignard couplings (a) (i) $.0 or $-1, Mg, I2, THF; (ii) $$ added with 
CuI. 

Initially the reaction between the C1 methoxy protected 1-bromo-4-(1,1-
dimethylheptyl)-2-methoxybenzene $.0 and (S)-(+)-ethyl 3-[4(2-
cyclohexenone)] propionate $$ was attempted. When the desired product was 
not yielded, the reaction using the C2 benzyloxy protected 1-bromo-4-(1,1-
dimethylheptyl)-2-benzyloxybenzene $-1 was attempted, as this was the 
compound used by previously published research for this Grignard coupling65, 
167. When this reaction did not succeed, a more detailed look at the compounds 
remaining showed that the desired Grignard product had not been formed, and 
that the two phenol protected 1-bromo-4-(1,1-dimethylheptyl)-2-
hydroxybenzenes $.0 and $-1 remained intact. If the Grignard product had 
been formed, but failed to react with the cyclohexenone, then on aqueous 
workup the debrominated products 1-(1,1-dimethylheptyl)-3-methoxybenzene  
and 1-(1,1-dimethylheptyl)-3-benzyloxybenzene  would have been identified 
(Figure 4.13). Note that during these reactions the expected white-grey 
precipitate on formation of the Grignard reagent was not seen. At the time this 
was thought to be due to the small quantities being used, with the entire 
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Grignard reagent being dissolved in the ether solvent. In retrospect this is 
further evidence that the Grignard reagent did not form. 
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Figure 4.13 Formation of the Grignard reagent and debromination on aqueous workup. 
 
The most likely reason for the Grignard reagent not forming is that the 
magnesium was not suitably active to allow initiation of the reaction. In 
particular, a magnesium oxide surface layer will prevent initiation, and an oily 
residue on the surface can increase this hindrance. To help remove any oily 
residue the magnesium was cleaned with hexane washings and then stored 
under an inert atmosphere. To help activate the magnesium, a catalytic amount 
of iodine, often used for this purpose, reduces some of the magnesium oxide 
allowing initiation of the reaction. In this case however, these methods were 
not sufficient.  
 
One of the previously published work on this reaction used the hydride 
reducing agent sodium bis(2-methoxyethoxy)aluminium hydride instead of 
iodine to remove the magnesium oxide surface layer and help initiate the 
reaction167. To determine if this catalyst would allow formation and coupling 
of the desired Grignard reagent, a trial reaction between the C1 benzyloxy 
protected 1-bromo-4-(1,1-dimethylheptyl)-2-benzyloxybenzene $-1 and 
cyclohex-2-enone was attempted, so as not to waste any more of the chirally 
purified (S)-(+)-ethyl 3-[4(2-cyclohexenone)] propionate $.0 (Scheme 4.9). 
This time a white-grey precipitate was seen on the formation on the Grignard 
reagent, although the desired product was again not yielded. Both mass 
spectrometry and NMR analysis showed that the debrominated 1-(1,1-
dimethylheptyl)-3-benzyloxybenzene was formed, confirming the formation of 
the Grignard reagent .  
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Scheme 4.9 Trial Grignard coupling (a) (i) $.0, Mg, sodium bis(2-methoxyethoxy)aluminium 
hydride (Red-Al®), THF; (ii) cyclohex-2-enone added with CuI. 
 
The reason the Grignard reagent did not react with the cyclohex-2-enone is 
currently unknown. All compounds were freshly purified, the tetrahydrofuran 
freshly dried, all apparatus flame dried and all parts of the reaction undertaken 
in an inert atmosphere. There are obvious difficulties in transferring a 
precipitate from one vessel to another, achieved with a wide bore cannula and 
solvent washing, and the addition of a solid such a copper iodide to the 
reaction mixture, achieved using a nitrogen filled dry bag. Even if the reaction 
was not rigorously dry and some of the Grignard reagent was lost, at least 
some 1,2 or 1,4 addition products would have been expected, but no evidence 
was found for the formation of either of these. This reaction has been repeated, 
with and without the addition of copper iodide, but in all cases, even though 
the Grignard reagent was confirmed to have been formed, no evidence of 
addition to the cyclohex-2-enone has been found. Work is therefore currently 
ongoing on how to improve and succeed at this reaction and therefore produce 
the desired compounds needed before any investigation of CP55,940 
substitutions on CB2 receptor binding can take place. One simple way 
envisaged to improve the practicalities of this reaction, is to use an organic 
soluble copper transmetallation agent such as copper bromide dimethylsulfide 
complex thus avoiding the need to add a solid under inert conditions182. 
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We have successfully synthesised (S)-(+)-ethyl 3-[4(2-cyclohexenone)] 
propionate $$ and the two phenol protected 1-bromo-4-(1,1-dimethylheptyl)-
2-hydroxybenzenes $.0 and $-1, but have so far been unable to perform the 
Grignard reaction necessary for the coupling of these two compounds that 
would allow synthesis of a range of substituted CP55-940 analogues and 
evaluate their effect on CB2 receptor binding.  
 
Though the synthesis of (S)-(+)-ethyl 3-[4(2-cyclohexenone)] followed an 
established pathway, we present more detailed characterisation of both the 
intermediates and final compound in Section 6. Furthermore, to evaluate the 
ephedrine recrystallisations that serve to separate the enantiomers of 1-
methoxy-bicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylic acid, a simple method 
for the production of a diastereoisomer complex and its analysis by proton 
NMR is demonstrated  
 
We also present an improved synthesis of the C2 benzyloxy protected 1-
bromo-4-(1,1-dimethylheptyl)-2-benzyloxybenzene $-1 and the C2 methoxy 
protected 1-bromo-4-(1,1-dimethylheptyl)-2-methoxybenzene $.0, using a 
Weinreb amide intermediate to facilitate the desired alkylations with the 
minimal number of synthetic steps. 
 
CP55-940 still presents a promising candidate for formation of a CB2 receptor 
fluorescent ligand, especially as it binds nearer the exit of the active site than 
do indole cannabinoids, potentially allowing any fluorophore and linker less 
opportunity to interfere with cannabinoid binding. With (S)-(+)-ethyl 3-[4(2-
cyclohexenone)] propionate $$ and the two phenol protected 1-bromo-4-(1,1-
dimethylheptyl)-2-hydroxybenzenes $.0 and $-1 already prepared in 
sufficient amounts to allow the synthesis of numerous substituted CP55-940 
analogues, it is hoped that work will be ongoing to succeed in our aims.
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During this thesis we have designed, synthesised and evaluated a series of 
cannabinoid ligands, with an aim of producing a fluorescently labelled CB2 
receptor selective ligand for use as a biomolecular tool. 
 
Efforts were initially focused on the alkylindoles, and in particular JWH-015 
,. The literature was reviewed for any relevant structure activity relationships, 
homology modelling and mutagenesis studies that would help in the 
identification of sites on the alkylindole scaffold where fluorophore attachment 
maybe tolerated. The 3 and 4-naphthyl positions of JWH-015 , were chosen to 
determine the effect of a range of substitutions at these positions on CB2 
receptor binding affinity. A total of fifteen compounds were evaluated, 
providing new structure activity relationship data for alkylindole CB2 receptor 
binding. The results confirmed that increasing steric bulk at these positions 
decreased CB2 receptor affinity and that hydrophobic substitutions were 
tolerated better than hydrophilic ones of a similar size. Although the 2-methyl-
-propyl-3-(4-hexyloxy-1-naphthoyl)-indole.$ analogue was found to be a 
poor CB2 receptor ligand, replacing the -propyl with a -pentyl resulted in 
the 2-methyl--pentyl-3-(4-hexyloxy-1-naphthoyl)-indole..analogue having 
significantly greater CB2 binding affinity. These results suggested that bulky 
substitution at the 4-naphthyl position of JWH-015 ,, could be tolerated to 
varying degrees, depending on optimisation of other pharmacophores. 
 
The success of the 4-naphthyl substituted JWH-015 series, fed into the work in 
designing a fluorescently labelled CB2 receptor ligand. The 4-naphthyl 
position was now chosen as a potential fluorophore ligation site. A variety of 
different linker length and types, as well as different fluorophores were chosen 
to aid in this development, the aim being to produce an array of non-
fluorescent and fluorescent compounds for investigation. Ten non-fluorescent, 
linker only analogues and eleven fluorescent analogues were evaluated, all 
leading to large decreases in CB2 binding affinities. Of the analogues with only 
a linker attached, the hexyl linker analogues of 2-methyl--propyl-3-(4-(tert-
butyl 6-hexyloxycarbamate)-1-naphthoyl)-indole,' and 2-methyl--propyl-3-
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(4-(4-aminohexyloxy)-1-naphthoyl)-indole,3 were found to have the highest 
CB2 receptor binding affinity of the series, suggesting that at that linker length 
there may be a receptor sub-site for which they can interact with. Of the 
fluorescent analogues, the NBD fluorophore produced the most promising 
compounds, but with insufficient CB2 receptor binding affinity to obtain their 
Ki values. This suggests that a smaller fluorophore such as NBD may be 
tolerated within that region of the receptor active site. The alkylindoles, and in 
particular substitutions to the naphthyl ring of JWH-015 , still offer a good 
opportunity for the development of fluorescently labelled CB2 receptor 
ligands. 
 
Efforts were then turned to the non-classical cannabinoids, and in particular 
CP55-940 -. Again the literature was reviewed for any relevant structure 
activity relationships, homology modelling and mutagenesis studies that would 
help in the identification of sites on the non-classical cannabinoid scaffold 
where fluorophore attachment may be tolerated. The C9 northern aliphatic 
group and C12 southern aliphatic group were chosen as candidates for 
investigation, with potential modification at the C1 phenol to induce CB2 
selectivity. Though the initial synthesis of the CP55-940 - precursors (S)-(+)-
ethyl 3-[4(2-cyclohexenone)] propionate $$ and two phenol protected 1-
bromo-4-(1,1-dimethylheptyl)-2-hydroxybenzenes $.0 and $-1, were 
successful, attempts to couple these compounds by the published Grignard 
method failed to yield the desired compound. Modification of reaction 
conditions and numerous trial reactions, failed to produce the desired Grignard 
coupling. The non-classical cannabinoids still are an interesting choice for 
investigating potential development of fluorescently labelled CB2 receptor 
ligands. 
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The breadth and depth of research into cannabis, the cannabinoid system and 
cannabinoid ligands continues apace and the development of fluorescent 
cannabinoids would offer a valuable tool for the whole field of research. With 
no fluorescently labelled cannabinoid for either the CB1 or CB2 receptor 
currently reported in the literature, our ongoing efforts at their design and 
synthesis should continue. 
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Although the research presented has not produced the desired fluorescent CB2 
receptor ligand, there is still more useful information to be gained from the 
fluorescent and non-fluorescent JWH-015 analogues developed so far. In 
particular, assessment of CB1 receptor affinity as well as functional assays at 
both receptors to determine agonist-antagonist properties for all compounds, 
will add to our understanding of the structure activity relationships at both 
receptors, as well as highlight any modifications that induce either CB1 or CB2 
receptor selectivity. Furthermore, application of fluorescent confocal 
microscopy, with the highest affinity fluorescent cannabinoids evaluated (i.e. a 
number of the NBD analogues), would allow spatial and temporal 
identification of fluorescent compounds binding to whole cell populations 
expressing either the CB1 or CB2 receptor. This will help confirm cannabinoid 
receptor binding for these low affinity ligands, although a complication is that 
as the fluorescent JWH-015 analogues are so highly hydrophobic it is 
envisaged that significant diffusion through the membrane into the cellular 
compartment will occur. 
 
Beyond further evaluation of the compounds already synthesised, a second 
generation of fluorescent JWH-015 analogues should be investigated. Initially 
there are a number of subtle improvements or alterations to the JWH-015 
scaffold that could be utilised to enhance cannabinoid receptor affinity. Most 
notably extension of the -alkyl side chain to an -pentyl group, should 
significantly improve both CB1 and CB2 receptor binding affinities, whereas as 
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removal of the indole 2-methyl group may improve affinities, as substitutions 
at the 3-naphthyl and possibly the 4- naphthyl position have been shown to be 
poorly tolerated in the presence of the 2-methyl group. Both such alterations 
would likely lead to a potential loss of any CB2 receptor selectivity present.  
 
If these simple alterations do not boost affinity enough, more fundamental 
changes in the fluorescent JWH-015 analogue should be investigated. Such 
changes may include;  
 
· use of longer linker lengths to help remove the bulky fluorophore from 
the receptor active site,  
· use of different fluorophores, though most other fluorophores are larger 
than the most promising NBD,  
· continued investigation of 3-naphthyl position which has already been 
shown to tolerate a degree of substitution like the 4-naphthyl position, 
· investigation of new substitution sites that have so far been neglected 
e.g. the 6 and 7-naphthyl positions which tolerate a degree of 
substitution or replacement of the indole with a pyrrole moiety where 
various aromatic substitution are well tolerated.  
 
Choosing which of these routes to develop and in which direction, will greatly 
benefit from the frequent developments in alkylindole structure activity 
relationships published in the literature, as well as the development of new and 
improved CB2 receptor homology models. 
 
When a suitable fluorescently labelled alkylindole cannabinoid e.g. with a Ki 
of 100 nM or less is developed, then this can go on to be used as a platform for 
use in numerous applications including;  
 
· high throughput screening for new cannabinoid ligand types,  
· confocal microscopy and single molecule detection techniques, to help 
advance our knowledge and understanding of the cannabinoid receptor 
system,  
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· in house homology model refinement, where a fluorescent cannabinoid 
with good affinity may help solve the questions concerning orientation 
of the alkylindoles in the active site, 
· bioassays for the identification of cannabinoid receptor over expression 
which could help guide diagnosis and therapy e.g. in some glioma 
tumours an over expression of CB2 receptor is positively correlated 
with severity and prognosis. 
 
On a more practical note, once a successful fluorescently labelled cannabinoid 
is developed, an assessment of both its core physiochemical properties and 
synthetic pathway will need to be undertaken. With respect to its 
physiochemical properties, any fluorescent cannabinoid is likely to be highly 
hydrophobic. This may cause difficulties in choosing an appropriate solvent to 
dissolve in, where some solvents such as DMSO are known have deleterious 
effects on cell membranes, and using such solvents may interfere with a 
number of assays. Furthermore, if a GPCR ligand is of a certain hydrophobic 
nature, excessive quantities may diffuse through cell membranes, meaning 
greatly increased quantities will be required for use in whole cell populations, 
as well as such cell compartment localisation complicating confocal 
microscopy applications. In terms of its synthesis, although a fluorescent 
cannabinoid is unlikely to be produced on an industrial scale, significant 
quantities may be required for the purposes of high throughput screening or 
bioassays. Therefore as well as significant scale up of synthesis, attention will 
need to be focused on minimising loses from relatively low yielding reactions 
e.g. the Fridel Crafts coupling between naphthyl and indole moieties or the 
final fluorophore conjugation step.  
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CP55-940 and other non-classical cannabinoid analogues are still very strong 
candidates for fluorophore ligation, especially as there have been no published 
attempts at producing fluorescent CP55-940 analogues. The fact that the non-
classical cannabinoids bind higher in the CB2 receptor than the alkylindoles, 
potentially offering more suitable placement of a bulky fluorophore, meaning 
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that such a fluorescent cannabinoid may be easier to achieve. Therefore efforts 
should continue on the development of various series of CP55-940 analogues.  
 
Initial focus should be on successful completion of the Grignard reaction 
between the chirally purified (S)-(+)-ethyl 3-[4(2-cyclohexenone)] propionate 
$$ and either of the two phenol protected 1-bromo-4-(1,1-dimethylheptyl)-2-
hydroxybenzenes $.0 and $-1. A number of suggestions on how this can be 
achieved have been commented on in section 4.6, but considering this reaction 
is the standard route employed by the industry for the production of the non-
classical cannabinoids, it should be a matter of when success will be and not if 
it will happen. 
 
Once the protected CP55-940 precursor is produced in sufficient quantities, 
and chiral purity checked, a systematic process of careful protection and 
deprotection of the C1 phenol, SAH and NAH, will allow selective substitution 
at any of these desired sites. Though work should probably focus on the SAH 
and NAH positions, which are more tolerant to bulky substitutions, the 
knowledge gained from assessing the effect of substitutents beyond a three 
carbon chain length at the C1 phenol, would add to our understanding of its 
structure activity relationships at the cannabinoid receptors. 
 
Similar to the JWH-015 analogue series documented in chapter 2, 
investigation at the C1 phenol, SAH and NAH, should focus on developing 
structure activity relationship data for a range of size and type of substitutions. 
In particular; bulky, hydrophobic and aromatic substitutions would be useful in 
determining which site, and type/length of linker, would be worth while 
investigating further. 
 
Once such a site is prioritised, a series similar to the JWH-015 analogues 
documented in chapter 3 should be synthesised with the aim of deriving a 
fluorescently labelled CP55-940 analogue with appropriate affinity at the CB2 
receptor. A range of linker lengths and types should be used, as well as a 
variety of fluorophore compounds. If a particular linker is found to be 
effective, a wide range of fluorophores could be used to improve both affinity 
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and spectroscopic properties. If a fluorescently labelled CP55-940 analogue is 
successfully synthesised then it should undergo detailed evaluation and 
development as discussed above in section 5.2.1 for the JWH-015 analogues. 
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Chemicals and solvents were purchased from standard suppliers and were used 
without further purification. Unless otherwise stated, reactions were carried 
out at ambient temperature, under atmospheric pressure and monitored by thin 
layer chromatography on Merck Kieselgel 60 F254 pre-coated aluminium 
backed plates. Visualisation was by examination under UV light (254nm + 
366mm), with use of potassium permanganate as a general stain and ninhydrin 
for amines. 
 
Purification by flash chromatography was carried out using Merck Kiesgel 60, 
230-400 mesh silica. Purification by preparative layer chromatography was 
carried out using Fluka silica gel GF254 on glass plates (200 mm x 200 mm x 
1mm). 
 
Proton (400 MHz) nuclear magnetic resonance and carbon (100 MHz) nuclear 
magnetic resonance spectra were recorded on a Bruker-AV 400 spectrometer.  
Spectra were assigned with the aid of DEPT-135, DEPT-90, COSY and HSQC 
NMR. Chemical shifts (δH and δC) are quoted on the δ-scale in ppm using 
residual solvent or tetramethylsilane as internal standard. Coupling constants 
() are recorded in hertz and signal multiplicities described by: s, singlet; d, 
doublet; t, triplet; q, quartet; br, broad; m, multiplet; app, apparent, and 
combinations thereof. 
 
High resolution mass spectra TOF-ES (+/-) were recorded on a Waters 2795 
Separation Module/Micromass LCT Platform. Melting points were either 
recorded uncorrected on a Gallerkamp 3A 3790 apparatus or on a Perkin 
Elmer Pyris 1 differential scanning calorimeter. FT-infrared spectra were 
recorded as KBr discs or as thin films between NaCl discs in the range of 
4000-600 cm-1 using an Avatar 360 Nicolet FTIR spectrophotometer. Optical 
rotation was measured on a Bellingham-Stanley ADP220 polarimeter. 
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Analytical reverse-phase high performance liquid chromatography (HPLC) 
was either performed on a Waters Millenium LC system, with Waters 515 
pumps and Waters 996 photodiode array detector, using a C8 (Vydac reverse 
phase C8 column (150 x 4.6 mm) flow rate 1mL/min) or C18 column 
(S.F.C.C. reverse phase C18 column (150 x 4.6 mm) flow rate 1mL/min or 
ACE reverse phase C18 column (250 x 4.6 mm) flow rate 1mL/min), or on a 
Waters automated LC system, with Water 2525 pump, Water 2767 sample 
manager and Waters 2487 dual λ absorbance detector using a C18 column 
(Onyx Monolith C18 column (100 x 4.6 mm), flow rate 3 mL/min or Waters 
Symmetry C18 column (75 x 4.6 mm), flow rate 1 mL/min). All solvents were 
degassed before use and all compounds for radioligand binding assays were 
purified until greater than 98 % pure with UV detection at 310 nm. 
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Sodium hydride (60% w/w in mineral oil, 2.287 g, 57.2 
mmol) was suspended in DMF (75 mL), cooled to 0 °C and 
2-methylindole (5.000 g, 38.1 mmol) was added. 1-bromopropane (4.16 mL, 
45.7 mmol) was added and the solution was stirred under an inert atmosphere 
for 3 h.  
 
Excess hydride was reacted with ice (5 mL), stirred for 5 min and the solution 
concentrated 
. The resulting solution was diluted with water (40 mL), 
and extracted with EtOAc (3 x 50 mL). The combined organics were washed 
with 2 M HCl(aq), water and brine, dried over MgSO4 and reduced 
. 
The crude product was purified by flash column chromatography (5:95 
Ether:Petroleum Ether 60/80) to yield the desired product (5.806 g, 89 %) as a 
clear oil.
 
δH (CDCl3) 7.55 (1H, d,  7.8 Hz, 4-H or 7-H), 7.29 (1H, d,  8.1 Hz, 4-H or 7-
H), 7.15 (1H, m, 5-H or 6-H), 7.08 (1H, m, 5-H or 6-H), 6.27 (1H, s, 2-H), 
4.05 (2H, t,  7.4 Hz, N-CH2), 2.45 (3H, s, 2-CH3), 1.81 (2H, m, CH2 β to 
amine), 0.98 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 136.7, 136.5, 128.0, 120.3, 119.6, 119.1, 109.0, 99.8 (8 x aromatic) 
44.8 (CH2, N-CH2), 23.5 (CH2, CH2 β to amine), 12.9 (CH3), 11.5 (CH3). 
 
ES-MS MH+ calcd for C12H15N1 174.13 found  174.13. 
 
FTIR (NaCl) 3053, 2963, 2933, 2875, 1611, 1551, 1479, 1463, 1400, 1356, 
1337,1310, 1223, 1172, 1138, 1104, 1013, 770, 746 cm-1. 
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Sodium hydride (60% w/w in mineral oil, 2.287 g, 57.2 
mmol) was suspended in DMF (75 mL), cooled to 0 °C and 
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2-methylindole (5.000 g, 38.1 mmol) was added. 1-bromopropane (5.20 mL, 
41.9 mmol) was added and the solution was stirred under an inert atmosphere 
for 2 h.  
 
Excess hydride was reacted with ice (5 mL), stirred for 5 min and the solution 
concentrated 
. The resulting solution was diluted with water (40 mL), 
and extracted with EtOAc (3 x 50 mL). The combined organics were washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (5:95 Ether:Petroleum 
Ether 60/80) to yield the desired product (7.540 g, 98 %) as a clear oil.
 
δH (CDCl3) 7.57 (1H, d,  7.8 Hz, 4-H or 7-H), 7.31 (1H, d,  8.1 Hz, 4-H or 7-
H), 7.18 (1H, m, 5-H o5 6-H), 7.10 (1H, m, 5-H or 6-H), 6.28 (1H, s, 2-H), 
4.09 (2H, t,  7.4 Hz, N-CH2), 2.47 (3H, s, 2-CH3), 1.79 (2H, m, CH2 β to 
amine), 1-43-1.36 (4H, m, 2 x CH2 pentyl), 0.98 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 136.6, 136.4, 128.1, 120.3, 119.7, 119.1, 109.0, 99.8 (8 x aromatic) 
43.2 (N-CH2), 30.0 (CH2 β to amine), 29.4, 22.5 (2 x CH2), 14.0 (CH3 pentyl), 
12.8 (CH3 indole). 
 
EP-MS MH+ calcd for C14H19N1 202.16 found  202.16. 
 
FTIR (NaCl) 3054, 2956, 2930, 2859, 1611, 1551, 1479, 1460, 1401, 1382, 
1356, 1338, 1311, 1232, 1168, 1140, 1014, 770, 746 cm-1. 
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4-Methoxy-1-naphthaldehyde (9.400 g, 50.5 mmol) was 
dissolved in tBuOH (75 mL) and 2-methyl-2-butene (35 mL), 
to which a solution of sodium chlorite (80% technical grade, 
7.5 g, 66.4 mmol) and sodium hydrogen phosphate monohydrate (9.9 g, 71.7 
mmol) in water (50 mL) was added dropwise, and the reaction mixture was 
stirred for 20 h. 

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The solution was concentrated 
, and washed with 2M HCl(aq) to 
precipitate a light brown solid. The precipitate was washed with DCM and 
water, oven dried and recrystallised from methanol to yield the desired 
compound (3.415 g, 34 %) as cream crystals. 
 
δH (DMSO-d6) 12.75 (1H, br s, COOH), 9.03 (1H, d,  8.5 Hz, 2-H), 8.26-8,22 
(2H, m, aromatic), 7.66 (1H, m, aromatic), 7.57 (1H, m, aromatic), 7.06 (1H, 
d,  8.5 Hz, 3-H), 4.05 (3H, s, CH3).
 
δC (DMSO-d6) 168.7 (4°, COOH), 158.9 (4°), 132.9 (CH), 132.8 (4°), 128.5, 
126.1, 126.0 (3 x CH), 125.4 (4°), 122.3 (CH), 119.3 (4°), 103.9 (CH), 56.5 
(CH3). 
 
EP-MS M- calcd for C12H10O3 201.0552 found  201.0560. 
 
FTIR (KBr) 3010, 2983, 2945, 2847, 2794, 2611, 2480, 1676, 1619, 1575, 
1514, 1469, 1453, 1430, 1328, 1300, 1265, 1218, 1191, 1159, 1149, 1097, 
1007, 911, 827, 789, 767, 636, 609 cm-1. 
 
m.p. 244 °C   lit. 236-243 °C124, 183. 
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4-Fluoronaphthalene-1-carboxylic acid (200 mg, 1.05 
mmol), thionyl chloride (500 µL, 6.90 mmol), and 
THF (3 mL) were refluxed at 90 °C for 1 h. Solvent 
and excess thionyl chloride was removed 
, 
DCM (5 mL) added and the resulting solution was added dropwise, at 0 °C 
under an inert atmosphere, to a solution of 2-methyl-1-propylindole ' (182 
mg, 1.05 mmol) and diethyl aluminium chloride (1M in hexanes, 1.58 mmol) 



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in DCM (5 mL). The reaction mixture was warmed to room temperature and 
stirred for 1 h. 
 
The reaction was quenched with ice (50 mL), diluted with 2M NaOH(aq) and 
extracted with DCM (3 x 20 mL). The combined organics were washed with 
2M NaOH(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (40:60 Ether:Petroleum 
Ether 60/80) to yield the desired product (156 mg, 43 %) as an brown solid. 
 
δH (CDCl3) 8.22 (2H, m, naphthyl), 7.63-7.52 (3H, naphthyl), 7.35 (1H, m, 
indole), 7.23-7.14 (3H, 2 x CH indole, 1 x CH naphthyl), 7.02 (1H, m, indole), 
4.11 (2H, t,  7.5 Hz, N-CH2), 4.08 (3H, s, OCH3), 2.53 (3H, s, CH3 indole), 
1.86 (2H, m, CH2 β to amine), 1.02 (3H, t,  7.4 Hz, CH3 propyl).
 
δF (CDCl3) 119.10. 
 
EP-MS MH+ calcd for C23H20N 1O1F 346.1607 found  346.1605. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 13.94 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 3.05 min. 
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4-Methoxynaphthalene-1-carboxylic acid '. 
(2.246 g, 11.1 mmol) and thionyl chloride (4.0 
mL, 55.5 mmol) were refluxed at 90 °C for 1 h. 
Excess thionyl chloride was removed 
, 
DCM (20 mL) added and the resulting solution was added dropwise, at 0 °C 
under an inert atmosphere, to a solution of 2-methyl-1-propylindole ' (1.920 
g, 11.1 mmol) and diethyl aluminium chloride (1M in hexanes, 16.7 mmol) in 
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DCM (10 mL). The reaction mixture was warmed to room temperature and 
stirred for 4 h. 
 
The reaction was quenched with ice (50 mL), diluted with 2M NaOH(aq) and 
extracted with DCM (3 x 50 mL). The combined organics were washed with 
2M NaOH(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (60:40 Ether:Petroleum 
Ether 60/80) to yield the desired product (1.962 g, 71 %) as an orange solid. 
 
δH (CDCl3) 8.39 (1H, m, naphthyl), 8.33 (1H, m, naphthyl), 7.62 (1H, d,  8.0 
Hz, 2-H naphthyl), 7.53 (2H, m, naphthyl), 7.34 (2H, m, indole), 7.21 (1H, m, 
indole), 7.05 (1H, m, indole), 6.82 (1H, d,  7.8 Hz, 3-H naphthyl), 4.11 (2H, t, 
 7.5 Hz, N-CH2), 4.08 (3H, s, OCH3), 2.53 (3H, s, CH3 indole), 1.86 (2H, m, 
CH2 β to amine), 1.02 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 193.2 (C=O), 157.3, 144.9, 136.1, 132.3, 131.9 (5 x 4°), 128.5 (CH 
2-naphthyl), 127.4 (CH), 127.3, 125.8 (2 x 4°), 125.7, 125.6, 122.1, 122.0, 
121.6, 121.3 (6 x CH), 115.3 (4°), 109.5 (CH), 102.7 (CH 3-naphthyl), 55.7 
(OCH3), 44.9 (N-CH2), 23.6 (CH2 β to amine), 12.6 (indole CH3), 11.5 (propyl 
CH3). 
 
EP-MS MH+ calcd for C24H23N 1O2 358.1802 found  358.1789. 
 
FTIR (KBr) 3240, 2963, 2934, 1645, 1623, 1578, 1513, 1464, 1440, 1411, 
1380, 1371, 1355, 1326, 1265, 1240, 1222, 1163, 1133, 1093, 1083, 1017, 
847, 833, 793, 777, 755, 739 cm-1. 
 
m.p. 122 °C. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 13.67 min. Monolith C18 gradient 20 - 95% MeOH(aq) over 
5 min, Rt = 4.89 min. 
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2-Methyl-1-propyl-3-(4-methoxy-1-naphthoyl)-
indole '-(3.890 g, 10.9 mmol) was dissolved in 
DCM (25 mL) and the solution brought to -78 °C 
under an inert atmosphere. Boron tribromide (1 M 
in hexanes, 12 mmol) was added, the solution slowly warmed to room 
temperature and stirred for 3 h.  
 
The reaction mixture was quenched in 2 M HCl (aq, 100 mL) and stirred for 
15 min. The layers were separated and the aqueous layer further extracted with 
DCM (2 x 50 mL). The combined organics were washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
flash column chromatography (25:75 Ethyl Acetate:Hexane) to yield the 
desired product (2.181 g, 58 %) as an orange solid. 
 
δH (CDCl3) 8.22 (2H, m, naphthyl), 7.45 (2H, m, naphthyl), 7.39 (1H, d,  7.8 
Hz, 2-H naphthyl), 7.34 (2H, m, indole), 7.20 (1H, m, indole), 7.04 (1H, m, 
indole), 6.69 (1H, d,  7.8 Hz, 3-H naphthyl), 4.12 (2H, t,  7.5 Hz, N-CH2), 
2.49 (3H, s, CH3 indole), 1.87 (2H, m, CH2 β to amine), 1.01 (3H, t,  7.4 Hz, 
CH3 propyl).
 
δC (CDCl3) 194.5 (C=O), 154.6, 145.8, 136.2, 132.0, 131.7 (5 x 4°), 128.3 (CH 
2-naphthyl), 127.4 (CH), 127.3 (4°), 125.3, 125.2 (2 x CH), 125.0 (4°), 122.3, 
122.3, 122.0, 121.4 (4 x CH), 115.7 (4°), 109.5 (CH), 108.1 (CH 3-naphthyl), 
44.9 (N-CH2), 22.9 (CH2 β to amine), 12.7 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS M+ calcd for C23H21N1O2 344.1651 found  344.1646. 
EP-MS M- calcd for C23H21N1O2 342.1500 found  342.1494. 
 




114 
FTIR (KBr) 3196, 2955, 2928, 2858, 1624, 1578.8, 1512, 1461, 1416, 1369, 
1347, 1260, 1247, 1226, 1202, 1161, 1150, 1086, 1055, 828, 776, 765, 750, 
740 cm-1.  
 
m.p. 212 °C. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 11.58 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 2.07 min. 
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4-Methoxynaphthalene-1-carboxylic acid '. (1.64 
g, 8.12 mmol) and thionyl chloride (3.0 mL, 40.6 
mmol) were refluxed at 90 °C for 1.5 h. Excess 
thionyl chloride was removed 
, DCM (30 
mL) added and the resulting solution was added 
dropwise, at 0 °C under an inert atmosphere, to a solution of 2-methyl-1-
pentyllindole '' (1.63 g, 8.12 mmol) and diethyl aluminium chloride (1M in 
hexanes, 12.2 mmol) in DCM (10 mL). The reaction mixture was warmed to 
room temperature, and stirred for 2 h. 
 
The reaction was quenched with ice (50 mL), diluted with sat. NaHCO3(aq) and 
extracted with DCM (3 x 100 mL). The combined organics were washed with 
sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (40:60 Ether:Petroleum 
Ether 60/80) to yield the desired product (2.22 g, 71 %) as a yellow oil. 
 
δH (CDCl3) 8.36 (1H, m, naphthyl), 8.30 (1H, m, naphthyl), 7.61 (1H, d,  8.0 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.34 (1H, m, indole), 7.28 (1H, m, 
indole), 7.20 (1H, m, indole), 7.03 (1H, m, indole), 6.82 (1H, d,  8.0 Hz, 3-H 
naphthyl), 4.15 (2H, t,  7.6 Hz, N-CH2), 4.09 (3H, s, OCH3), 2.54 (3H, s, CH3 
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indole), 1.82 (2H, m, CH2 β to amine), 1.40 (4H, m, 2 x CH2 pentyl) 0.94 (3H, 
t,  7.4 Hz, CH3 pentyl).
 
δC (CDCl3) 193.2 (C=O), 157.2, 144.8, 136.0, 132.4, 131.9 (5 x 4°), 128.5 (CH 
2-naphthyl), 127.5 (CH), 127.3, 125.8 (2 x 4°), 125.6, 125.6, 122.1, 122.0, 
121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 102.6 (CH 3-naphthyl), 55.7 
(OCH3), 43.4 (N-CH2), 29.4 (CH2 β to amine), 29.1, 22.4 (2 x CH2 pentyl), 
14.0 (CH3 propyl), 12.5 (CH3 indole). 
 
EP-MS MH+ calcd for C26H27N 1O2 386.2115 found  386.2128. 
 
FTIR (KBr) 2957, 2932, 2859, 1623, 1608, 1579, 1510, 1462, 1412, 1371, 
1324, 1227, 1203, 1161, 1096, 1080, 1024, 839, 819, 750, 714 cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 15.37 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 4.09 min. 
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2-Methyl-1-pentyl-3-(4-methoxy-1-naphthoyl)-
indole '/(2.10 g, 5.45 mmol) was dissolved in 
DCM (20 mL) and the solution brought to -50 °C 
under an inert atmosphere. Boron tribromide (1 M 
in hexanes, 6 mmol) was added, the solution 
slowly warmed to room temperature and stirred for 3 h.  
 
The reaction mixture was quenched in 2 M HCl (aq, 100 mL) and stirred for 
15 min. The layers were separated and the aqueous layer further extracted with 
DCM (75 mL). The combined organics were washed with H2O and brine, 
dried over MgSO4 and reduced 
, to yield the desired crude product 
(1.35 g, 67 %) as a brown solid, used without further purification. A sample of 
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the crude product was purified by preparatory layer chromatography (50:50 
Ether:Petroleum Ether 40/60).  
 
δH (CDCl3) 8.21 (2H, m, naphthyl), 7.45 (2H, m, naphthyl), 7.38 (1H, d,  7.8 
Hz, 2-H naphthyl), 7.34 (2H, m, indole), 7.20 (1H, m, indole), 7.04 (1H, m, 
indole), 6.68 (1H, d,  7.8 Hz, 3-H naphthyl), 4.13 (2H, t,  7.6 Hz, N-CH2), 
2.48 (3H, s, CH3 indole), 1.81 (2H, m, CH2 β to amine), 1.43-1.35 (4H, 2 x 
CH2 pentyl) 1.01 (3H, t,  7.4 Hz, CH3 pentyl).
 
δC (CDCl3) 193.9 (C=O), 154.1, 145.5, 136.1, 132.3, 132.1 (5 x 4°), 128.2 (CH 
2-naphthyl), 127.4 (CH), 127.3 (4°), 125.5, 125.3 (2 x CH), 124.9 (4°), 122.2, 
122.1, 121.8, 121.4 (4 x CH), 115.2 (4°), 109.4 (CH), 108.0 (CH 3-naphthyl), 
43.4 (N-CH2), 29.4, 29.1 (2 x CH2), 22.4 ( CH2 β to amine), 14.0 (CH3 propyl), 
12.6 (CH3 indole). 
 
EP-MS M- calcd for C25H25N1O1 370.1813 found  370.1825. 
 
FTIR (KBr) 3201, 2966, 2932, 2873, 1580, 1568, 1504, 1461, 1413, 1368, 
1348, 1263, 1237, 1220, 1159, 1084, 1058, 1024, 1009, 994, 853, 825, 751, 
715, 686, 623 cm-1. 
 
m.p. 190 °C. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 13.30 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 3.22 min.
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Sodium hydride (60% w/w in mineral oil, 3.9 mg, 
0.087 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(4-hydroxy-1-
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naphthoyl)-indole ', (20 mg, 0.058 mmol). 1-Bromopropane (6.3 µL, 0.070 
mmol) was added and the solution was stirred under an inert atmosphere for 24 
h.  
 
Excess hydride was reacted with 2 M HCl(aq) (4 mL), diluted with DCM (4 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 15 mL). The combined organics were 
washed with sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 

. The crude product was purified by preparatory layer chromatography 
(50:50 Ethyl Acetate:Hexane) to yield the desired product (6 mg, 27 %) as a 
yellow oil. 
 
δH (CDCl3) 8.41 (1H, m, naphthyl), 8.31 (1H, m, naphthyl), 7.59 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.32 (2H, m, indole), 7.20 (1H, m, 
indole), 7.03 (1H, m, indole), 6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 4.19 (2H, t, 
 6.4 Hz, O-CH2), 4.13 (2H, t,  7.5 Hz, N-CH2), 2.54 (3H, s, CH3 indole), 
2.03 (2H, m, CH2 β to ether), 1.87 (2H, m, CH2 β to amine), 1.19 (3H, t,  7.5 
Hz, CH3 O-propyl), 1.02 (3H, t,  7.4 Hz, CH3 N-propyl). 

δC (CDCl3) 193.3 (C=O), 156.8, 144.8, 136.0, 132.1, 131.4 (5 x 4°), 128.7 (CH 
2-naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.2, 122.0, 
121.6, 121.3 (6 x CH), 115.4 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 69.8 
(O-CH2), 44.9 (N-CH2), 23.0, 22.7 (2 x CH2), 12.7, 11.5, 10.8 (3 x CH3). 
 
EP-MS MH+ calcd for C26H27N 1O2 386.2120 found  386.2127. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 15.50 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 3.87 min.
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Sodium hydride (60% w/w in mineral oil, 10 mg, 
0.255 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(4-hydroxy-1-
naphthoyl)-indole ', (60 mg, 0.175 mmol). 1-
bromobutane (23 µL, 0.204 mmol) was added and the solution was stirred 
under an inert atmosphere for 15 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (20 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 

. The crude product was purified by preparatory layer chromatography 
(40:60 Ether:Petroleum Ether 60/80) to yield the desired product (15 mg, 
22 %) as a yellow oil. 
 
δH (CDCl3) 8.40 (1H, m, naphthyl), 8.31 (1H, m, naphthyl), 7.60 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.33 (2H, m, indole), 7.20 (1H, m, 
indole), 7.04 (1H, m, indole), 6.81 (1H, d,  8.0 Hz, 3-H naphthyl), 4.23 (2H, t, 
 6.4 Hz, O-CH2), 4.13 (2H, t,  7.6 Hz, N-CH2), 2.54 (3H, s, CH3 indole), 
1.99 (2H, m, CH2 β to ether), 1.89 (2H, m, CH2 β to amine), 1.67 (2H, m, CH2 
γ to ether), 1.08 (3H, t,  7.4 Hz, CH3 butyl), 1.02 (3H, t,  7.4 Hz, CH3 
propyl).
 
δC (CDCl3) 193.3 (C=O), 156.8, 144.8, 136.1, 132.1, 132.0 (5 x 4°), 128.8 (CH 
2-naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.2, 122.0, 
121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 68.1 
(O-CH2), 44.9 (N-CH2), 31.3 (CH2 β to ether), 23.0 (CH2 β to amine), 19.5 
(CH2 γ to ether), 14.0 (butyl CH3), 12.6 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C27H29N 1O2 400.2277 found  400.2308. 
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FTIR (NaCl) 3450, 2960, 2874, 1623, 1578, 1509, 1458, 1413, 1369, 1325. 
1264, 1238, 1220, 1161, 1078, 750 cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 16.37 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 4.30 min. 
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Sodium hydride (60% w/w in mineral oil, 9 mg, 
0.225 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(4-hydroxy-1-
naphthoyl)-indole ', (52 mg, 0.152 mmol). 1-
bromohexane (20 µL, 0.180 mmol) was added and the solution was stirred 
under an inert atmosphere for 15 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (20 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 

. The crude product was purified by preparatory layer chromatography 
(40:60 Ether:Petroleum Ether 60/80) to yield the desired product (13 mg, 
20 %) as a yellow oil. 
 
δH (CDCl3) 8.40 (1H, m, naphthyl), 8.31 (1H, m, naphthyl), 7.59 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.52 (2H, m, naphthyl), 7.32 (2H, m, indole), 7.20 (1H, m, 
indole), 7.03 (1H, m, indole), 6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 4.22 (2H, t, 
 6.4 Hz, O-CH2), 4.13 (2H, t,  7.5 Hz, N-CH2), 2.54 (3H, s, CH3 indole), 
1.99 (2H, m, CH2 β to ether), 1.87 (2H, m, CH2 β to amine), 1.63 (2H, m, CH2 
γ to ether), 1.48 – 1.42 (4H, 2 x CH2 hexyl), 1.03 (3H, t,  7.4 Hz, CH3 
propyl), 0.96 (3H, m, CH3 hexyl).
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δC (CDCl3) 193.3 (C=O), 156.8, 147.8, 136.0, 132.0, 132.0 (5 x 4°), 128.8 (CH 
2- naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.2, 122.0, 
121.5, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 68.4 
(O-CH2), 44.9 (N-CH2), 31.7 (CH2 hexyl), 29.2 (CH2 β to ether), 26.0 (CH2 γ 
to ether), 23.0 (CH2 β to amine), 22.7 (CH2 hexyl), 14.1 (CH3 hexyl) 12.6 (CH3 
indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C29H33N 1O2 428.2584 found  428.2613. 
 
FTIR (NaCl) 3432, 2930, 2855, 1617, 1578, 1509, 1459, 1413, 1368, 1326, 
1238, 1220, 1161, 1078, 750 cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 17.89 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min then 95 % MeOH(aq) for 1 min, Rt = 5.10 min. 
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Sodium hydride (60% w/w in mineral oil, 8 mg, 
0.210 mmol) was suspended in DMF (5 mL), and 
added to 2-methyl-1-propyl-3-(4-hydroxy-1-
naphthoyl)-indole ', (50 mg, 0.146 mmol). 
Benzylbromide (20 µL, 0.168 mmol) was added and the solution was stirred 
under an inert atmosphere for 20 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (20 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 

. The crude product was purified by preparatory layer chromatography 
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(30:70 Ethyl Acetate:Hexane) to yield the desired product (21 mg, 32 %) as a 
yellow oil. 
 
δH (CDCl3) 8.47 (1H, m, naphthyl), 8.31 (1H, m, naphthyl), 7.67 – 7.37 (8H, 5 
x CH benzyl, 3 x CH naphthyl), 7.35 (2H, m, indole), 7.21 (1H, m, indole), 
7.04 (1H, m, indole), 6.91 (1H, d,  8.0 Hz, 3-H naphthyl), 5.35 (2H, s, O-
CH2), 4.14 (2H, t,  7.5 Hz, N-CH2), 2.55 (3H, s, CH3 indole), 1.87 (2H, m, 
CH2 β to amine) 1.03 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 193.2 (C=O), 156.2, 144.9, 136.7, 136.1, 132.7, 132.0 (6 x 4°), 
128.7, 128.4, 128.1, 127.6, 127.5 (5 x CH), 127.3, 125.7 (2 x 4°), 125.6, 125.6, 
122.3, 122.0, 121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 104.0 (CH 3-
naphthyl), 70.3 (O-CH2), 44.9 (N-CH2), 23.0 (CH2 β to amine), 12.6 (CH3 
indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C30H27N 1O2 434.2120 found  434.2129. 
 
FTIR (NaCl) 3428, 2958, 2930, 2871, 1607, 1579, 1509, 1461, 1427, 1413, 
1370, 1325, 1125, 1161, 1074, 1025, 870, 838, 818, 751, 696, 665 cm-1 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 15.63 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 4.14 min. 
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Sodium hydride (60% w/w in mineral oil, 9 mg, 
0.225 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(4-hydroxy-1-
naphthoyl)-indole ', (52 mg, 0.152 mmol). Allyl 
bromide (16 µL, 0.180 mmol) was added and the solution was stirred under an 
inert atmosphere for 15 h.  
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Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (20 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with sat. NaHCO3(aq) and brine, dried over MgSO4 and reduced 

. The crude product was purified by preparatory layer chromatography 
(30:70 Ethyl Acetate:Hexane) to yield the desired product (10 mg, 17 %) as a 
yellow oil. 
 
δH (CDCl3) 8.43 (1H, m, naphthyl), 8.28 (1H, m, naphthyl), 7.59 (1H, d,  8.0 
Hz, 2-H naphthyl), 7.52 (2H, m, naphthyl), 7.34 (1H, m, indole), 7.27 (1H, m, 
indole) 7.20 (1H, m, indole), 7.03 (1H, m, indole), 6.82 (1H, d,  8.0 Hz, 3-H 
naphthyl), 6.23 (1H, m, allyl), 5.58 (1H, m, allyl), 5.46 (1H, m, allyl), 4.81 
(2H, m, O-CH2), 4.13 (2H, t,  7.5 Hz, N-CH2), 2.54 (3H, s, CH3 indole), 1.87 
(2H, m, CH2 β to amine), 1.03 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 193.2 (C=O), 156.1, 144.9, 136.1 (3 x 4°), 132.9 (CH allyl), 132.6, 
132.0 (2 x 4°), 128.4 (CH 2-naphthyl), 127.3 (CH), 127.3, 125.9 (2 x 4°), 
125.6, 125.6, 122.2, 122.0, 121.6, 121.3 (6 x CH), 117.8 (CH2 allyl), 115.3 
(4°), 109.5 (CH), 103.8 (CH 3-naphthyl), 69.1 (O-CH2), 44.8 (N-CH2), 23.0 
(CH2 β to amine), 12.6 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C26H26N 1O2 384.1964 found  384.1971. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 14.78 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 3.50 min. 
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Sodium hydride (60% w/w in mineral oil, 8 mg, 
0.209 mmol) was suspended in DMF (2 mL), and 
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added to 2-methyl-1-pentyl-3-(4-hydroxy-1-naphthoyl)-indole '3 (50 mg, 
0.136 mmol). 1-bromohexane (18 µL, 0.161 mmol) was added and the solution 
was stirred under an inert atmosphere for 18 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (10 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (15 mL). The combined organics were 
washed with 2 M HCl(aq) and brine, dried over MgSO4 and reduced 
. 
The crude product was purified by preparatory layer chromatography (20:80 
Ethyl Acetate:Hexane) to yield the desired product (12 mg, 19 %) as a yellow 
oil. 
 
δH (CDCl3) 8.39 (1H, m, naphthyl), 8.30 (1H, m, naphthyl), 7.59 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.35 (2H, m, indole), 7.19 (1H, m, 
indole), 7.03 (1H, m, indole), 6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 4.22 (2H, t, 
 6.4 Hz, O-CH2), 4.15 (2H, t,  7.6 Hz, N-CH2), 2.53 (3H, s, CH3 indole), 
1.98 (2H, m, CH2 β to ether), 1.82 (2H, m, CH2 β to amine), 1.62 (2H, m, CH2 
γ to ether), 1.48 – 1.34 (8H, 2 x CH2 pentyl, 2 x CH2 hexyl) 0.98 – 0.86 (6H, 
CH3 pentyl, CH3 hexyl).
 
δC (CDCl3) 193.2 (C=O), 156.8, 144.7, 136.0, 132.1, 132.0 (5 x 4°), 128.7 (CH 
2-naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.2, 122.0, 
121.5, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 68.4 
(O-CH2), 43.4 (N-CH2), 31.7, 29.4, 29.2, 29.1, 28.0, 22.7, 22.4 (7 x CH2), 
14.1, 14.0 (2 x CH3), 12.5 (CH3 indole). 
 
EP-MS MH+ calcd for C31H37N 1O2 456.2897 found  456.2921. 
 
FTIR (NaCl) 2958, 2922, 2851, 1726, 1607, 1580, 1510, 1462, 1412, 1371, 
1324, 1261, 1227, 1160, 1096, 1081, 1019, 797, 775, 749 cm-1. 
 
124 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 19.05 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min then 95 % MeOH(aq) for 1 min, Rt = 5.62 min.
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Sodium hydride (60% w/w in mineral oil, 8 mg, 
0.209 mmol) was suspended in DMF (5 mL), and 
added to 2-methyl-1-pentyl-3-(4-hydroxy-1-
naphthoyl)-indole '3 (50 mg, 0.136 mmol). 
Benzylbromide (19 µL, 0.160 mmol) was added 
and the solution was stirred under an inert atmosphere for 22 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (10 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 15 mL). The combined organics were 
washed with 2 M HCl(aq) and brine, dried over MgSO4 and reduced 
. 
The crude product was purified by preparatory layer chromatography (50:50 
Ethyl Acetate:Hexane) to yield the desired product (15 mg, 24 %) as a yellow 
oil. 
 
δH (CDCl3) 8.47 (1H, m, naphthyl), 8.32 (1H, m, naphthyl), 7.63 – 7.28 (8H, 5 
x CH benzyl, 3 x CH naphthyl and 1 x CH indole), 7.21 (1H, m, indole), 7.04 
(1H, m, indole), 6.91 (1H, d,  8.0 Hz, 3-H naphthyl), 5.35 (2H, s, O-CH2), 
4.15 (2H, t,  7.6 Hz, N-CH2), 2.55 (3H, s, CH3 indole), 1.82 (2H, m, CH2 β to 
amine), 1.42 (4H, m, 2 x CH2 pentyl) 0.96 (3H, t,  6.5 Hz, CH3 pentyl). 
 
δC (CDCl3) 193.1 (C=O), 156.3, 144.8, 136.7, 136.0, 132.8, 132.0 (6 x 4°), 
128.7, 128.3, 128.1, 127.6, 127.5 (5 x CH), 127.3, 126.0 (2 x 4°), 125.6, 125.6, 
122.3, 122.0, 121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 104.1 (CH 3-
naphthyl), 70.3 (O-CH2), 43.4 (N-CH2), 29.4 (CH2 β to amine), 29.1, 22.4 (2 x 
CH2 pentyl), 14.0 (CH3 propyl), 12.5 (CH3 indole). 
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EP-MS MH+ calcd for C32H31N 1O2 462.2428 found  462.2427. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 17.31 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 4.74 min. 
 
*'))$3)
.,
 
1,8-Naphthoic anhydride (20.0 g, 101 mmol) was 
dissolved in conc. sulphuric acid (80 mL), cooled to 0 °C 
and a solution of conc. nitric acid (4.19 mL, 101 mmol) in conc. sulphuric acid 
(20 mL) was added dropwise, and the solution was  stirred for 1.5 h. 
 
The reaction was quenched with ice water, and the precipitate was washed 
with water and ether, oven dried and recrystallised from acetic acid to produce 
the desired product (16.9 g, 69 %) as light brown crystals.  
 
δH (CDCl3) 9.38 (1H, d,  = 2.2 Hz, naphthyl), 9.26 (1H, d,  = 2.2 Hz, 
naphthyl), 8.85 (1H, dd,  = 1.1 + 7.3 Hz, naphthyl), 8.57 (1H, dd,  = 1.1 + 
7.3 Hz, naphthyl), 8.05 (1H, dd,  = 7.4 + 8.2 Hz, naphthyl).
 
FTIR (KBr) 3404, 3373, 3101, 3039, 1780, 1736, 1632, 1596, 1543, 1508, 
1456, 1420, 1344, 1363, 1293, 1234, 1197, 1181, 1142, 1128, 1082, 1043, 
1018, 937, 799, 791, 757 721, 704, 675 cm-1. 
 
m.p. 225 °C   lit. 252-253 °C134. 
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Method A 
 
3-Nitro-1,8-naphthoic anhydride ., (5.00 g, 20.6 mmol) was suspended in a 
solution of NaOH (3.29 g, 82.3 mmol) in water (200 mL), and a solution of 
yellow mercury (II) oxide (5.80 g, 26.8 mmol) dissolved in 3:1 water:acetic 
acid (20 mL) was added. The reaction was then stirred at reflux for 72 h, then 
cooled, filtered and left to air dry.  
 
The solid was suspended in 2 M HCl(aq) (200 mL) and conc. HCl (50 mL), and 
refluxed for 4 h. The solution was cooled, the crude product filtered, dried and 
recrystallised from acetone to from the desired product (0.81 g, 18 %) as light 
brown crystals.  
 
Method B 
 
3-Nitro-1,8-naphthoic anhydride ., (10.7 g, 44.0 mmol) was split into 11 
equal portions, each suspended in 1 M NaOH(aq) (10 mL) and stirred for 15 
min at 60 °C. To each was added a solution of yellow mercury (II) oxide (998 
mg, 4.6 mmol) dissolved in 3:1 water:acetic acid (4 mL) with stirring for 10 
min at 60 °C. Each solution was sealed in a microwave tube (20 mL) and using 
a Biotage Initiator 2.0 the temperature was increased to 200 °C gradually over 
2 min and then microwaved at 200 °C for 28 min.  
 
The solutions were combined, acidified to pH 1 with conc. HCl and heated at 
100 °C for 18 h with stirring. The solution was cooled, the crude product 
filtered, dried and recrystallised from acetone to yield the desired product 
(3.32 g, 35 %) as light brown crystals.  
 
δH (DMSO-d6) 13.85 (1H, br s, COOH) 9.24 (1H, d,  = 2.4 Hz, naphthyl), 
8.97 (1H, app d,  = 8.2 Hz, naphthyl), 8.75 (1H, d,  = 2.5 Hz, naphthyl), 8.42 
 
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(1H, app d,  = 8.2 Hz, naphthyl), 7.92 (1H, m, naphthyl), 7.81 (1H, m, 
naphthyl).
 
δC (DMSO-d6) 167.6 (C=O), 144.3, 133.4, 133.1 (3 x 4°), 132.1, 131.7 (2 x 
CH), 130.1 (4°), 129.3, 128.7, 126.3, 122.9 (4 x CH). 
 
EP-MS M- calcd for C11H7N1O4 216.0341 found  216.0285. 
 
FTIR (KBr) 3067, 2643, 2643, 2604, 2360, 2342, 1700, 1653, 1617, 1597, 
1539, 1528, 1507, 1455, 1412, 1337, 1287, 1254, 1203, 1163, 1146, 1102, 
927, 915, 870, 796, 760, 688, 668, 625 cm-1. 
 
m.p. 264 °C   lit. 266-272 °C134, 184. 
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3-Nitro-1-naphthoic acid .3 (2.80 g, 12.9 mmol) and 10 % 
palladium on activated charcoal (0.48 g) was dispersed in a mixture of EtOH 
(40 mL), 2 M NaOH(aq) (7.5 mL) and water (15 mL), and stirred for 18 h under 
a hydrogen atmosphere.  
 
The solution was filtered through a Celite 521 plug and reduced 
 to the 
desired product (2.55 g, 98 %) as an orange oil. The crude product was used 
without any further purification. 
 
δH (DMSO d6) 8.67 (1H, app d,  = 8.4 Hz, naphthyl), 7.43 (1H, app d,  = 8.0 
Hz, naphthyl), 7.25 (1H, d,  = 2.4 Hz, naphthyl), 7.19 (1H, m, naphthyl), 7.01 
(1H, m, naphthyl), 6.71 (1H, d,  = 2.0 Hz, naphthyl).
 
δC (DMSO d6) 173.0 (C=O), 146.1, 141.6, 135.8 (3 x 4°), 128.8, 125.4, 125.3 
(3 x CH), 125.1 (4°), 120.5, 119.0, 106.4 (3 x CH). 
 
=
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EP-MS MH+ calcd for C11H9N1O2 188.0712 found  188.0696. 
 
FTIR (KBr) 3404, 2258, 2130, 1658, 1290, 1152, 1048, 1026, 1000, 826, 765 
cm-1.  
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Sodium 3-amino-1- naphthalene-1-carboxylate .0 (730 
mg, 3.47 mmol) was dissolved in water (25 mL), and 2 M 
sulphuric acid(aq) (5 mL) was added to release the free acid as a fine 
precipitate. The suspension was cooled to 5 °C and a solution of sodium nitrite 
(255 mg, 3.70 mmol) in water (5 mL) was added dropwise and stirred for 45 
min. This solution was added dropwise to a refluxing solution of 40% 
sulphuric acid(aq) (80 mL) over 50 min and stirred for a further 15 min.  
 
The hot solution was filtered through glass wool and the filtrate cooled to 
precipitate the desired product (463 mg, 63 %) as a brown solid. The crude 
product was used without any further purification. 
 
δH (DMSO d6)13.15 (1H, br s, COOH) 10.01 (1H, br s, OH), 8.70 (1H, app d, 
 = 8.4 Hz, naphthyl), 7.78 (1H, app d,  = 8.0 Hz, naphthyl), 7.72 (1H, d,  = 
2.6 Hz, naphthyl), 7.46 (1H, m, naphthyl), 7.40 – 7.35 (2H, 2 x naphthyl).
 
δC (DMSO d6) 168.8 (C=O), 154.3, 135.8, 129.6 (3 x 4°), 127.4, 126.8 (2 x 
CH), 125.9 (4°), 125.9, 124.7, 122.4, 114.3 (4 x CH). 
 
EP-MS M- calcd for C11H8O3 187.04 found  187.03. 
 
FTIR (KBr) 3075, 2952. 2850, 2360, 2342, 1717, 1705, 1699, 1684, 1558, 
1540, 1507, 1457, 1436, 1339, 1243, 1195, 1155, 1021, 911, 795, 760, 668   
cm-1. 
 
m.p. 238-240 °C lit. 239-246 °C134, 184. 
 
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Sodium hydride (60% w/w in mineral oil, 516 mg, 12.9 
mmol) was suspended in DMF (40 mL), and 3-hydroxy-1-naphthoic acid -1 
(800 mg, 4.26 mmol) added. Methyl iodide (640 µL, 10.3 mmol) was added 
and the solution was stirred under an inert atmosphere for 18 h. 
 
The solution was reduced 
, excess hydride reacted with 2 M HCl(aq) 
(50 mL), diluted with DCM (50 mL), and stirred for 10 min. The resulting 
solution was separated and the aqueous layer extracted with DCM (2 x 50 
mL). The combined organics were washed with sat. NaHCO3(aq) and brine, 
dried over MgSO4 and reduced 
 to yield the crude product (640 mg, 
70 %) as an orange oil. The crude product was used without any further 
purification. 
 
δH (CDCl3) 8.81 (1H, m, naphthyl), 7.87 (1H,  = 2.4 Hz, naphthyl), 7.80 (1H, 
m, naphthyl), 7.50 (2H, m, naphthyl), 7.35 (1H,  = 2.8 Hz, naphthyl), 4.02 
(3H, s, CH3), 3.97 (3H, s, CH3).
 
δC (CDCl3) 167.6 (C=O), 156.1, 135.3, 128.6 (3 x 4°), 127.4(CH), 126.8 (4°), 
126.7, 125.7, 125.3, 122.7, 111.3 (5 x CH), 55.6, 52.3 (2 x CH3). 
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Potassium hydroxide (768 mg, 14.0 mmol) was dissolved in 
MeOH (50 mL), methyl 3-methoxynaphthalene-1-
carboxylate -$ (600 mg, 2.78 mmol) added, and the solution refluxed for 20 h.  
 
The solution was reduced 
 to an oil, which was dissolved in 1.5 M 
NaOH(aq) (50 mL) and washed with DCM (2 x 20 mL). The aqueous phase was 
acidified to pH 2 and extracted with DCM (3 x 20 mL). The combined 
organics were washed with 2 M HCl(aq) and brine, dried over MgSO4 and 
 

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reduced 
. The crude product was purified by recrystallisation from 
ethanol:water (1:1) to yield the desired product (320 mg, 57 %) as brown 
crystals. 
 
δH (CDCl3) 9.95 (1H, m, naphthyl), 8.05 (1H,  = 2.7 Hz, naphthyl), 7.82 (1H, 
m, naphthyl), 7.52 (2H, m, naphthyl), 7.40 (1H,  = 2.7 Hz, naphthyl), 3.99 
(3H, s, CH3).
 
m.p. 156 °C   lit. 156-157 °C185. 
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3-Methoxynaphthalene-1-carboxylic acid - (320 mg, 
1.58 mmol) and thionyl chloride (575 µL, 8.00 mmol) 
were refluxed at 90 °C for 2 h. Excess thionyl 
chloride was removed 
, DCM (5 mL) added 
and the resulting solution was added dropwise, at 0 °C under an inert 
atmosphere, to a solution of 2-methyl-1-propylindole ' (277 mg, 1.60 mmol) 
and diethyl aluminium chloride (1M in hexanes, 2.40 mmol) in DCM (5 mL). 
The reaction mixture was warmed to room temperature, and stirred for 3 h. 
 
The reaction was quenched with ice (20 mL), diluted with 2M NaOH(aq) and 
extracted with DCM (3 x 20 mL). The combined organics were washed with 
water and brine, dried over MgSO4 and reduced 
. The crude product 
was purified by flash column chromatography (60:40 Ether:Petroleum Ether 
40/60) to yield the desired product (515 mg, 90 %) as an orange foam. 
 
δH (CDCl3) 7.98 (1H, d,  8.5 Hz, naphthyl), 7.82 (1H, d,  8.3 Hz, naphthyl), 
7.47 (1H, m, naphthyl), 7.34-7.25 (5H, 3 x naphthyl, 2 x indole), 7.20 (1H, m, 
indole), 7.04 (1H, m, indole), 4.11 (2H, t,  7.5 Hz, N-CH2), 3.98 (3H, s, 
OCH3), 2.49 (3H, s, CH3 indole), 1.85 (2H, m, CH2 β to amine), 1.02 (3H, t,  
7.4 Hz, CH3 propyl).
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δC (CDCl3) 192.6 (C=O), 156.8, 145.7, 142.3, 136.2, 135.2 (5 x 4°), 127.1 
(CH), 127.0 (4°), 126.8 (CH). 125.9 (4°), 125.5, 124.4, 122.3, 122.1, 121.3, 
117.9 (6 x CH), 114.7 (4°), 109.5 (CH), 107.8 (CH), 55.5 (OCH3), 44.9 (N-
CH2), 22.9 (CH2 β to amine), 12.6 (indole CH3), 11.4 (propyl CH3). 
 
EP-MS MH+ calcd for C24H23N 1O2 358.1802 found  358.1808. 
 
FTIR (KBr) 2695, 2360, 1617, 1558, 1507, 1458, 1412, 1290, 1226, 1169, 
1091, 1041, 949, 813, 747cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 13.62 min. Monolith C18 gradient 20 - 95% MeOH(aq) over 
5 min, Rt = 2.85 min. 
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2-Methyl-1-propyl-3-(3-methoxy-1-naphthoyl)-
indole -'(440 mg, 1.23 mmol) was dissolved in 
DCM (10 mL) and the solution brought to -50 °C 
under an inert atmosphere. Boron tribromide (1 M 
in hexanes, 1.40 mmol) was added, the solution slowly warmed to room 
temperature and stirred for 3 h.  
 
The reaction mixture was quenched in 1 M HCl (aq, 20 mL) and stirred for 15 
min. The layers were separated and the aqueous layer further extracted with 
DCM (3 x 50 mL). The combined organics were washed with H2O and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
flash column chromatography (50:50 Ether:Petroleum Ether 40/60 to yield the 
desired product (302 g, 71 %) as an orange solid. 
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δH (CDCl3) 7.87 (1H, d,  8.4 Hz, naphthyl), 7.82 (1H, d,  8.3 Hz, naphthyl), 
7.38 (2H, m, indole), 7.32 (1H, m, naphthyl), 7.28-7.18 (5H, 3 x naphthyl, 2 x 
indole), 7.05 (1H, m, indole), 4.08 (2H, t,  7.5 Hz, N-CH2), 2.38 (3H, s, CH3 
indole), 1.81 (2H, m, CH2 β to amine), 0.99 (3H, t, 7.4 Hz, CH3 propyl).
 
δC (CDCl3) 193.4 (C=O), 153.4, 146.4, 142.0, 136.2, 135.3, 131.7 (6 x 4°), 
126.8, 126.6 (2 x CH), 125.5 (4°), 125.2, 124.1, 122.5, 122.4, 121.4, 117.8, (6 
x CH), 114.7 (4°), 111.8, 109.5 (2 x CH), 44.9 (N-CH2), 22.9 (CH2 β to 
amine), 12.6 (CH3 indole), 11.4 (CH3 propyl). 
 
EP-MS M- calcd for C23H21N1O2 342.1500 found  342.1483. 
 
FTIR (KBr) 3160, 2967, 2931, 2877, 1620, 1587, 1571, 1504, 1460, 1414, 
1380, 1347, 1223, 1209, 1173, 1132, 1091, 836, 747, 681, 559 cm-1.  
 
m.p. 196 °C. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 18.53 min. Monolith C18 gradient 20 - 95% MeOH(aq) over 
5 min, Rt = 2.09  min.  
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Sodium hydride (60% w/w in mineral oil, 4 mg, 
0.105 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(3-hydroxy-1-
naphthoyl)-indole -. (25 mg, 0.073 mmol). 1-
bromohexane (9.4 µL, 0.084 mmol) was added and 
the solution was stirred under an inert atmosphere for 24 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (10 
mL), and stirred for 5 min. The resulting solution was separated and the 



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aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with water and brine, dried over MgSO4 and reduced 
. The 
crude product was purified by preparatory layer chromatography (70:30 
Ether:Petroleum Ether 40/60) to yield the desired product (5 mg, 16 %) as a 
yellow oil. 
 
δH (CDCl3) 7.97 (1H, d,  8.4 Hz, naphthyl), 7.79 (1H, d,  8.2 Hz, naphthyl), 
7.45 (1H, m, naphthyl), 7.36-7.25 (5H, 3 x naphthyl, 2 x indole), 7.19 (1H, m, 
indole), 7.04 (1H, m, indole), 4.17-4.08 (4H, O-CH2 and N-CH2), 2.49 (3H, s, 
CH3 indole), 1.90-1.79 (4H, CH2 β to ether and CH2 β to amine), 1.49 (2H, m, 
CH2 γ to ether), 1.41 – 1.32 (4H, 2 x CH2 hexyl), 1.02 (3H, t,  7.4 Hz, CH3 
propyl), 0.92 (3H, m, CH3 hexyl).
 
δC (CDCl3) 192.7 (C=O), 156.3, 145.6, 142.2, 136.2, 135.3 (5 x 4°), 127.0 
(CH), 127.0 (4°), 126.7 (CH). 125.9 (4°), 125.5, 124.3, 122.3, 122.1, 121.3, 
118.3 (6 x CH), 114.7 (4°), 109.5, 108.8 (2 x CH), 68.3 (O-CH2), 44.9 (N-
CH2), 31.6 (CH2 hexyl), 29.2 (CH2 β to ether), 25.7 (CH2 γ to ether), 22.9 
(CH2 β to amine), 22.6 (CH2 hexyl), 14.0 (CH3 hexyl) 12.6 (CH3 indole), 11.5 
(CH3 propyl). 
 
EP-MS MH+ calcd for C29H33N 1O2 428.2584 found  428.2601. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 18.86 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min then 95 % MeOH(aq) for 1 min, Rt = 5.03  min. 
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Sodium hydride (60% w/w in mineral oil, 4 mg, 
0.105 mmol) was suspended in DMF (2 mL), and 
added to 2-methyl-1-propyl-3-(3-hydroxy-1-
naphthoyl)-indole -. (25 mg, 0.073 mmol). 




134 
Benzylbromide (10.0 µL, 0.084 mmol) was added and the solution was stirred 
under an inert atmosphere for 24 h.  
 
Excess hydride was reacted with 2 M HCl(aq) (5 mL), diluted with DCM (10 
mL), and stirred for 5 min. The resulting solution was separated and the 
aqueous layer extracted with DCM (2 x 10 mL). The combined organics were 
washed with water and brine, dried over MgSO4 and reduced 
. The 
crude product was purified by preparatory layer chromatography (40:60 
Ether:Petroleum Ether 40/60) to yield the desired product (10 mg, 32 %) as a 
yellow oil. 
 
δH (CDCl3) 7.99 (1H, d,  8.4 Hz, naphthyl), 7.81 (1H, d,  8.2 Hz, naphthyl), 
7.54 – 7.28 (10H, 5 x CH benzyl, 4 x CH naphthyl, 1 x CH indole), 7.20 (1H, 
m, indole), 7.04 (1H, m, indole), 7.04 (1H, m, indole), 5.23 (2H, s, O-CH2), 
4.11 (2H, t,  7.5 Hz, N-CH2), 2.47 (3H, s, CH3 indole), 1.85 (2H, m, CH2 β to 
amine) 1.05 (3H, t,  7.4 Hz, CH3 propyl).
 
δC (CDCl3) 192.6 (C=O), 155.9, 145.7, 142.3, 136.7, 136.2, 135.2 (6 x 4°), 
128.6, 128.0, 127.5, 127.1, (4 x CH), 127.0 (4°), 126.8 (CH), 126.1 (4°), 
125.5, 124.6, 122.3, 122.1, 121.3, 118.4 (6 x CH), 114.7 (4°), 109.5, 109.4 (2 x 
CH), 70.2 (O-CH2), 44.9 (N-CH2), 22.9 (CH2 β to amine), 12.6 (CH3 indole), 
11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C30H27N 1O2 434.2120 found  434.2093. 
 
FTIR (NaCl) 3062, 2964, 2931, 2876, 2361, 2342, 1772, 1734, 1717, 1699, 
1684, 1653, 1616, 1558, 1540, 1507, 1457, 1418, 1288, 1224, 1172, 1091, 
1019, 747, 668 cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 15.68 min. Monolith C18 gradient 60 – 95 % MeOH(aq) over 
5 min, Rt = 4.09 min. 
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Ethanolamine (13.000 g, 16.4 mmol), butylphenyl carbonate 
(3.80 g, 19.6 mmol) and triethylamine (2.30 mL, 16.5 mmol) 
were dissolved in EtOH (15 mL), and stirred for 20 h. 
 
The solution was reduced 
, suspended in water (20 mL), neutralised 
with 1 M HCl(aq) and extracted with DCM (4 x 20 mL). The combined 
organics were washed with 1 M NaOH(aq) and brine, dried over MgSO4 and 
reduced 
. The crude product was purified by flash column 
chromatography (50:50 EtOAc:Hexane) to yield the desired product (1.99 g, 
76 %) as a clear oil. 
 
δH (CDCl3) 5.14 (1H, br s, NH), 3.68 (2H, t,  4.8 Hz, OCH2), 3.28 (2H, m, 
NCH2), 2.06 (1H, s, OH), 1.44 (9H, s, 3 x CH3). 
 
δC (CDCl3) 156.9 (C=O), 79.7 (4° tert-butyl), 62.4 (OCH2), 43.1 (NCH2), 28.4 
(3 x CH3). 
 
ES-MS MeCN + MNa+ calcd for C7H15N1O3 225.1215 found  225.1217. 
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4-Aminobutan-1-ol (700 mg, 7.86 mmol), butylphenyl carbonate 
(1.80 g, 9.27 mmol) and triethylamine (1.10 mL, 7.91 mmol) 
were dissolved in EtOH (15 mL), and stirred for 20 h. 
 
The solution was reduced 
, suspended in water (20 mL), neutralised 
with 1 M HCl(aq) and extracted with DCM (4 x 20 mL). The combined 
organics were washed with 1 M NaOH(aq) and brine, dried over MgSO4 and 
reduced 
. The crude product was purified by flash column 
chromatography (50:50 EtOAc:Hexane) to yield the desired product (946 mg, 
65 %) as a clear oil. 

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δH (CDCl3) 4.67 (1H, br s, NH), 3.68 (2H, t,  6.0 Hz, OCH2), 3.16 (2H, m, 
NCH2), 2.02 (1H, s, OH) 1.62-1.55 (4H, 2 x CH2), 1.44 (9H, s, 3 x CH3). 
 
δC (CDCl3) 156.3 (C=O), 79.2 (4° tert-butyl), 62.0 (OCH2), 40.3 (NCH2), 29.6 
(CH2), 28.4 (3 x CH3), 26.5 (CH2). 
 
ES-MS MH+ calcd for C9H19N1O3 190.1 found  190.1. 
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6-Aminohexan-1-ol (1.00 g, 8.53 mmol), butylphenyl carbonate 
(2.00 g, 10.3 mmol) and triethylamine (1.30 mL, 9.35 mmol) 
were dissolved in EtOH (15 mL), and stirred for 20 h. 
 
The solution was reduced 
, suspended in water (20 mL), 
neutralised with 1 M HCl(aq) and extracted with DCM (4 x 20 
mL). The combined organics were washed with 1 M NaOH(aq) and brine, dried 
over MgSO4 and reduced 
. The crude product was purified by flash 
column chromatography (2:98 MeOH:DCM) to yield the desired product (1.83 
g, 96 %) as a clear oil. 
 
δH (CDCl3) 4.53 (1H, br s, NH), 3.66 (2H, m, OCH2), 3.15 (2H, m, NCH2), 
2.19 (1H, s, OH) 1.62-1.30 (8H, 4 x CH2), 1.46 (9H, s, 3 x CH3). 
 
ES-MS MNa+ calcd for C11H23N1O3 240.1565 found  240.1568. 
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8-Aminoctanioc acid (600 mg, 3.77 mmol) and p-
toluenesulphonic acid monohydrate (1.45 g, 7.63 mmol) were 
dissolved in ethanol (25 mL) and refluxed for 20 h. 
 

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The solution was reduced 
, dissolved in NaOH(aq) (20 mL) and DCM 
(20 mL), layers separated and the aqueous phase extracted with DCM (2 x 20 
mL). The combined organics were washed with brine, dried over MgSO4 and 
reduced 
, to yield the desired product (593 mg, 84 %) as a foamy 
white solid. The crude product was used without any further purification. 
 
δH (CDCl3) 4.15 (2H, q,  7.2 Hz, OCH2), 2.69 (2H, t,  7.0 Hz, NCH2), 2.30 
(2H, t,  7.5 Hz, CH2C=O), 1.63 (2H, m, CH2 β to ester), 1.45 (2H, m, CH2 β 
to amine), 1.37-1.28 (6H, 3 x CH2), 1.27 (3H, t,  7.1 Hz,  CH3). 
 
δC (CDCl3) 173.9 (C=O), 60.2 (OCH2), 42.2 (NCH2), 34.4, 33.8, 29.1, 29.1, 
26.7, 24.9 (6 xCH2), 14.3 (CH3). 
 
ES-MS MH+ calcd for C10H21N1O2 188.1645 found  188.1638. 
 
FTIR (KBr) 2928, 2858, 1729, 1616, 1567, 1490, 1475, 1419, 1380, 1321, 
1261, 1222, 1184 cm-1. 
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To a stirred solution of ethyl 8-aminooctanoate/- (355 mg, 1.90 
mmol) in chloroform (10 mL) was added trityl chloride (560 mg, 
2.01 mmol) and triethylamine (265 µL, 1.90 mmol), and the 
solution stirred for 20 h. 
 
The solution was washed with water and brine, dried over 
MgSO4 and reduced 
. The crude product was purified by 
flash column chromatography (10:90 EtOAc:Hexane) to yield the desired 
product (728 mg, 89 %) as a clear oil. 
 
δH (CDCl3) 7.51-7.48 (6H, 6 x CH trityl), 7.36-7.27 (6H, 6 x CH trityl), 7.22-
7.18 (3H, 3 x CH trityl), 4.14 (2H, q,  7.1 Hz, OCH2), 2.29 (2H, t,  7.6 Hz, 
CH2C=O), 2.12 (2H, t,  7.0 Hz, NCH2), 1.59 (2H, m, CH2 β to ester), 1.48 

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(2H, m, CH2 β to amine), 1.35-1.25 (6H, 3 x CH2), 1.27 (3H, t,  7.1 Hz,  
CH3). 
 
δC (CDCl3) 173.9 (C=O), 146.4 (4º), 128.7, 128.0, 127.9, 127.7, 127.3, 126.1 
(6 x CH trityl*), 70.9 (4º), 60.2 (OCH2), 43.5 (NCH2), 34.4, 30.8, 29.3, 29.1, 
27.2, 25.0 (6 xCH2), 14.3 (CH3). 
 
*Note: the trityl group appears as six chemically identifiable CH groups, three 
of which are twice the magnitude of the other three. 
 
ES-MS MH+ calcd for C29H35N1O2 430.2741 found  430.2725. 
 
FTIR (NaCl) 3431, 2928, 2853, 2096, 1733, 1646, 1489, 1447, 1181, 1109, 
1032, 706 cm-1. 
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To a stirred solution of ethyl 8-(tritylamino)octanoate // (700 mg, 
1.63 mmol) in THF was added lithium aluminium hydride (124mg, 
3.26 mmol), the solution stirred at 0 ºC for 1 h and then refluxed 
for 1.5 h. 
 
The reaction was quenched in 1:1 MeOH:H2O (10 mL), the 
solution filtered with THF and chloroform washing, and organic solvents 
removed 
. The solution was extracted with DCM (3 x 10 mL), and the 
combined organics were washed with brine, dried over MgSO4 and reduced 

. The crude product was purified by flash column chromatography (2:98 
MeOH:DCM) to yield the desired product (410 mg, 65 %) as a clear oil. 
 
δH (CDCl3) 7.54-7.48 (6H, 6 x CH trityl), 7.38-7.27 (6H, 6 x CH trityl), 7.22-
7.18 (3H, 3 x CH trityl), 3.65 (2H, t,  6.5 Hz, OCH2), 2.12 (2H, t,  7.0 Hz, 
NCH2), 1.56 (2H, m, CH2 β to alcohol), 1.49 (2H, m, CH2 β to amine), 1.38-
1.27 (8H, 4 x CH2). 



 

139 
 
δC (CDCl3) 146.4 (4º), 128.7, 128.0, 127.9, 127.7, 127.3, 126.1 (6 x CH 
trityl*), 70.9 (4º), 63.1 (OCH2), 43.5 (NCH2), 32.8, 30.9, 29.6, 29.4, 27.3, 25.7 
(6 xCH2). 
 
* see ethyl 8-(tritylamino)octanoate //. 

ES-MS MH+ calcd for C27H33N1O1 388.2635 found  388.2598. 
 
FTIR (NaCl) 3421, 2927, 2853, 2095, 1645, 1489, 1448, 1032, 706 cm-1. 
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2-(2-(2-Chloroethoxy)ethoxy)ethanol (4.43 g, 26.3 mmol) and 
sodium azide (5.13 g, 78.9 mmol) were dissolved in DMF (50 mL), 
warmed to 70 ºC and stirred for 18 h.  
 
The solution was reduced 
, dissolved in water (100 mL) and 
DCM (50 mL), layers separated and the aqueous phase extracted with DCM (2 
x 50 mL). The combined organics were washed with brine, dried over MgSO4 
and reduced 
. The crude product was purified by flash column 
chromatography (EtOAc) to yield the desired product (4.43 g, 99 %) as a 
yellow oil. 
 
δH (CDCl3) 3.76 (2H, m, CH2), 3.72-3.68 (6H, 3 x CH2), 3.63 (2H, m, CH2), 
3.42 (2H, t,  5.0 Hz, CH2), 2.31 (1H, br s, OH). 
 
δC (CDCl3) 72.5, 70.7, 70.4,70.1, 61.8, 50.7 (6 xCH2). 

ES-MS MNa+ calcd for C6H13N3O3 198.1 found  198.1. 
 
FTIR (NaCl) 3409, 2868, 2110, 1456, 1347, 1300, 1120 cm-1. 
 

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Method A 
 
2-(2-(2-Azidoethoxy)ethoxy)ethanol /3 (1.00 g, 5.71 mmol) and 
tin (II) chloride (2.70 g, 14.2 mmol ) were suspended in EtOH 
(20 mL) and stirred at reflux for 2 h. 
 
The solution was reduced 
, suspended in water (10 mL), basified to 
pH 10 with 2 M NaOH(aq) and extracted with EtOAc (3 x 10 mL). The 
combined organics were washed with brine, dried over MgSO4 and reduced 

. The crude product was purified by flash column chromatography (3:3:1 
MeOH:DCM:TEA) to yield the desired product (363 mg, 54 %) as a yellow 
oil. 
 
Method B 
 
2-(2-(2-Azidoethoxy)ethoxy)ethanol /3 (4.43 g, 26.2 mmol), 
triphenylphosphine (7.53 g, 28.7 mmol ) and water (700 µL, 38.9 mmol) were 
suspended in ether (50 mL) and stirred at reflux for 5 h. 
 
The solution was filtered and reduced 
. The crude product was 
purified by flash column chromatography (3:3:1 MeOH:DCM:TEA) to yield 
the desired product (1.22 g, 31 %) as a yellow oil. 
 
δH (DMSO-d6) 3.57-3.54 (6H, 3 x CH2), 3.50 (2H, m, CH2), 3.43 (2H, m, 
CH2), 2.88 (2H, t,  5.5 Hz, CH2). 
 
δC (DMSO-d6) 72.8, 70.1, 70.0, 70.0, 60.6, 39.2 (6 xCH2). 

ES-MS MH+ calcd for C6H15N1O3 150.1125 found  150.1133. 
 

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2-(2-(2-Aminoethoxy)ethoxy)ethanol /0 (1.22 g, 8.19 mmol), 
potassium hydroxide (500 mg, 8.91 mmol) and di-butyl 
dicarbonate (1.96 g, 8.98 mmol) were dissolved in water (20 mL) 
and stirred for 16 h. 
 
The solution was extracted with DCM (3 x 50 mL) and the 
combined organics were washed with brine, dried over MgSO4 and reduced 

. The crude product was purified by flash column chromatography 
(80:20 EtOAc:Hexane) to yield the desired product (1.52 g, 68 %) as a clear 
oil. 
 
δH (CDCl3) 5.23 (1H, br s, NH), 3.70 (2H, m, CH2), 3.63-3.55 (6H, 3 x CH2), 
3.52 (2H, m, CH2), 3.27 (2H, m, CH2), 2.96 (1H, br s, OH), 1.40 (9H, s, 3 x 
CH3). 
 
δC (CDCl3) 156.0 (COOH), 79.2 (4º), 72.6, 70.3, 70.2, 70.2, 61.6, 40.3 (6 
xCH2), 28.4 (CH3). 

ES-MS M+ calcd for C11H23N1O5 250.2 found  250.2. 
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2-Methyl--propyl-3-(4-hydroxy-1-naphthoyl)-
indole ', (129 mg, 0.376 mmol), -butyl 2-
hydroxyethylcarbamate / (62 mg, 0.385 mmol) 
and triphenylphosphine (147 mg, 0.561 mmol) were dissolved in THF (40 mL) 
under an inert atmosphere. Diethyl azodicarboxylate (120 µL, 0.763 mmol) 
was added dropwise and the solution was stirred for 18 h. 
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The solution was reduced 
, dissolved in EtOAc (50 mL)washed with 
2 M NaOH(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (50:50 EtOAc:Hexane) 
to yield the desired product (70 mg, 37 %) as a yellow oil. 
 
δH (CDCl3) 8.37 (1H, m, naphthyl), 8.29 (1H, m, naphthyl), 7.58 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.52 (2H, m, naphthyl), 7.34 (1H, m, indole), 7.26 (1H, m, 
indole), 7.19 (1H, m, indole), 7.02 (1H, m, indole), 6.80 (1H, d,  8.0 Hz, 3-H 
naphthyl), 5.12 (1H, m, NH), 4.28 (2H, t,  5.1 Hz, O-CH2), 4.13 (2H, t,  7.5 
Hz, N-CH2 propyl), 3.76 (2H, m, N-CH2 carbamate) 2.54 (3H, s, CH3 indole), 
1.87 (2H, m, CH2 β to propyl amine), 1.50 (9H, s, 3 x CH3 Bu), 1.03 (3H, t,  
7.4 Hz, CH3 N-propyl). 

δC (CDCl3) 193.1 (C=O), 156.0, 145.0, 136.1, 132.8, 131.9 (5 x 4°), 128.3 (CH 
2-naphthyl), 127.6 (CH), 127.4, 127.3 (2 x 4°), 125.7, 125.7 (2 x CH), 125.6 
(4°), 122.0, 122.0, 121.6, 121.2 (4 x CH), 115.2 (4°), 109.5 (CH), 103.5 (CH 
3-naphthyl), 79.7 (4° Bu), 67.7 (O-CH2), 44.9 (N-CH2 propyl), 40.2 (N-CH2 
carbamate), 28.4 (3 x CH3 Bu), 23.0, (CH2 β to propyl amine), 12.6 (CH3 
indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C30H34N 2O4 487,2591 found  487.2595. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 14.36 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 
5 min, Rt = 3.35 min.
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2-Methyl--propyl-3-(4-hydroxy-1-naphthoyl)-
indole ', (135 mg, 0.393 mmol), -butyl 4-
hydroxybutylcarbamate /' (74 mg, 0.392 mmol) 
and triphenylphosphine (155 mg, 0.592 mmol) 
were dissolved in THF (25 mL) under an inert 
atmosphere. Diethyl azodicarboxylate (108 µL, 0.683 mmol) was added 
dropwise and the solution was stirred for 20 h. 
 
The solution was reduced 
, dissolved in EtOAc (50 mL)washed with 
2 M NaOH(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (70:30 Ether:Petroleum 
Ether 40:60) to yield the desired product (152 mg, 75 %) as a yellow oil. 
 
δH (CDCl3) 8.37 (1H, m, naphthyl), 8.30 (1H, m, naphthyl), 7.58 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.34 (1H, m, indole), 7.30 (1H, m, 
indole), 7.19 (1H, m, indole), 7.03 (1H, m, indole), 6.79 (1H, d,  8.0 Hz, 3-H 
naphthyl), 4.68 (1H, m, NH), 4.23 (2H, t,  5.1 Hz, O-CH2), 4.12 (2H, t,  7.5 
Hz, N-CH2 propyl), 3.29 (2H, m, N-CH2 carbamate) 2.53 (3H, s, CH3 indole), 
2.02 (2H, m, CH2 β to ether), 1.91-1.79 (4H, CH2 β to propyl amine and CH2 β 
to carbamate), 1.48 (9H, s, 3 x CH3 Bu), 1.02 (3H, t,  7.4 Hz, CH3 N-propyl). 

δC (CDCl3) 193.2 (C=O), 156.5, 156.1, 144.9, 136.1, 132.3, 132.0 (6 x 4°), 
128.6 (CH 2-naphthyl), 127.5 (CH), 127.3, 125.8 (2 x 4°), 125.6, 125.5, 122.1, 
122.0, 121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.4 (CH 3-naphthyl), 
79.3 (4° Bu), 67.8 (O-CH2), 44.9 (N-CH2 propyl), 40.4 (N-CH2 carbamate), 
28.5 (3 x CH3 Bu), 27.1 (CH2 β to ether), 26.6 (CH2 β to propyl amine),  23.0, 
(CH2 β to carbamate amine), 12.6 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C32H38N 2O4 515.2904 found  515.2875. 
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Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 15.24 min. Monolith C18 gradient 60 - 95% MeOH(aq) 
+0.06% TFA over 5 min, Rt = 3.68 min. 
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2-Methyl--propyl-3-(4-hydroxy-1-naphthoyl)-
indole ', (100 mg, 0.292 mmol), -butyl 2-
hydroxyhexylcarbamate /. (55 mg, 0.291 
mmol) and triphenylphosphine (152 mg, 0.580 
mmol) were dissolved in DCM (25 mL) under 
an inert atmosphere. Diethyl azodicarboxylate 
(91 µL, 0.580 mmol) was added dropwise and the solution was stirred for 20 h. 
 
The solution was washed with 2 M NaOH(aq) and brine, dried over MgSO4 and 
reduced 
. The crude product was purified by flash column 
chromatography (5:95 MeOH:DCM) to yield the desired product (138 mg, 
87 %) as a yellow oil. 
 
δH (CDCl3) 8.38 (1H, m, naphthyl), 8.29 (1H, m, naphthyl), 7.58 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.33 (1H, m, indole), 7.29 (1H, m, 
indole), 7.19 (1H, m, indole), 7.02 (1H, m, indole), 6.79 (1H, d,  8.0 Hz, 3-H 
naphthyl), 4.67 (1H, m, NH), 4.21 (2H, t,  6.3 Hz, O-CH2), 4.13 (2H, t,  7.5 
Hz, N-CH2 propyl), 3.17 (2H, m, N-CH2 carbamate), 2.52 (3H, s, CH3 indole), 
1.99 (2H, m, CH2 β to ether), 1.86 (2H, m, CH2 β to propyl amine), 1.65-1.45 
(6H, 3x CH2), 1.47 (9H, s, 3 x CH3 Bu), 1.02 (3H, t,  7.4 Hz, CH3 N-propyl). 

δC (CDCl3) 193.3 (C=O), 156.7, 156.0, 144.8, 136.0, 132.2, 132.0 (6 x 4°), 
128.7 (CH 2-naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.1, 
122.0, 121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 
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68.2 (O-CH2), 44.9 (N-CH2 propyl), 40.6 (N-CH2 carbamate), 30.3 (4° Bu), 
30.1 (CH2 β to ether), 29.2 (CH2), 28.4 (3 x CH3 Bu), 26.8 (CH2), 26.0 (CH2 β 
to propyl amine), 12.5 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C34H42N 2O4 543.3217 found  543.3185. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 16.35 min. Monolith C18 gradient 60 - 95% MeOH(aq) 
+0.06% TFA over 5 min, Rt = 4.40 min. 
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2-Methyl--propyl-3-(4-hydroxy-1-naphthoyl)-
indole ', (200 mg, 0.583 mmol), 8-
(tritylamino)octan-1-ol /, (226 mg, 0.584 
mmol) and triphenylphosphine (229 mg, 0.875 
mmol) were dissolved in THF (20 mL) under an 
inert atmosphere. Diethyl azodicarboxylate (239 
mg, 1.04 mmol) was added dropwise and the solution was stirred for 20 h. 
 
The solution was reduced 
, dissolved in EtOAc (50 mL)washed with 
2 M NaOH(aq) and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (25:75 EtOAc:Hexane) 
to yield the desired product (230 mg, 55 %) as a yellow oil. 
 
δH (CDCl3) 8.38 (1H, m, naphthyl), 8.30 (1H, m, naphthyl), 7.58 (1H, d,  8.0 
Hz, 2-H naphthyl), 7.54-7.48 (8H, 2 x CH naphthyl and 6 x CH trityl), 7.34 
(1H, m, indole), 7.32-7.24 (7H, 1 x CH indole and 6 x CH trityl), 7.21-7.17 
(4H, 1 x CH indole and 3 x CH trityl), 7.02 (1H, m, indole), 6.79 (1H, d,  8.0 
Hz, 3-H naphthyl), 4.21 (2H, t,  6.4 Hz, O-CH2), 4.13 (2H, t,  7.5 Hz, N-CH2 
propyl), 2.54 (3H, s, CH3 indole), 2.15 (2H, m, N-CH2 trityl amine), 1.97 (2H, 
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m, CH2 β to ether), 1.86 (2H, m, CH2 β to propyl amine), 1.75-1.26 (10H, 5 x 
CH2), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C50H52N 2O2 713.4102 found  713.4069. 
 
FTIR (NaCl) 3419, 3054, 2986, 2929, 2855, 2685, 2410, 2305, 1608, 1510, 
1421, 1264, 1160, 1078, 909, 896, 750 cm-1. 
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2-Methyl--propyl-3-(4-hydroxy-1-naphthoyl)-
indole ', (100 mg, 0.292 mmol), -butyl 2-
(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate ,1 
(79 mg, 0.292 mmol) and triphenylphosphine 
(152 mg, 0.580 mmol) were dissolved in DCM 
(25 mL) under an inert atmosphere. Diethyl 
azodicarboxylate (91 µL, 0.580 mmol) was 
added dropwise and the solution was stirred for 20 h. 
 
The solution was washed with 2 M NaOH(aq) and brine, dried over MgSO4 and 
reduced 
. The crude product was purified by flash column 
chromatography (5:195 MeOH:DCM) to yield the desired product (152 mg, 
91 %) as a yellow oil. 
 
δH (CDCl3) 8.39 (1H, m, naphthyl), 8.27 (1H, m, naphthyl), 7.57 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.33 (1H, m, indole), 7.26 (1H, m, 
indole), 7.19 (1H, m, indole), 7.02 (1H, m, indole), 6.82 (1H, d,  8.0 Hz, 3-H 
naphthyl), 5.06 (1H, m, NH), 4.41 (2H, t,  4.8 Hz, CH2), 4.13 (2H, t,  7.5 Hz, 
O-CH2), 3.84 (2H, m, CH2), 3.72 (2H, m, CH2), 3.60 (2H, t,  5.1 Hz, CH2 β 
carbamate amine), 3.35 (2H, m, N-CH2 carbamate), 2.53 (3H, s, CH3 indole), 
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1.86 (2H, m, CH2 β to propyl amine), 1.45 (9H, s, 3 x CH3 Bu), 1.03 (3H, t,  
7.4 Hz, CH3 N-propyl). 
 
δC (CDCl3) 193.2 (C=O), 156.3, 144.9, 136.1, 133.1, 132.8, 131.9 (6 x 4°), 
128.2 (CH 2-naphthyl), 127.5 (CH), 127.3, 125.8 (2 x 4°), 125.6, 125.6, 122.2, 
122.0, 121.6, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.6 (CH 3-naphthyl), 
79.2 (4º Bu), 71.0, 70.4, 70.4, 69.8, 67.9 (5 x CH2), 44.9 (N-CH2 propyl), 40.4 
(N-CH2 carbamate), 28.4 (4° Bu), 23.0 (CH2 β to propyl amine), 12.5 (CH3 
indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C34H42N 2O6 575.3116 found  575.3080. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 14.99 min. Monolith C18 gradient 60 - 95% MeOH(aq) 
+0.06% TFA over 5 min, Rt = 3.27 min. 
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2-Methyl--propyl-3-(4-(-butyl 2-
ethoxycarbamate)-1-naphthoyl)-indole,$ (46 mg, 
0.095 mmol) was dissolved in a mixture of 
DCM:TFA:H2O (50:45:5 3 mL) and stirred for 3 
h. 
 
The solution was reduced 
, dissolved in EtOAc (10 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (64:35:1 
Ether:Petroleum Ether 40/60:TEA) to yield the desired product (16 mg, 44 %) 
as a yellow oil. 
 
δH (CDCl3) 8.39 (1H, m, naphthyl), 8.10 (1H, m, naphthyl), 7.47-7.30 (5H, 3 x 
CH naphthyl and 2 x CH indole), 7.17 (1H, m, indole), 7.00 (1H, m, indole), 






148 
6.68 (1H, d,  8.0 Hz, 3-H naphthyl), 4.28 (2H, m, O-CH2), 4.07 (2H, t,  7.4 
Hz, N-CH2 propyl), 3.35 (2H, m, N-CH2 primary amine) 2.39 (3H, s, CH3 
indole), 1.81 (2H, m, CH2 β to propyl amine), 0.98 (3H, t,  7.4 Hz, CH3 N-
propyl). 

δC (CDCl3) 193.4 (C=O), 155.2, 145.6, 136.1, 133.3, 131.5 (5 x 4°), 127.7 (CH 
2-naphthyl), 127.4 (CH), 127.2 (4°), 126.0 (CH), 125.4 (2 x 4°), 125.2, 122.5, 
122.3, 121.9, 121.2 (5 x CH), 115.0 (4°), 109.6 (CH), 103.7 (CH 3-naphthyl), 
64.3 (O-CH2), 44.9 (N-CH2 propyl), 39.1 (N-CH2 primary amine), 22.9, (CH2 
β to propyl amine), 12.6 (CH3 indole), 11.4 (CH3 propyl). 
 
EP-MS MH+ calcd for C25H26N 2O2 387.2067 found  387.2072. 
 
Analytical RP-HPLC Vydac C8 gradient 5 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 16.88 min. Symmetry C18 gradient 5 - 95% MeOH(aq) 
+0.1% formic acid over 20 min, Rt = 12.20 min.
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2-Methyl--propyl-3-(4-(-butyl 4-
butoxycarbamate)-1-naphthoyl)-indole, (100 
mg, 0.195 mmol) was dissolved in a mixture of 
DCM:TFA:H2O (50:45:5 5 mL) and stirred for 2 
h. 
 
The solution was reduced 
, dissolved in EtOAc (10 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (98:2 Ether:TEA) 
to yield the desired product (35 mg, 43 %) as a yellow oil. 
 
δH (CDCl3) 8.29 (1H, m, naphthyl), 8.16 (1H, m, naphthyl), 7.50-7.29 (5H, 3 x 
CH naphthyl and 2 x CH indole), 7.17 (1H, m, indole), 7.01 (1H, m, indole), 
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6.69 (1H, d,  8.1 Hz, 3-H naphthyl), 4.08-4.03 (4H, O-CH2 and N-CH2 
propyl), 2.95 (2H, m, CH2) 2.41 (3H, s, CH3 indole), 1.88-1.84 (4H, m, 2 x 
CH2), 1.79 (2H, m, CH2 β to propyl amine), 0.98 (3H, t,  7.4 Hz, CH3 N-
propyl). 
 
δC (CDCl3) 193.6 (C=O), 155.2, 145.5, 136.1, 132.3, 131.7 (5 x 4°), 128.1 (CH 
2-naphthyl), 127.7 (CH), 127.2 (4°), 125.8 (CH), 125.7 (4°), 125.3, 122.2, 
122.2, 121.9, 121.2 (5 x CH), 115.1 (4°), 109.5 (CH), 103.5 (CH 3-naphthyl), 
67.3 (O-CH2), 44.9 (N-CH2 propyl), 39.7 (N-CH2 primary amine), 26.1, 24.7, 
22.9 (3 x CH2), 12.6 (CH3 indole), 11.4 (CH3 propyl). 
 
EP-MS MH+ calcd for C27H30N 2O2 415.2380 found  415.2405. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 9.73 min. Monolith C18 gradient 60 - 95% MeOH(aq) 
+0.06% TFA over 5 min, Rt = 0.69 min. 
 
*)"
)9)
)')=.)=.)
"<
<
>)$)
>),3
 
2-Methyl--propyl-3-(4-(-butyl 6-
hexyloxycarbamate)-1-naphthoyl)-indole,' (200 
mg, 0.369 mmol) was dissolved in a mixture of 
DCM:TFA:H2O (50:45:5 20 mL) and stirred for 3 
h. 
 
The solution was reduced 
, dissolved in EtOAc (10 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (5:94:1 
MeOH:DCM:TEA) to yield the desired product (30 mg, 18 %) as a yellow oil. 
 
δH (CDCl3) 8.35 (1H, m, naphthyl), 8.17 (1H, m, naphthyl), 7.51 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.44 (2H, m, naphthyl), 7.34-7.28 (2H, indole), 7.16 (1H, 
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m, indole), 7.01 (1H, m, indole), 6.73 (1H, d,  8.1 Hz, 3-H naphthyl), 4.11 
(2H, m, O-CH2), 4.06 (2H, t,  7.4 Hz, N-CH2 propyl), 2.83 (2H, m, N-CH2 
primary amine) 2.43 (3H, s, CH3 indole), 1.88 (2H, m, CH2 β to ether), 1.81 
(2H, m, CH2 β to propyl amine), 1.63 (2H, m, CH2 β to primary amine), 1.54 
(2H, m, CH2 γ to ether), 1.39 (2H, m, CH2 γ to primary amine), 0.97 (3H, t,  
7.4 Hz, CH3 N-propyl). 
 
δC (CDCl3) 193.5 (C=O), 156.6, 145.2, 136.1, 132.1, 131.8 (5 x 4°), 128.4 (CH 
2-naphthyl), 127.5 (CH), 127.2, 125.8 (4°), 125.6, 125.4, 122.2, 122.2, 121.8, 
121.2 (6 x CH), 115.2 (4°), 109.5 (CH), 103.5 (CH 3-naphthyl), 67.9 (O-CH2), 
44.9 (N-CH2 propyl), 39.8 (N-CH2 primary amine),28.8, 27.4, 26.1, 25.6, 22.9 
(5 x CH2), 12.5 (CH3 indole), 11.4 (CH3 propyl). 
 
EP-MS MH+ calcd for C29H34N 2O2 443.2699 found  443.2688. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 10.89 min. Symmetry C18 gradient 5 - 95% MeOH(aq) 
+0.1% formic acid over 20 min, Rt = 14.60 min. 
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2-Methyl--propyl-3-(4-(8-
(tritylamino)octyloxy)-1-naphthoyl)-indole ,. 
(230 mg, 0.323 mmol) was dissolved in a 
mixture of DCM:TFA:H2O (90:9:1 20 mL) and 
stirred for 1 h. 
 
The solution was reduced 
, dissolved in ether (10 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by flash column chromatography (18:90:2 
MeOH:DCM:TEA) to yield the desired product (94 mg, 62 %) as a yellow oil. 
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δH (CDCl3) 8.37 (1H, m, naphthyl), 8.21 (1H, m, naphthyl), 7.84 (2H, br s, 
NH2), 7.54 (1H, d,  8.0 Hz, 2-H naphthyl), 7.48 (2H, m, naphthyl), 7.35-7.30 
(2H, indole), 7.18 (1H, m, indole), 7.01 (1H, m, indole), 6.76 (1H, d,  8.1 Hz, 
3-H naphthyl), 4.17 (2H, t,  6.2 Hz, O-CH2), 4.08 (2H, t,  7.5 Hz, N-CH2 
propyl), 2.78 (2H, m, N-CH2 primary amine) 2.46 (3H, s, CH3 indole), 1.92 
(2H, m, CH2 β to ether), 1.82 (2H, m, CH2 β to propyl amine), 1.59-1.51 (4H, 
2 x CH2), 1.40-1.23 (6H, 3 x CH2), 0.99 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
δC (CDCl3) 193.6 (C=O), 156.7, 145.3, 136.1, 132.0, 131.8 (5 x 4°), 128.4 (CH 
2-naphthyl), 127.6 (CH), 127.3, 125.9 (4°), 125.6, 125.4, 122.3, 122.1, 121.8, 
121.2 (6 x CH), 115.2 (4°), 109.5 (CH), 103.5 (CH 3-naphthyl), 68.1 (O-CH2), 
44.9 (N-CH2 propyl), 39.9 (N-CH2 primary amine), 28.9, 28.8, 28.7, 27.3, 
26.1, 25.9, 22.9 (7 x CH2), 12.6 (CH3 indole), 11.4 (CH3 propyl). 
 
EP-MS MH+ calcd for C31H38N 2O2 471.3006 found  471.3003. 
 
FTIR (NaCl) 3426, 2932, 2855, 1683, 1623, 1580, 1510, 1462, 1415, 1371, 
1326, 1265, 1239, 1204, 1135, 1077, 840, 799, 779, 751, 722 cm-1. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 11.76 min. Monolith C18 gradient 60 - 95% MeOH(aq) 
+0.06% TFA over 5 min, Rt = 0.69 min. 
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2-Methyl--propyl-3-(4-(tert-butyl 2-(2-(2-
ethoxy)ethoxy)ethylcarbamate)-1-naphthoyl)-
indole,0 (100 mg, 0.0236 mmol), sodium 
bicarbonate ( 2.0 mg, 0.0238 mmol) and di-
butyl dicarbonate (12.4 mg, 0.0568 mmol) were 
dissolved in water (5 mL) and THF (0.2 mL) 
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and stirred for 24 h. 
 
The solution was reduced 
, dissolved in ether (20 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (1:2 
EtOAc:Hexane) to yield the desired product (5 mg, 37 %) as a yellow oil. 
 
δH (CDCl3) 8.38 (1H, m, naphthyl), 8.30 (1H, m, naphthyl), 7.59 (1H, d,  8.0 
Hz, 2-H naphthyl), 7.51 (2H, m, naphthyl), 7.35-7.28 (2H, indole), 7.19 (1H, 
m, indole), 7.02 (1H, m, indole), 6.89 (1H, d,  8.1 Hz, 3-H naphthyl), 4.52 
(1H, br s, NH), 4.22 (2H, t,  6.4 Hz, O-CH2), 4.13 (2H, t,  7.5 Hz, N-CH2 
propyl), 3.14 (2H, m, N-CH2 carbamate), 2.54 (3H, s, CH3 indole), 2.01 (2H, 
m, CH2 β to ether), 1.87 (2H, m, CH2 β to propyl amine), 1.64-1.43 (10H, 5 x 
CH2), 1.47 (9H, s, 3 x CH3 Bu), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 

δC (CDCl3) 193.2 (C=O), 156.8, 156.0, 144.8, 136.0, 132.1, 132.0 (6 x 4°), 
128.7 (CH 2-naphthyl), 127.5 (CH), 127.3, 125.9 (2 x 4°), 125.6, 125.5, 122.2, 
122.0, 121.5, 121.3 (6 x CH), 115.3 (4°), 109.4 (CH), 103.3 (CH 3-naphthyl), 
79.0 (4° Bu), 68.3 (O-CH2), 44.9 (N-CH2 propyl), 40.6 (N-CH2 carbamate), 
30.1, 29.4, 29.3, 29.2 (4 x CH2), 28.4 (3 x CH3 Bu), 26.8, 26.2, 23.0 (3 x 
CH2), 12.5 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C36H46N 2O4 571.3530 found  571.3552. 
 
Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) over 20 min, Rt 
= 17.61 min. Monolith C18 gradient 5 – 95 % MeOH(aq) +0.1 % formic acid 
over 5 min then 95 % MeOH(aq) for 1 min, Rt = 5.65 min. 
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2-Methyl--propyl-3-(4-(-butyl 2-(2-(2-
ethoxy)ethoxy)ethylcarbamate)-1-naphthoyl)-
indole ,- (100 mg, 0.174 mmol) was dissolved 
in a mixture of DCM:TFA:H2O (50:45:5 10 
mL) and stirred for 2 h. 
 
The solution was reduced 
, dissolved in EtOAc (10 mL) and washed 
with water and brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (5:94:1 
MeOH:DCM:TEA) to yield the desired product (24 mg, 29 %) as a yellow oil. 
 
δH (CDCl3) 8.37 (1H, m, naphthyl), 8.24 (1H, m, naphthyl), 7.54 (1H, d,  7.9 
Hz, 2-H naphthyl), 7.50 (2H, m, naphthyl), 7.35-7.27 (2H, m, indole), 7.19 
(1H, m, indole), 7.02 (1H, m, indole), 6.81 (1H, d,  8.0 Hz, 3-H naphthyl), 
4.39 (2H, m, CH2), 4.08 (2H, t,  7.5 Hz, N-CH2 propyl), 4.04 (2H, m, CH2), 
3.83 (2H, m, CH2), 3.70 (2H, m, CH2), 3.59 (2H, t,  5.1 Hz, CH2), 2.93 (2H, t, 
 5.1 Hz, CH2), 2.50 (3H, s, CH3 indole), 1.85 (2H, m, CH2 β to propyl amine), 
1.01 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
δC (CDCl3) 193.3 (C=O), 156.2, 145.1, 136.1, 132.7, 131.8 (5 x 4°), 128.1 (CH 
2-naphthyl), 127.6 (CH), 127.3, 125.8 (4°), 125.7, 125.5, 122.2, 122.1, 121.7, 
121.2 (6 x CH), 115.2 (4°), 109.5 (CH), 103.8 (CH 3-naphthyl), 70.9, 70.7, 
70.2, 69.7, 67.9 (5 x CH2), 44.9 (N-CH2 propyl), 40.7 (CH2), 23.0 (CH2 β to 
propyl amine), 12.5 (CH3 indole), 11.5 (CH3 propyl). 
 
EP-MS MH+ calcd for C29H34N 2O4 475.2591 found  475.2585. 
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Analytical RP-HPLC Vydac C8 gradient 20 - 100% MeCN(aq) +0.06% TFA 
over 20 min, Rt = 9.60 min. Monolith C18 gradient 60 - 95% MeOH(aq) over 5 
min, Rt = 0.54 min. 
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2-Methyl--propyl-3-(4-(4-aminoethoxy)-1-
naphthoyl)-indole ,/ (2.2 mg, 5.87 µmol), 
dansyl chloride (1.7 mg, 6.30 µmol) and 
triethylamine (0.6 mg, 5.94 µmol) were 
dissolved in DCM (2 mL) and the solution 
stirred for 20 h protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
preparatory layer chromatography (40:60 EtOAc:Hexane) to yield the desired 
product (1.6 mg, 44 %) as a yellow oil. 
 
δH (CDCl3) 8.37 (2H, m, dansyl), 8.25 (1H, m, naphthyl), 8.00 (1H, m, 
naphthyl), 7.61 (1H, m, dansyl), 7.55-7.41 (5H, 2 x CH naphthyl, 2 x CH 
indole, 1 x CH dansyl), 7.33 (1H, m, naphthyl), 7.22-7.17 (3H, 2 x CH dansyl 
and 1 x CH indole), 7.01 (1H, m, indole), 6.48 (1H, m, naphthyl), 5.35 (1H, m, 
NH), 4.13 (2H, t,  7.4 Hz, N-CH2 propyl), 4.04 (2H, m, O-CH2), 3.53 (2H, m, 
N-CH2 sulphonamide), 2.96 (6H, br s, N(CH3)2), 2.52 (3H, s, CH3 indole), 
1.86 (2H, m, CH2 β to propyl amine), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C37H37N 3O4S 620.2578 found  620.2587. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 13.00 min. Monolith C18 gradient 80 – 95 % MeOH(aq) over 
5 min, Rt = 1.13 min. 
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2-Methyl--propyl-3-(4-(4-aminobutoxy)-1-
naphthoyl)-indole ,, (2.2 mg, 5.30 µmol), 
dansyl chloride (1.2 mg, 4.44 µmol) and 
triethylamine (0.9 mg, 8.91 µmol) were 
dissolved in DCM (2 mL) and the solution 
stirred for 20 h protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
preparatory layer chromatography (25:75 Ether:Petroleum Ether 40/60) to 
yield the desired product (1.0 mg, 29 %) as a yellow oil. 
 
δH (CDCl3) 8.56 (1H, m, naphthyl), 8.35-8.23 (4H, 3 x CH dansyl and 1 x CH 
naphthyl), 7.61-7.47 (5H, 2 x CH naphthyl, 2 x CH indole, 1 x CH dansyl), 
7.33 (1H, m, naphthyl), 7.29-7.17 (3H, 2 x CH dansyl and 1 x CH indole), 7.03 
(1H, m, indole), 6.69 (1H, m, naphthyl), 4.70 (1H, m, NH), 4.13 (2H, t,  7.4 
Hz, N-CH2 propyl), 4.07 (2H, m, O-CH2), 3.07 (2H, m, N-CH2 sulphonamide), 
2.90 (6H, br s, N(CH3)2), 2.53 (3H, s, CH3 indole), 1.92-1.82 (4H, 2 x CH2), 
1.74 (2H, m, CH2), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C39H41N 3O4S 648.2891 found  648.2905. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 14.06 min. Monolith C18 gradient 80 – 95 % MeOH(aq) over 
5 min, Rt = 1.38 min. Found not to be > 98 % pure.  
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2-Methyl--propyl-3-(4-(4-aminohexyloxy)-1-
naphthoyl)-indole ,3 (11.7 mg, 26.5 µmol), 
dansyl chloride (8.0 mg, 29.1 µmol) and 
triethylamine (5.3 mg, 52.5 µmol) were 
dissolved in DCM (2 mL) and the solution 
stirred for 3 h protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
preparatory layer chromatography (25:75 Ether:Petroleum Ether 40/60) to 
yield the desired product (8.2 mg, 46 %) as a yellow oil. 
 
δH (CDCl3) 8.58 (1H, m, naphthyl), 8.34-8.29 (4H, 3 x CH dansyl and 1 x CH 
naphthyl), 7.61-7.48 (5H, 2 x CH naphthyl, 2 x CH indole, 1 x CH dansyl), 
7.34 (1H, m, naphthyl), 7.28-7.16 (3H, 2 x CH dansyl and 1 x CH indole), 7.03 
(1H, m, indole), 6.69 (1H, m, naphthyl), 4.56 (1H, m, NH), 4.15-4.08 (4H,  N-
CH2 propyl and O-CH2), 2.93 (2H, m, N-CH2 sulphonamide), 2.90 (6H, br s, 
N(CH3)2), 2.54 (3H, s, CH3 indole), 1.89-1.78 (4H, 2 x CH2), 1.51-1.40 (4H, 2 
x CH2), 1.31 (2H, m, CH2), 1.02 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C41H45N 3O4S 676.3204 found  676.3243. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 15.29 min. Monolith C18 gradient 80 – 95 % MeOH(aq) over 
5 min, Rt = 1.87 min. 
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2-Methyl--propyl-3-(4-(4-aminoctyloxy)-1-
naphthoyl)-indole ,0 (2.1 mg, 4.50 µmol), 
dansyl chloride (1.4 mg, 5.19 µmol) and 
triethylamine (0.9 mg, 8.91 µmol) were 
dissolved in DCM (1 mL) and the solution 
stirred for 16 h protected from light. 
 
The solution was diluted in EtOAc (10 mL) and 
washed with brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (50:50 
EtOAc:Hexane) to yield the desired product (1.3 mg, 41 %) as a yellow oil. 
 
δH (CDCl3) 8.56 (1H, m, naphthyl), 8.35-8.27 (4H, 3 x CH dansyl and 1 x CH 
naphthyl), 7.62-7.48 (5H, 2 x CH naphthyl, 2 x CH indole, 1 x CH dansyl), 
7.37-7.28 (3H, 2 x CH dansyl and 1 x CH naphthyl), 7.21(1H, m, indole), 7.03 
(1H, m, indole), 6.78 (1H, d,  8.0 Hz, naphthyl), 4.54 (1H, m, NH), 4.18 (2H, 
m, N-CH2 propyl), 4.14 (2H, m, O-CH2), 1.91 (2H, m, N-CH2 sulphonamide), 
2.90 (6H, br s, N(CH3)2), 2.55 (3H, s, CH3 indole), 1.95-1.84 (4H, 2 x CH2), 
1.51 (2H, m, CH2), 1.39 (2H, m, CH2), 1.29 (2H, m, CH2), 1.22-1.18 (4H, 2 x 
CH2) 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C43H49N 3O4S 704.3517 found  704.3492. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 16.54 min. Monolith C18 gradient 80 – 95 % MeOH(aq) over 
5 min, Rt = 2.57 min.  
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2-Methyl--propyl-3-(4-(2-(2-(2-
ethoxy)ethoxy)ethylamine)-1-naphthoyl)-indole
31 (2.2 mg, 4.67 µmol), dansyl chloride (1.4 
mg, 5.19 µmol) and triethylamine (0.5 mg, 4.95 
µmol) were dissolved in DCM (2 mL) and the 
solution stirred for 20 h protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
preparatory layer chromatography (50:50 EtOAc:Hexane) to yield the desired 
product (1.4 mg, 42 %) as a yellow oil. 
 
δH (CDCl3) 8.38-8.36 (2H, 1 x CH naphthyl and 1 x CH dansyl), 8.31-8.25 
(3H, 3 x CH dansyl and 1 x CH naphthyl), 7.58-7.48 (5H, 2 x CH naphthyl, 2 
x CH indole, 1 x CH dansyl), 7.34 (1H, m, 1 x CH naphthyl), 7.28-7.16 (3H, 2 
x CH dansyl and 1 x CH indole), 7.00 (1H, m, indole), 6.82 (1H, m, naphthyl), 
5.51 (1H, m, NH), 4.40 (2H, m, CH2), 4.14 (2H,  7.4 Hz, N-CH2 propyl), 4.07 
(2H, m, CH2), 3.72 (2H, m, CH2), 3.51 (2H, m, CH2), 3.46 (2H, m, CH2), 3.07 
(6H, br s, N(CH3)2), 2.54 (3H, s, CH3 indole), 1.86 (2H, m, CH2 β to propyl 
amine) 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C41H45N 3O6S 708.3102 found  708.3109. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 13.62 min. Monolith C18 gradient 80 – 95 % MeOH(aq) over 
5 min, Rt = 1.13 min. Found not to be > 98 % pure.  
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2-Methyl--propyl-3-(4-(4-aminoethoxy)-1-
naphthoyl)-indole ,/ (1.5 mg, 4.00 µmol) 4-
fluoro-7-nitrobenzofurazan (0.7 mg, 3.82 µmol) 
and triethylamine (0.4 mg, 3.96 µmol) were 
dissolved in DCM (2 mL) and the solution stirred for 18 h protected from 
light. 
 
The solution was diluted in DCM (10 mL) and washed with brine, dried over 
MgSO4 and reduced 
. The crude product was purified by preparatory 
layer chromatography (50:50 EtOAc:Hexane) to yield the desired product (0.4 
mg, 19 %) as an orange oil. 
 
δH (CDCl3) 8.57 (1H, d,  8.6 Hz, nitrobenzofurazan), 8.26 (2H, m, naphthyl), 
7.56 (1H, d,  7.9 Hz, 2-H naphthyl), 7.52 (2H, m, naphthyl), 7.34 (1H, m, 
indole), 7.23-7.18 (2H, indole), 7.01 (1H, m, indole), 6.84 (1H, d,  8.0 Hz, 3-
H naphthyl), 6.82 (1H, m, NH), 6.41 (1H, d,  8.6 Hz, nitrobenzofurazan), 4.57 
(2H, m, O-CH2), 4.16-4.07 (4H, 2 x CH2), 2.56 (3H, s, CH3 indole), 1.87 (2H, 
m, CH2 β to propyl amine), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C31H27N 5O5 550.2085 found  550.2100. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 14.26 min. Monolith C18 gradient 60 – 95 % MeOH(aq) over 
5 min, Rt = 3.35 min. 
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2-Methyl--propyl-3-(4-(4-aminobutoxy)-1-
naphthoyl)-indole ,, (1.5 mg, 3.65 µmol) 4-
fluoro-7-nitrobenzofurazan (0.7 mg, 3.82 µmol) 
and triethylamine (0.7 mg, 6.93 µmol) were 
dissolved in DCM (2 mL) and the solution stirred 
for 20 h protected from light. 
 
The solution was diluted in EtOAc (10 mL) and washed with brine, dried over 
MgSO4 and reduced 
. The crude product was purified by preparatory 
layer chromatography (60:40 EtOAc:Hexane) to yield the desired product (0.6 
mg, 29 %) as an orange oil. 
 
δH (CDCl3) 8.49 (1H, d,  8.6 Hz, nitrobenzofurazan), 8.33 (1H, m, naphthyl), 
8.28 (1H, m, naphthyl), 7.59 (1H, d,  7.9 Hz, 2-H naphthyl), 7.51 (2H, m, 
naphthyl), 7.34 (1H, m, indole), 7.24-7.17 (2H, indole), 7.01 (1H, m, indole), 
6.81 (1H, d,  8.0 Hz, 3-H naphthyl), 6.39 (1H, m, NH), 6.22 (1H, d,  8.6 Hz, 
nitrobenzofurazan), 4.33 (2H, m, O-CH2), 4.14 (2H, t,  7.5 Hz, N-CH2 
propyl), 3.35 (2H, m, N-CH2 secondary amine), 2.57 (3H, s, CH3 indole), 2.22-
2.18 (4H, 2 x CH2), 1.88 (2H, m, CH2 β to propyl amine), 1.03 (3H, t,  7.4 
Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C33H31N 5O5 578.2398 found  578.2428. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 14.75 min. Monolith C18 gradient 60 – 95 % MeOH(aq) over 
5 min, Rt = 3.37 min. 
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2-Methyl--propyl-3-(4-(4-aminohexyloxy)-1-
naphthoyl)-indole ,3 (2.1 mg, 4.87 µmol) 4-
fluoro-7-nitrobenzofurazan (0.8 mg, 4.37 µmol) 
and triethylamine (0.5 mg, 4.95 µmol) were 
dissolved in DCM (2 mL) and the solution stirred 
for 18 h protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with brine, dried over 
MgSO4 and reduced 
. The crude product was purified by preparatory 
layer chromatography (50:50 EtOAc:Hexane) to yield the desired product (0.5 
mg, 17 %) as an orange oil. 
 
δH (CDCl3) 8.51 (1H, d,  8.6 Hz, nitrobenzofurazan), 8.37 (1H, m, naphthyl), 
8.28 (1H, m, naphthyl), 7.58 (1H, d,  7.9 Hz, 2-H naphthyl), 7.50 (2H, m, 
naphthyl), 7.34 (1H, m, indole), 7.26-7.17 (2H, indole), 7.01 (1H, m, indole), 
6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 6.22 (1H, m, NH), 6.19 (1H, d,  8.6 Hz, 
nitrobenzofurazan), 4.27 (2H, m, O-CH2), 4.14 (2H, t,  7.5 Hz, N-CH2 
propyl), 3.55 (2H, m, N-CH2 secondary amine), 2.57 (3H, s, CH3 indole), 2.03 
(2H, m, CH2), 1.98-1.71 (4H, 2 x CH2), 1.03 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C35H35N 5O5 606.2716 found  606.2734. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 16.08 min. Monolith C18 gradient 60 – 95 % MeOH(aq) over 
5 min, Rt = 3.95 min. 
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2-Methyl--propyl-3-(4-(4-aminooctyloxy)-1-
naphthoyl)-indole ,0 (1.8 mg, 3.85 µmol) 4-
fluoro-7-nitrobenzofurazan (0.7 mg, 3.82 µmol) 
and triethylamine (0.8 mg, 7.92 µmol) were 
dissolved in DCM (2 mL) and the solution stirred 
for 20 h protected from light. 
 
The solution was diluted in EtOAc (20 mL) and 
washed with brine, dried over MgSO4 and reduced 
. The crude 
product was purified by preparatory layer chromatography (50:50 
EtOAc:Hexane) to yield the desired product (0.5 mg, 21 %) as an orange oil. 
 
δH (CDCl3) 8.51 (1H, d,  8.6 Hz, nitrobenzofurazan), 8.38 (1H, m, naphthyl), 
8.29 (1H, m, naphthyl), 7.59 (1H, d,  8.0 Hz, 2-H naphthyl), 7.52 (2H, m, 
naphthyl), 7.34 (1H, m, indole), 7.25-7.16 (2H, indole), 7.01 (1H, m, indole), 
6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 6.32 (1H, m, NH), 6.18 (1H, d,  8.6 Hz, 
nitrobenzofurazan), 4.25 (2H, m, O-CH2), 4.15 (2H, m, N-CH2 propyl), 3.47 
(2H, m, N-CH2 secondary amine), 2.57 (3H, s, CH3 indole), 2.02 (2H, m, 
CH2), 1.86 (2H, m, CH2), 1.80 (2H, m, CH2), 1.70-1.46 (8H, 4 x CH2), 1.03 
(3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C37H39N 5O5 634.3029 found  634.3013. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 17.13 min. Found not to be > 98 % pure. 
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2-Methyl--propyl-3-(4-(2-(2-(2-
ethoxy)ethoxy)ethylamine)-1-naphthoyl)-indole
31 (2.5 mg, 5.40 µmol) 4-fluoro-7-
nitrobenzofurazan (1.0 mg, 5.46 µmol) and 
triethylamine (0.6 mg, 5.94 µmol) were dissolved 
in DCM (2 mL) and the solution stirred for 18 h 
protected from light. 
 
The solution was diluted in DCM (10 mL) and washed with brine, dried over 
MgSO4 and reduced 
. The crude product was purified by preparatory 
layer chromatography (50:50 EtOAc:Hexane) to yield the desired product (0.5 
mg, 15 %) as an orange oil. 
 
δH (CDCl3) 8.43 (1H, d,  8.6 Hz, nitrobenzofurazan), 8.35 (1H, m, naphthyl), 
8.26 (1H, m, naphthyl), 7.52 (1H, d,  8.0 Hz, 2-H naphthyl), 7.47 (2H, m, 
naphthyl), 7.34 (1H, m, indole), 7.19 (2H, m, indole), 6.99 (1H, m, indole), 
6.88 (1H, m, NH), 6.80 (1H, d,  8.0 Hz, 3-H naphthyl), 6.04 (1H, d,  8.6 Hz, 
nitrobenzofurazan), 4.48 (2H, m, CH2), 4.19-4.10 (4H, 2 x CH2), 3.88 (2H, m, 
CH2), 3.85-3.76 (4H, 2 x CH2), 3.52 (2H, m, CH2), 2.56 (3H, s, CH3 indole), 
1.87 (2H, m, CH2 β to propyl amine), 1.01 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C35H35N 5O7 638.2615 found  638.2577. 
 
Analytical RP-HPLC Vydac C8 gradient 20 – 100 % MeCN(aq) + 0.06 % TFA 
over 20 min, Rt = 14.31 min. Monolith C18 gradient 60 – 95 % MeOH(aq) over 
5 min, Rt = 2.88 min. 
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2-Methyl--propyl-3-(4-(4-
aminoethoxy)-1-naphthoyl)-
indole ,/ (1.3 mg, 3.36 µmol), 
5-carboxyfluorescein--succinimdyl ester  (1.0 mg, 2.10 µmol) and 
triethylamine (0.5 mg, 4.95 µmol) were dissolved in DCM (1 mL) and the 
solution stirred for 3 h protected from light. 
 
The solution was reduced 
, and purification by preparatory layer 
chromatography (5:94:1 MeOH:DCM:AcOH) yields the desired product (2.3 
mg, 92 %) as an orange oil. 
 
δH (CDCl3) 9.04 (1H, m, aromatic), 8.53 (1H, m, aromatic), 8.43 (1H, d,  8.1 
Hz, aromatic), 8.16 (1H, d,  8.3 Hz, aromatic), 8.00 (1H, m, aromatic), 7.59-
7.35 (3H, aromatic), 7.19-7.08 (4H, aromatic), 6.97 (1H, m, aromatic), 6.51 
(2H, m, aromatic), 5.99 (2H, m, aromatic), 5.91 (2H, m, aromatic), 4.42 (2H, 
m, CH2), 4.20 (2H, m, CH2), 3.90 (2H, m, CH2), 2.70 (3H, s, CH3 indole), 2.39 
(2H, CH2), 0.90 (3H, m,  CH3 N-propyl). 
 
EP-MS MH+ calcd for C46H36N 2O8 745.2550 found  745.2533. 
 
Analytical RP-HPLC Vydac C8 gradient 50 – 100 % MeCN(aq) +0.06 % TFA 
over 20 min, Rt = 4.98 min. Ace C18 gradient 70 – 100 % MeOH(aq) +0.06 % 
TFA over 20 min, Rt = 11.24 min. 
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2-Methyl--propyl-3-(4-(4-
aminobutoxy)-1-naphthoyl)-
indole ,, (1.3 mg, 3.23 µmol), 
5-carboxyfluorescein--
succinimdyl ester  (1.0 mg, 2.10 µmol) and triethylamine (0.5 mg, 4.95 µmol) 
were dissolved in DCM (1 mL) and the solution stirred for 3 h protected from 
light. 
 
The solution was reduced 
, and purification by preparatory layer 
chromatography (5:94:1 MeOH:DCM:AcOH) yields the desired product (2.4 
mg, 96 %) as an orange oil. 
 
δH (CDCl3) 8.79 (1H, m, aromatic), 8.52 (1H, m, aromatic), 8.32 (1H, d,  7.4 
Hz, aromatic), 8.02 (1H, d,  8.0 Hz, aromatic), 7.87 (1H, d,  6.6 Hz, 
aromatic), 7.58-7.39 (3H, aromatic), 7.17-7.10 (3H, aromatic), 7.05 (1H, d,  
8.1 Hz, aromatic), 6.98 (1H, m, aromatic), 6.52 (2H, d,  9.2 Hz, aromatic), 
5.99 (2H, m, aromatic), 5.92 (2H, m, aromatic), 4.32 (2H, m, CH2), 4.20 (2H, 
m, CH2), 2.71 (3H, s, CH3 indole), 2.04-1.97 (4H, 2 x CH2), 1.91-1.84 (4H, 2 x 
CH2), 0.91 (3H, t,  7.4 Hz, CH3 N-propyl). 
 
EP-MS MH+ calcd for C48H40N 2O8 773.2863 found  773.2905. 
 
Analytical RP-HPLC Vydac C8 gradient 50 – 100 % MeCN(aq) +0.06 % TFA 
over 20 min, Rt = 10.02 min. Ace C18 gradient 70 – 100 % MeOH(aq) +0.06 % 
TFA over 20 min, Rt = 13.04 min. 
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2-Methyl--propyl-3-(4-(4-
aminohexyloxy)-1-naphthoyl)-
indole ,3 (1.4 mg, 2.52 µmol), 
5-carboxyfluorescein--
succinimdyl ester  (1.0 mg, 
2.10 µmol) and triethylamine (0.5 mg, 4.95 µmol) were dissolved in DCM (1 
mL) and the solution stirred for 3 h protected from light. 
 
The solution was reduced 
, and purification by preparatory layer 
chromatography (5:94:1 MeOH:DCM:AcOH) yields the desired product (1.9 
mg, 94 %) as an orange oil. 
 
δH (CDCl3) 8.67 (1H, m, aromatic), 8.47 (1H, m, aromatic), 8.31 (1H, d,  8.0 
Hz, aromatic), 8.01 (1H, d,  7.6 Hz, aromatic), 7.84 (1H, m, aromatic), 7.58-
7.46 (3H, aromatic), 7.18-7.03 (4H, aromatic), 6.97 (1H, m, aromatic), 6.52 
(2H, d,  9.2 Hz, aromatic), 5.98 (2H, m, aromatic), 5.91 (2H, m, aromatic), 
4.27 (2H, m, CH2), 4.20 (2H, m, CH2), 4.11 (2H, m, CH2), 2.70 (3H, s, CH3 
indole), 2.02-1.85 (4H, 2 x CH2), 1.80-1.69 (4H, 2 x CH2), 1.45 (2H, CH2) 
0.92 (3H, m, CH3 N-propyl). 
 
EP-MS MH+ calcd for C50H44N 2O8 801.3176 found  801.3210. 
 
Analytical RP-HPLC Vydac C8 gradient 50 – 100 % MeCN(aq) +0.06 % TFA 
over 20 min, Rt = 7.22 min. Ace C18 gradient 70 – 100 % MeOH(aq) +0.06 % 
TFA over 20 min, Rt = 15.25 min. 
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2-Methyl--propyl-3-(4-(4-
aminooctyloxy)-1-naphthoyl)-
indole ,0 (1.5 mg, 3.18 µmol), 
5-carboxyfluorescein--
succinimdyl ester  (1.0 mg, 
2.10 µmol) and triethylamine 
(0.5 mg, 4.95 µmol) were dissolved in DCM (1 mL) and the solution stirred 
for 3 h protected from light. 
 
The solution was reduced 
, and purification by preparatory layer 
chromatography (5:94:1 MeOH:DCM:AcOH) yields the desired product (2.1 
mg, 80 %) as an orange oil. 
 
EP-MS MH+ calcd for C52H48N 2O8 829.3489 found  829.3427. 
 
Analytical RP-HPLC Vydac C8 gradient 50 – 100 % MeCN(aq) +0.06 % TFA 
over 20 min, Rt = 8.62 min. Ace C18 gradient 70 – 100 % MeOH(aq) +0.06 % 
TFA over 20 min, Rt = 17.62 min. 
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2-Methyl--propyl-3-(4-(2-(2-
(2-ethoxy)ethoxy)ethylamine)-
1-naphthoyl)-indole31 (1.5 
mg, 3.16 µmol), 5-
carboxyfluorescein--
succinimdyl ester  (1.0 mg, 
2.10 µmol) and triethylamine 
(0.5 mg, 4.95 µmol) were dissolved in DCM (1 mL) and the solution stirred 
for 3 h protected from light. 
 
The solution was reduced 
, and purification by preparatory layer 
chromatography (5:94:1 MeOH:DCM:AcOH) yields the desired product (2.4 
mg, 91 %) as an orange oil. 
 
δH (CDCl3) 8.48 (1H, m, aromatic), 8.00(1H, m, aromatic), 8.04-7.97 (3H, 
aromatic), 7.49-7.40 (4H, aromatic), 7.18-7.12 (3H, aromatic), 6.98 (1H, m, 
aromatic), 6.93 (1H, m, aromatic), 6.61 (2H, m, aromatic), 6.67 (2H, m, 
aromatic), 6.54 (2H, m, aromatic), 4.42 (2H, m, CH2), 4.20 (2H, m, CH2), 4.11 
(2H, m, CH2), 3.98 (2H, m, CH2), 3.79-3.75 (4H, 2 x CH2), 3.66 (2H, m, CH2), 
2.88 (3H, s, OCH3), 1.73 (2H, m, CH2), 1.00 (3H, m, CH3 N-propyl). 
 
EP-MS MH+ calcd for C50H44N 2O10 833.3074 found  833.3109. 
 
Analytical RP-HPLC Vydac C8 gradient 50 – 100 % MeCN(aq) +0.06 % TFA 
over 20 min, Rt = 4.92 min. Ace C18 gradient 70 – 100 % MeOH(aq) +0.06 % 
TFA over 20 min, Rt = 11.02 min. 
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Methyl 1-methoxybicyclo[2.2.2]-oct-5-ene-2-carboxylate (18.0 g, 91.7 mmol) 
was added to a solution of potassium hydroxide (16.8 g, 299 mmol) in MeOH 
(100 mL), and the reaction mixture was refluxed for 15 h.  
 
The reaction was quenched with water (100 mL) and reduced 
 to yield 
a light brown solid. This was dissolved in water (400 mL), washed with DCM, 
acidified with conc. HCl to pH 1, and extracted with DCM (3 x 100 mL). The 
combined organics were washed with water and brine, dried over MgSO4 and 
reduced 
. The crude product was recrystallised from 2,2,4-
trimethylpentane to yield the desired product (14.6 g, 87 %) as off white 
crystals. 
 
δH (CDCl3)* 6.38-6.31 (3H, exo 5-H, exo 6-H and endo 5-H), 6.22 (1H, dd,  
8.9 and 0.7Hz, endo 6-H), 3.52 (3H, s, endo -OCH3), 3.51 (3H, s, exo -OCH3), 
2.76 (1H, ddd,  9.9, 4.0 and 0.5Hz, endo 2-H), 2.65-2.60 (2H, exo 2-H and 
endo 4-H), 2.58 (1H, m, exo 4-H), 2.22 (1H, ddd, 13.0, 4.4 and 2.5Hz, exo 1 
x 3-H), 2.03 (1H, app dq,  13.2 and 3.6Hz, endo 1 x 3-H), 1.88-1.52 (8H, exo 
1 x 3-H, exo 7-H, exo 1 x 8-H, endo 1 x 3-H, endo 7-H and endo 1 x 8-H), 
1.46-1.36 (2H, exo 1 x 8-H and endo 1 x 8-H). Endo:Exo ratio found to be 
23:10. 
 
δC (CDCl3)* 175.7 (exo COOH), 175.2 (endo COOH), 135.6 (CH, C-5), 135.5 
(CH, C-5), 132.4 (CH, exo C-6), 129.9 (CH, endo C-6), 79.7 (4˚, C-1), 79.7 
(4˚, C-1), 51.6 (CH3, -OCH3), 51.4 (CH3, -OCH3), 47.0 (CH, C-2), 45.9 (CH, 
C-2), 30.2, 29.9 (2 x CH2), 29.3, 29.1 (2 x CH, exo C-4 and endo C-4), 27.2, 
26.1, 25.2, 24.7 (4 x CH2). 
 
*Note: each proton and carbon signal is duplicated, as both the exo and endo 
diastereoisomers are present. 
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EP-MS M- calcd for C10H14O3 181.0870 found  181.0874. 
 
FTIR (KBr) 2951, 2871, 2832, 2747, 2663, 1705 (C=O), 1424, 1378, 1350, 
1321, 1230, 1197, 1178, 1122, 1091, 1017, 954, 687 cm-1. 
 
m.p. 80-89 °C  lit. 77-81 °C166, 168. 
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1-Methoxybicyclo[2.2.2]-oct-5-ene-2-carboxylic acid )
$'' (16.8 g, 92.3 mmol) was dissolved in a solution of sodium bicarbonte 
(20.0 g, 238 mmol) and sodium hydroxide (1.44 g, 36.0 mmol) in water (300 
mL). This was added to a solution of iodine (28.2 g, 111 mmol) and potassium 
iodide (30.1 g, 181 mmol) in water (200 mL), and stirred with the exclusion of 
light for 18 h. 
 
The reaction mixture was quenched with DCM (200 mL), stirred for 45 min, 
and 20% sodium thiosulphate solution (50 mL) was added to facilitate 
extraction. The layers were separated and the aqueous layer extracted with 
DCM (3 x 100 mL). The combined organics were washed with 20% sodium 
thiosulphate(aq) (2 x 100 mL), sat. NaHCO3 solution (100 mL) and brine (150 
mL), dried over MgSO4 and reduced 
. The crude product was 
recrystallised from PrOH to yield the desired product )$'- (17.6 g, 89 %)* 
as white crystals. 
 
δH (CDCl3) 4.95 (1H, d,  1.5Hz, 4-H), 4.44 (1H, dd,  2.0 and 3.6Hz, 5-H), 
3.25 (3H, s, -OCH3), 2.58 (1H, app dt,  10.7 and 1.5 Hz, 2-H), 2.41(1H, m, 1 
x CH), 2.26 (1H, ddd,  15.3, 10.8. 3.2Hz, 1 x 7-H), 2.13-2.04 (3H, 6-H, 1 x 7-
H and 1 x 9-H), 1.99 (1H, m, 1 x CH), 1.83 (1H, m, 1 x CH). 
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δC (CDCl3) 178.2 (4°, C-1), 86.0 (CH, C-4), 80.1 (4°, C-3), 50.6 (CH3, -
OCH3), 40.6 (CH, C-2), 32.0 (CH, C-6), 29.1 (CH2), 29.0 (CH, C-5), 26.6, 
17.9 (2 x CH2). 
 
EP-MS MH+ calcd for C10H13IO3 309.0 found  309.0. 
 
FTIR (KBr) 2940, 2873, 2835, 1777 (C=O), 1450, 1339, 1362, 1314, 1195, 
1145, 1102, 1083, 1018, 990, 975, 959, 926, 907, 722, 660 cm-1. 
 
m.p. 129 °C   lit. 125-126 °C166, 168. 
 
The aqueous layers from the reaction were acidified with conc. HCl to pH 1, 
and extracted with DCM (3 x 100 mL). The combined organics were washed 
with 20% aq sodium thiosulphate solution (3 x 100 mL), water (200 mL) and 
brine (250 mL), dried over MgSO4 and reduced 
 to yield the desired 
product )$'. (4.19 g, 58 %)* as a yellow solid. 
 
δH (CDCl3) 6.37-6.32 (2H, 2 x CH alkene), 3.51 (3H, s, -OCH3), 2.63 (1H, 
ddd,  11.4, 4.6 and 3.0Hz, 2-H), 2.57 (1H, m, 4-H), 2.18 (1H, m, 1 x 3-H), 
1.85-1.53 (4H, 1 x 3-H, 2 x 7-H and 1 x 8-H), 1.41 (1H, m, 1 x 8-H). 
 
EP-MS M- calcd for C10H14O3 181.0870 found  181.0874. 
 
*Note: theoretical yield calculated from the endo:exo ratio of 23:10 as 
determined with the preparation of 1-methoxybicyclo[2.2.2]-oct-5-ene-2-
carboxylic acid)$'' above. 
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Iodolactone )$'- (13.3 g, 43.1 mmol) and zinc dust (4.23 g, 65.1 mmol) 
were suspended in EtOH (250 mL) and the reaction mixture was stirred and 
refluxed under an inert atmosphere for 3 h. 
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The reaction mixture was cooled, filtered through a Celite 521 plug with EtOH 
washings, and reduced 
 to a solid which was dissolved in DCM (50 
mL) and 2M HCl(aq) (50 mL). The layers were separated and aqueous layer 
extracted with DCM (2 x 25 mL). The combined organics were extracted with 
15% NaOH(aq) (3 x 25 mL), and the combined aqueous layers were acidified to 
pH 1 with conc. HCl and extracted with DCM (3 x 40 mL). The combined 
organics were washed with water and brine, dried over MgSO4 and reduced 

. The crude product was recrystallised from petroleum ether 100/120 to 
yield the desired product (5.43 g, 69 %) as white crystals. 
 
δH (CDCl3) 6.35 (1H, dd,  8.9 and 6.5Hz, 5-H), 6.22 (1H, dd,  8.9 and 0.7Hz, 
6-H), 3.53 (3H, s, -OCH3), 2.75 (1H, ddd,  9.9, 3.7 and 0.5Hz, 2-H), 2.63 
(1H, m, 4-H), 2.07 (1H, app dq,  13.2 and 3.6Hz, 1 x 3-H), 1.83 (1H, m, 1 x 
3-H), 1.79-1.67 (2H, 1x 7-H and 1x 8-H), 1.56 (1H, m, 1 x 7-H), 1.41 (1H, m, 
1 x 8-H). 
 
δC (CDCl3) 174.2 (COOH), 136.0 (CH, C-5), 129.5 (CH, C-6), 79.9 (4˚, C-1), 
51.5 (CH3, -OCH3), 47.1 (CH, C-2), 29.4 (CH2), 29.3 (CH, C-4), 26.9, 26.3 (2 
x CH2). 
 
EP-MS M- calcd for C10H14O3 181.0870 found  181.0850. 
 
m.p. 82-83 °C  lit. 80-82 °C166, 168. 
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1-Methoxybicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylic acid )$'/ (3.20 g, 
17.6 mmol) and (+)-ephedrine* (4.50 g, 27.2 mmol) were dissolved in EtOAc 
(25 mL) at reflux under an inert atmosphere. The solution was allowed to cool 
to room temperature and to crystallise at 4 ºC for 18 h. 
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The crystals were filtered and recrystallisation from EtOAc to yield the desired 
product (1.85 g, 60 %) as white crystals. 
 
*Note: (+)-ephedrine freshly prepared from (+)-ephedrine hydrochloride. 
 
[α]D +15.3˚ [23.1 ˚C, MeOH]      lit. +13.2˚ and +14.3˚ [MeOH]
166, 168.* 
 
δH (CDCl3) 7.38-7.22 (5H, aromatic), 6.83 (3H, br s, NH2
+ and OH), 6.30-6.22 
(2H, alkene), 5.12 (1H, m, 1-H ephedrine), 3.40 (3H, s, -OCH3), 3.01 (1H, m, 
2-H ephedrine), 2.77 (1H, m, 2-H acid), 2.62 (3H, s, NH2
+-CH3), 2.55 (1H, m, 
4-H acid), 1.90 (1H, m, 1 x 3-H acid), 1.73 (1H, m, 1 x 3-H acid), 1.68-1.34 
(4H, 7-H and 8-H acid), 0.98 (3H, d,  6.6 Hz, 3-H ephedrine). 
 
δC (CDCl3) 179.3 (4˚, COO
-), 141.0 (4˚, aromatic), 133.1 (CH, alkene), 132.0 
(CH, alkene), 128.2 (CH, aromatic), 127.1 (CH, aromatic), 126.0 (CH, 
aromatic), 79.6 (4˚, C-1 acid), 71.4, 61.1 (2 x CH, ephedrine), 51.0 (CH3, -
OCH3), 48.7 (CH, C-2 acid), 32.5 (CH3, N-CH3 ephedrine), 32.2 (CH2), 29.5 
(CH, C-4 acid), 28.3, 25.3 (2 x CH2), 11.2 (CH3, C-3 ephedrine). 
 
m.p. 131 °C   lit. 135-136 °C166, 168. 
 
*Literature sources do not quote temperature for [α]D results. 
 
*=	.	>)=)>)$)"<
)
?&&@))-)
))?@<
$'3
 
(+)-Ephedrine salt of (-)-1-methoxybicyclo[2.2.2]-oct-5-ene-2-
[endo]carboxylic acid $', (1.75 g, 5.04 mmol) was partitioned between DCM 
(40 mL) and 2 M HCl(aq) (20 mL) and stirred for 3 h. 
 
The layers were separated and the aqueous layer was extracted with DCM (2 x 
20 mL). The combined organic layers were washed with 2M HCl(aq), water and 
)
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brine, dried over MgSO4 and reduced 
 to yield the desired product 
(870 mg, 95 %) as a white solid. The crude product was used without any 
further purification. 
 
[α]D -7.3˚ [21.9 ˚C, MeOH] 
[α]D -20.7˚ [22.4 ˚C, DCM] lit. -26.3˚ and -25.0˚ [DCM]
166, 168.*  
 
δH (CDCl3) 6.35 (1H, dd,  8.8 and 6.6Hz, 5-H), 6.22 (1H, d,  8.8Hz. 6-H), 
3.50 (3H, s, -OCH3), 2.77 (1H, dd,  9.9 and 4.1, 2-H), 2.62 (1H, m, 4-H), 1.99 
(1H, m, 1 x 3-H), 1.84 (1H, m, 1 x 3-H), 1.76-1.66 (2H, 1 x 7-H and 1 x 8-H), 
1.57 (1H, m, 1 x 7-H), 1.42 (1H, m, 1 x 8-H). 
 
δC (CDCl3) 178.0 (COOH), 135.5 (CH, C-5), 130.0 (CH, C-6), 79.7 (4˚, C-1), 
51.4 (CH3, -OCH3), 47.0 (CH, C-2), 29.9 (CH2), 29.2 (CH, C-4), 27.2 26.0 (2 
x CH2). 
 
EP-MS M- calcd for C10H14O3 181.1 found  181.1. 
 
*Literature sources do not quote temperature for [α]D results. 
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(-)-1-Methoxy-bicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylic acid $'3 (0.870 g, 
4.77 mmol) and para-toluenesulfonic acid (95.0 mg, 0.500 mmol) were 
dissolved in EtOH (10 mL) and refluxed under an inert atmosphere for 21 h.   
 
The reaction was cooled, reduced 
, partitioned between water (15 mL) 
and DCM (15 mL) and separated. The aqueous layer was further extracted 
with DCM (2 x 15 mL) and the combined organic layers were washed with sat. 
NaHCO3(aq), 1 M HCl(aq) and brine, dried over MgSO4 and reduced 
. 
The crude product was purified by flash column chromatography (10:90 
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EtOAc:Hexane) to yield the desired product (0.572 g, 57 %) as a colourless 
oil. 
 
[α]D of -3.97˚ [22.6 ˚C, MeOH]   
[α]D of -3.08˚ [21.8 ˚C, CHCl3]  lit. -5.1˚ [CHCl3]
166.* 
 
δH (CDCl3) 6.28 (1H, dd,  8.7 and 6.3Hz, 5-H), 6.23 (1H, d,  8.7 Hz, 6-H), 
4.11 (2H, m, -OCH2), 3.38 (3H, s, -OCH3), 2.89 (1H, dd,  9.9 and 5.5 Hz, 2-
H), 2.57 (1H, m, 4-H), 1.90 (1H, m, 1 x 3-H), 1.69-1.37 (5H, 1 x 3-H, 7-H and 
8-H), 1.24 (3H, t,  7.1Hz, CH3 β to ester) 
 
δC (CDCl3) 174.6 (4˚, ester), 132.8 (CH, C-5), 132.4 (CH, C-6), 79.0 (4˚, C-1), 
60.4 (CH2, -OCH2), 50.8 (CH3, -OCH3), 46.3 (CH, C-2), 33.0 (CH2, C-3), 29.3 
(CH, C-4), 28.5, 24.5 (2 x CH2), 14.2 (CH3, CH3 β to ester) 
 
EP-MS MH+ calcd for C12H18O3 211.1334 found  211.1351. 
 
*Literature source does not quote temperature for [α]D results. 
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(-) Ethyl 1-methoxybicyclo[2.2.2]-oct-5-ene-2-[endo]carboxylate $'0 (1.00 g, 
4.76 mmol) was dissolved in DCM (30 mL) and cooled to -25˚C. 1 M boron 
tribromide in DCM (5.30 mmol) was added dropwise over 10 min, and the 
reaction mixture was stirred at -25˚C for 1 h. 
 
The reaction was quenched with sat. NaHCO3(aq) (20 mL) and stirred for 45 
min. The layers were separated and the aqueous layer was extracted with DCM 
(2 x 20 mL). The combined organic layers were washed with water and brine, 
dried over MgSO4, reduced 
 to yield the desired product (567 mg, 

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61 %) as a yellow oil. The crude product was used without any further 
purification. 
 
[α]D of +14.9˚ [21.4 ˚C, MeOH] 
 
δH (CDCl3) 6.20-6.18 (2H, alkene), 4.14 (2H, m, -OCH2), 2.69 (1H, dd,  10.6 
and 4.9 Hz, 2-H), 2.56 (1H, m, 4-H), 2.04 (1H, m, 1 x 3-H), 1.70-1.34 (5H, 1 x 
3-H, 7-H and 8-H), 1.25 (3H, t, J 7.1Hz, CH3 β to ester). 
 
δC (CDCl3) 175.4 (4˚,ester), 136.9 (CH, C-5), 132.5 (CH, C-6), 72.9 (4˚, C-1), 
60.8 (CH2, -OCH2), 48.8 (CH, C-2), 32.1 (CH2, C-3), 31.4 (CH, C-4), 29.6, 
25.6 (2 x CH2), 14.2 (CH3, CH3 β to ester). 
 
EP-MS MH+ calcd for C11H16O3 197.1178 found  197.1166. 
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To a solution of (+)-ethyl 1-hydroxybicyclo[2.2.2]-oct-5-
ene-2-[endo]carboxylate $.1 (134 mg, 0.694 mmol) in 
tBuOH (10 mL) at 35 ˚C, was added potassium butoxide 
(8.0 mg, 0.071mmol) and the solution stirred at 35 ˚C for 1 h. 
 
The reaction was quenched with water (10 mL) and EtOAc (10 mL), stirred for 
10 min, layers separated and the aqueous layer extracted with EtOAc (15 mL). 
The combined organics were washed with water and brine, dried over MgSO4 
and reduced 
. The crude product was purified by preparatory layer 
chromatography (50:50 Ether:Petroleum Ether 40/60) to yield the desired 
product (103 mg, 78 %) as a yellow oil. 
 
δH (CDCl3) 6.83 (1H, ddd,  10.2, 2.7 and 1.4 Hz, 3-H), 6.01 (1H, ddd, J 10.7, 
2.5 and 0.4 Hz, 2-H), (2H, q,  7.1Hz, -OCH2), 2.56-2.32 (5H), 2.13 (1H, m), 
1.95-1.64 (3H), 1.27 (3H, t,  7.1 Hz, CH3). 

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δC (CDCl3) 199.5, 173.0 (2 x 4°, 2 x C=O), 153.7 (CH, C-3), 129.5 (CH, C-2), 
60.6 (CH2, OCH2), 36.8 (CH2), 35.3 (CH, C-4), 31.6, 29.5, 28.3 (3 x CH2), 
14.2 (CH3). 
 
EP-MS MH+ calcd for C11H16O3 197.1178 found  197.1163. 
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3-methoxybenzoyl chloride (4.99 g, 22,92 mmol) and N,O-
dimethylhydroxylamine hydrochloride (3.43 g, 35.2 mmol) was suspended in 
DCM (150 mL). The solution was cooled to 0˚C, triethylamine (9.8 mL, 70.3 
mmol) was added, and the solution was stirred for 20 h. 
 
The solution was reduced 
, and partitioned between water (100 mL) 
and DCM (100 mL), the layers were separated and the aqueous layer extracted 
with DCM (2 x 50 mL). The combined organic layers were washed with water 
and brine, dried over MgSO4 and reduced 
. The crude product was 
purified by flash column chromatography (2:1 Ether:Toluene) to yield the 
desired product (3.69 g, 65 %) as a colourless oil. 
 
δH (CDCl3) 7.31 (1H, app t,  7.9 Hz, 5-H), 7.24 (1H, app dt,  7.6 and 1.2Hz, 
aromatic), 7.20 (1H, dd,  2.4 and 1.5Hz, 2-H), 6.98 (1H, ddd,  8.2, 1.6 and 
1.1Hz, aromatic), 3.83 (3H, s, PhOCH3), 3.58 (3H, s,CH3), 3.35 (3H, s, CH3). 
 
δC (CDCl3) 169.7 (C=O), 159.2, 135.4 (2 x 4°, aromatic), 129.1 (CH, C-5), 
120.4, 116.6 (2 x CH), 113.3 (CH, C-2), 61.1 (CH3, PhOCH3), 55.4, 33.88 (2 x 
CH3). 
 
EP-MS MH+ calcd for C10H13NO3 196.0974 found  196.0985. 
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Mg turnings (620 mg, 24.6 mmol) and iodine (trace amount) were suspended 
in THF (25 mL) and 1-bromohexane (2.63 ml, 18.4 mmol) was added 
dropwise over 30 min, and stirred for 60 min. (3-methoxyphenyl)--methoxy-
-methylcarboxamide $.. (1.20 g, 6.15 mmol) was dissolved in THF (10 mL) 
under an inert atmosphere, added to the reaction mixture and the solution was 
stirred for 1 h. 
 
The reaction was quenched with 2 M HCl(aq) (10 mL), stirred for 10 min, 
partitioned between petroleum ether 40/60 (20 mL) and water (20 mL), the 
layers were separated and the aqueous layer extracted with petroleum ether 
40/60  (2 x 20 mL). The combined organic layers were washed with water and 
brine, dried over MgSO4 and reduced 
. The crude product was purified 
by flash column chromatography (1:9 EtOAc:Hexane) to yield the desired 
product (1.25 g, 92 %) as a colourless oil. 
 
δH (CDCl3) 7.54 (1H, ddd,  7.7, 1.2 and 1.2 Hz, aromatic), 7.49 (1H, dd,  2.5 
and 1.6 Hz, 2-H), 7.36 (1H, app t,  7.9 Hz, 5-H), 7.10 (1H, ddd,  8.2, 2.7 and 
0.9 Hz, aromatic), 3.85 (3H, s, OCH3), 2.95 (2H, t,  7.4Hz, CH2 α to 
carbonyl), 1.73 (2H, m, CH2 β to carbonyl), 1.43-1.25 (6H, 3 x CH2), 0.89 
(3H, m, CH3). 
 
δC (CDCl3) 200.4 (C=O), 159.8, 138.5 (2 x 4°, aromatic), 129.5 (CH, C-5), 
120.7, 119.3 (2 x CH), 112.3 (CH, C-2), 55.4 (CH3, OCH3), 38.8 (CH2, CH2 α 
to carbonyl), 31.7, 29.1 (2 x CH2), 24.4 (CH2, CH2 β to carbonyl), 22.6 (CH2), 
14.1 (CH3). 
 
EP-MS MH+ calcd for C14H20O2 221.1542 found  221.1529. 
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To a solution of 1 M titanium tetrachloride (31.5 

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mmol) in DCM (80 mL) under an inert atmosphere at -30 ºC was added 
dropwise 2 M dimethyl zinc (31.5 mmol) and stirred fro 30 min. The solution 
was cooled to 45 ºC and a solution of 1-(3-methoxyphenyl)heptan-1-one $.- 
(2.89 g, 13.1 mmol) in DCM (20 mL) was added dropwise under an inert 
atmosphere. The solution was slowly warmed to room temperature and the 
reaction stirred for 24 h. 
 
The reaction was quenched in sat NaHCO3(aq) (100 mL), acidified to pH 1 with 
2 M HCl(aq), the layers separated and the aqueous layer extracted with DCM (2 
x 50 mL). The combined organic layers were washed with water and brine, 
dried over MgSO4 and reduced 
. The crude product was purified by 
flash column chromatography (10:90 Ether:Hexane) to yield the desired 
product (3.00 g, 98 %) as a brown oil. 
 
δH (CDCl3) 7.25 (1H, app t,  8.0 Hz, 4-H), 6.95 (1H, ddd,  7.8, 1.7 and 0.9 
Hz, aromatic), 6.90 (1H, app t,  2.2 Hz, 2-H), 6.74 (1H, ddd,  8.1, 2.5 and 0.7 
Hz, aromatic), 3.83 (3H, s, OCH3), 1.59 (2H, m, CH2 α to dimethyl), 1.30 (6H, 
s, 2 x CH3, 1,1-dimethyl)1.29-1.01 (6H, 3 x CH2), 0.84 (3H, m, terminal CH3). 
 
δC (CDCl3) 159.3, 151.7 (2 x 4°, aromatic), 128.8 (CH, C-5), 118.5, 112.6, 
109.7 (3 x CH), 55.1 (CH3, OCH3), 44.6 (CH2 α to dimethyl), 37.8 (4°), 31.7, 
30.0 (2 x CH2), 29.0 (2 x CH3, 1,1-dimethyl), 24.4, 22.7 (2 x CH2), 14.1 
(terminal CH3). 
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1-(1,1-dimethylheptyl)-3-methoxybenzene$./ (800 mg, 3.42 mmol) was 
dissolved in DCM (10 mL) and cooled to -30 ˚C. 1 M boron tribromide in 
DCM (6.84 mmol) was added dropwise over 15 min, and the reaction mixture 
was stirred at for 22 h. 
 

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The reaction was quenched with water (20 mL) and stirred for 30 min. The 
layers were separated and the aqueous layer was extracted with DCM (2 x 10 
mL). The combined organic layers were washed with water and brine, dried 
over MgSO4, and reduced 
. The crude product was purified by flash 
column chromatography (20:80 EtOAc:Hexane) to yield the desired product 
(578 mg, 77 %) as a brown oil. 
 
δH (CDCl3) 7.19 (1H, app t,  7.9 Hz, 4-H), 6.93 (1H, ddd,  7.9, 1.7 and 0.9 
Hz, aromatic), 6.84 (1H, app t,  2.1 Hz, 2-H), 6.67 (1H, ddd,  8.0, 2.8 and 0.8 
Hz, aromatic), 4.92 (1H, br s, OH) 1.59 (2H, m, CH2 α to dimethyl), 1.30 (6H, 
s, 2 x CH3, 1,1-dimethyl), 1.30-1.03 (6H, 3 x CH2), 0.87 (3H, m, terminal 
CH3). 
 
δC (CDCl3) 155.2, 152.1 (2 x 4°, aromatic), 129.1 (CH, C-5), 118.5, 113.1, 
112.1 (3 x CH), 44.6 (CH2 α to dimethyl), 37.7(4°), 31.8, 30.0 (2 x CH2), 29.0 
(2 x CH3, 1,1-dimethyl), 24.7, 22.7 (2 x CH2), 14.1 (terminal CH3). 
 
EP-MS M- calcd for C15H24O1 219.1754 found  219.1758. 
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To a solution of 1-(1,1-dimethylheptyl)-3-
hydroxybenzene$., (922 mg, 4.51 mmol) in DCM (5 mL) was added 
dropwise bromine (230 µL, 4.51 mmol) and the solution stirred for 22 h.  
 
The solution was washed with 20% sodium thiosulphate(aq), sat. NaHCO3(aq) 
and brine, dried over MgSO4, and reduced 
. The crude product was 
purified by flash column chromatography (2:98 EtOAc:Hexane) to yield the 
desired product (1.11 g, 83 %) as a clear oil. 
 
δH (CDCl3) 7.37 (1H, d,  8.5 Hz, 6-H), 7.02 (1H, d,  2.3 Hz, 3-H), 6.80 (1H, 
dd,  8.5 and 2.3 Hz, 5-H), 5.44 (1H, br s, OH), 1.57 (2H, m, CH2 α to 

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dimethyl), 1.27 (6H, s, 2 x CH3, 1,1-dimethyl), 1.26-1.03 (6H, 3 x CH2), 0.86 
(3H, m, terminal CH3). 
 
δC (CDCl3) 151.9, 151.7 (2 x 4° aromatic), 131.2, 119.8, 114.0 (3 x CH), 106.7 
(4°, C-1), 44.4 (CH2 α to dimethyl), 37.7 (4º), 31.8, 30.0 (2 x CH2), 28.9 (2 x 
CH3, 1,1-dimethyl), 24.6, 22.7 (2 x CH2), 14.1 (terminal CH3). 
 
EP-MS M- calcd for C15H23Br1O1 297.0854 and 299. 0834 found  297.0848 
and 299.0812. 
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To a solution of 1-bromo-4-(1,1-
dimethylheptyl)-2-hydroxybenzene $.3 (110 mg, 0.368 mmol) in DMF (10 
mL) was added a methyl iodide (108 mg, 0.761 mmol) and potassium 
carbonate (158 mg, 1.14 mmol), and the solution stirred for 2 h. 
 
The solution was partitioned between water (10 mL) and DCM (10 mL), layers 
separated and the aqueous layer extracted with DCM (2 x 10 mL). The 
combined organics were washed with water and brine, dried over MgSO4 and 
reduced 
. The crude product was purified by preparatory layer 
chromatography (5:95 Ether:Petroleum Ether 60/80) to yield the desired 
product (72 mg, 61 %) as a yellow oil. 
 
δH (CDCl3) 7.44 (1H, d,  8.3 Hz, 6-H), 6.88 (1H, d,  2.1 Hz, 3-H), 6.82 (1H, 
dd,  8.3 and 2.1 Hz, 5-H), 3.90 (3H, s ,OCH3), 1.59 (2H, m, CH2 α to 
dimethyl), 1.29-1.02 (6H, s, 2 x CH3, 1,1-dimethyl), 1.30-1.02 (6H, 3 x CH2), 
0.87 (3H, m, terminal CH3). 
 
δC (CDCl3) 155.4, 151.0 (2 x 4° aromatic), 132.5, 119.7, 110.1 (3 x CH), 108.3 
(4°, C-1), 56.1 (CH3, OCH3) 44.5 (CH2 α to dimethyl), 38.0 (4°), 31.8, 30.0 (2 

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x CH2), 29.0 (2 x CH3, 1,1-dimethyl), 24.6, 22.7 (2 x CH2), 14.1 (terminal 
CH3). 
 
EP-MS MH+ calcd for C16H26Br1O1 313.1167 and 315.1147 found  
313.1166 and 315.1119. 
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Sodium hydride (60% w/w in mineral oil, 100 
mg, 2.51 mmol) was suspended in DMF (5 mL), 
and added to 1-(1,1-dimethylheptyl)-3-
hydroxybenzene$.3 (500 mg, 1.68 mmol). Benzylbromide (400 mg, 2.34 
mmol) was added and the solution was stirred under an inert atmosphere for 24 
h.  
 
Excess hydride was reacted with water, diluted with EtOAc (20 mL), and 
stirred for 5 min. The resulting solution was separated and the aqueous layer 
extracted with EtOAc (2 x 10 mL). The combined organics were washed with 
water and brine, dried over MgSO4 and reduced 
. The crude product 
was purified by flash column chromatography (5:95 Ether:Petroleum Ether 
60/80)  to yield the desired product (592 mg, 91 %) as a yellow oil. 
 
δH (CDCl3) 7.50 (2H, m, benzyl), 7.46 (1H, d,  8.3 Hz, 6-H), 7.40 (2H, m, 
benzyl), 7.33 (1H, m, benzyl), 6.90 (1H, d,  2.1 Hz, 3-H), 6.82 (1H, dd,  8.3 
and 2.1 Hz, 5-H), 5.19 (2H, s ,OCH2), 1.52 (2H, m, CH2 α to dimethyl), 1.29-
0.92 (6H, 3 x CH2), 1.25 (6H, s, 2 x CH3, 1,1-dimethyl), 0.87 (3H, t,  7.1 Hz, 
CH3). 
 
δC (CDCl3) 155.5, 150.8, 136.79 (3 x 4° aromatic), 132.6 (CH, C-6), 128.6, 
127.9, 127.2 (3 x CH benzyl), 120.1 (CH, C-5), 112.7.1 (CH, C-3), 109.3 (4°, 
C-1), 71.0 (CH2, OCH2) 44.5 (CH2 α to dimethyl), 37.9 (4°), 31.8, 30.0 (2 x 
CH2), 28.9 (2 x CH3, 1,1-dimethyl), 24.6, 22.7 (2 x CH2), 14.1 (terminal CH3). 

+
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EP-MS MH+ calcd for C22H30Br1O1 389.1480 and 391.1460 found  
389.1463 and 391.1451. 
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All compounds for radioligand binding assays were purified by preparative 
layer chromatography, to greater than 98% purity; this was confirmed using 
two different analytical reverse phase high performance liquid chromatography 
methods and accurate mass spectrometry of the product to within 10 parts per 
million.  
 
Human CB2 receptor -transfected Chinese hamster ovary (CHO) cells 
(originally a kind gift from GSK Pharmaceuticals, Harlow, UK)  were grown 
in our own laboratories in Dubelcco’s modified Eagle’s medium containing 
5% foetal calf serum, 2 mM L-glutamine, 600 µg/mL Geneticin®, and 300 
µg/mL hygromycin B, in a Sanyo CO2 incubator (95 % O2: 5 % CO2) at 37 °C. 
Passaging of cells was every 3-4 days, using trypsin to detach the cells, which 
were then suspended in fresh media. Flasks were grown to confluence and the 
cells harvested by removing excess media and collecting cells in ice cold 
phosphate buffer solution. This work was kindly carried out by Marlene 
Groenen.  
 
Cell disruption was performed using a Polytron hand held electric 
homogeniser in Tris buffer (50 mM Tris, 5 mM MgCl2, 2nM EDTA, pH 7.0). 
The homogenate was centrifuged at 30,000g at 4 °C for 10 min, and the pellet 
was re-suspended in Tris buffer. Homogenisation and centrifugation were 
repeated twice and the final pellet was resuspended in Tris buffer to a protein 
concentration of 5 mg/mL. This work was kindly carried out by Professor 
David Kendall. 
 
Radioligand binding assay tubes were prepared in triplicate containing 0.25 
nM [3H] CP55-940 (Perkin-Elmer Life Sciences), approximately 3 µL 
membrane protein solution and the desired concentration of compound under 
investigation, diluted in Tris buffer to a final volume of 1 mL (50 mM Tris, 5 
mM MgCl2, 2 mM EDTA, plus 0.2 mg/mL bovine serum albumin, pH7.0). 
Stock drugs and compounds for testing were diluted in the same buffer 
containing 5 mg/mL bovine serum albumin to improve solubility. Tubes were 
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incubated for 90 min at 30 °C and then a Brandel cell harvester was used to 
isolate membranes and hence separate bound from unbound radioligand. The 
filtered membranes [3H] CP55-940 content was then quantified by liquid 
scintillation counting. Specific binding was calculated by subtracting non-
specific binding (determined in the presence of the CB2 receptor antagonist 
SR144528 1 µM), and nonlinear regression analysis was carried out using 
GraphPad Prism 3 (GraphPad Software). Ki values for the test compounds 
were determined from IC50 values using a [
3H] CP55-940 KD value of 0.5 nM 
in the Cheng–Prusoff equation: 
 
Ki = IC50/(1+ C/KD), where C is the concentration of [
3H] CP55-940 in each 
assay. 
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